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 Immunomodulation As A Potential Therapeutic Approach for Alzheimer’s Disease 
 
William Veljko Nikolic 
ABSTRACT 
 
Alzheimer’s disease (AD) is the most prevalent form of progressive dementia and 
is characterized by the accumulation of amyloid beta (Aβ) peptide in the brain and in the 
cerebral vessels forming cerebral amyloid angiopathy (CAA). As previously reported, an 
active immunization strategy of mice with Aβ1-42 peptide results in decreased Th1 and 
increased Th2 cytokine responses as well as an effectively clearance of CNS Aβ. This 
approach has also yielded favorable results for many patients, unfortunately, a small 
percentage of these study participants developed severe aseptic meningoencephalitis 
likely secondary to CNS invasion of activated T-cells. We have previously demonstrated 
that disruption of CD40-40L pathway reduces Aβ plaque load, promotes Th2 response, 
and rescues from cognitive impairments. However, direct blockage of the CD40 pathway 
by passive vaccination with anti-CD40L antibody leads to immunosupression. Therefore, 
in its current form this therapeutic strategy poses an unacceptable risk to the recipient of 
treatment, aged individual. For those reasons, the identification and characterization of 
alternative modulators/inhibitors of CD40 signaling may be necessary for the 
development of safe and effective AD immunotherapy. 
 This proposal introduces novel immunomodulatory therapies that are based on 
previous vaccination strategies or cell based therapies across medial field. We showed 
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that transcutaneous vaccination can both be efficacious and safe, thus clearly 
demonstrating that the right combination of the antigens, adjuvants, and the routes of 
administration are crucial for the right vaccine. Furthermore, we demonstrated that the 
effects of current Aβ vaccine strategies could be enhanced by a simultaneous blockade of 
CD40-40L signaling. As an alternative approach, we explored the possibility of cell-
based therapies and showed that human umbilical cord blood cells, which are currently 
used as a treatment for systemic lupus erythematosus and leukemia, and currently 
investigated against stroke, amyotropic lateral sclerosis, age-related macular 
degeneration, multiple sclerosis, and Parkinson’s disease, and showed that not just they 
improved the AD like pathology in transgenic animals but altered both the brain and 
peripheral inflammation levels. Lastly, we discussed the involvement of microglia, one of 
the key players in both AD pathogenesis and Aβ clearance and suggesed that microglia in 
actuality has a continuum of physiological activation states that contribute to 
proinflammation, antiinflammation, and phagocytosis. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 The impact of Alzheimer’s disease 
First described in 1906 by Alois Alzheimer, the Alzheimer’s disease (AD) is the 
leading cause of dementia among elderly. Dementia is a collective name for progressive 
degenerative brain syndromes, which affect memory, behavior, emotions, and thinking. 
Currently, about 10 percent of Americans over the age of 65 and half of those over age of 
85 have been diagnosed with AD, which equates to over 5.2 million Americans that 
suffer from this disease. According to 2008 Alzheimer’s Association Facts and Figures 
report, AD is the seventh-leading cause of death in U.S. and where every 71 seconds 
someone develops AD. The report also estimates that the direct and indirect costs of 
Alzheimer's and other dementias to Medicare, Medicaid and businesses amount to more 
than $148 billion each year, which makes it a third most expensive disease to threat in the 
U.S. 
 Generally speaking, Alzheimer’s disease can be divided into three basic stages. 
The early stage is characterized by mild cognitive decline, i.e. word- or name-finding 
problems, decline in ability to organize, and performance issues in social or work 
settings. The middle stage is characterized by severe cognitive decline (confusion, 
disorientation, and delusions), disruption in normal sleep/walking cycle, and increasing 
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episodes of urinary or fecal incontinence. The late and final stage of AD is characterized 
by the loss of capacity of recognizable speech, individuals lose the ability to work, lose 
the ability to walk without assistance, then the ability to sit without support, the ability to 
smile, the ability to hold their head up, and individuals need help with eating and toileting 
and there is general incontinence of urine. 
  
1.2 Pathology of Alzheimer’s disease 
Brain regions being affected early are entorhinal cortex, hippocampus, and basal 
forebrain. These are small specialized structures that play a crucial role in memory. Over 
time, the disease destroys large areas of the brain that control vital body functions and as 
a result AD patients typically die from pneumonia or lack of nutrition. Pathologically 
speaking, major AD characteristics are senile plaques (caused by amyloid beta peptide 
deposition), neurofibrilary tangles (caused by tau protein deposition), and neuronal loss 
(characterized by dystrophic neurites). Amyloid or “senile” plaque is primarily composed 
of 39-43 amino acid peptide amyloid beta (Aβ). Aβ is derived by a proteolytic cleavage 
of amyloid precursor protein (APP). There are  Aβ is normally water soluble, however it 
does have a tendency to aggregate, ex. especially longer forms of the peptide (Aβ1-40 and 
Aβ1-42) as regular β-plated sheet conformations and come out as insoluble amyloid 
plaques. These plaques are normally detergent resistant. Aβ can also be deposited as 
diffused deposits, often believed to be the intermediate step before the more compact 
amyloid plaques form. In recent years, Aβ deposition has been identified in the vascular 
wall. This is know as a cerebral amyloid angiopathy (CAA), a pathology that was 
identified in as much as 83 percent of AD patients (Ellis et al., 1996). Neurofibrilary 
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tangles are intraneuronal inclusions of abnormal fibers that consist of paired helical 
filaments. The filaments consist of microtubule-associated hyperphosphorylated tau 
proteins. Lastly, neuronal loss is thought to originate from amyloid plaques, 
inflammatory reactions due to cytokine releases, oxidative injury that disrupt neuronal 
metabolic and ionic homestasis, and impaired neuronal trafficking due to 
hyperphosphorylated tau filaments.  
 
1.3 Microglia and central nervous system 
Microglia are somewhat enigmatic central nervous system (CNS) cells that have 
been traditionally regarded as CNS macrophages (MΦs).  They represent about 10% of 
the adult CNS cell population (Pessac et al., 2001).  In mice, microglial progenitors can 
be detected in neural folds at the early stages of embryogenesis.  Murine microglia are 
thought to originate from the yolk sac at a time in embryogenesis when 
monocyte/macrophage progenitors (of hematopoeitic origin) are also found (Pessac et al., 
2001) (Alliot et al., 1999).  Based on this observation, it is now generally accepted that 
adult mouse microglia originate from monocyte/macrophage precursor cells migrating 
from the yolk sac into the developing CNS, most likely independently of CCR2 (Mildner 
et al., 2007).  Once CNS residents, these newly migratory cells actively proliferate during 
development, thereby giving rise to the resident CNS microglial cell pool.  More recently 
however, it has been shown that bone marrow-derived cells can enter the CNS and 
become cells that phenotypically resemble microglia in the adult mouse (Eglitis and 
Mezey, 1997) (Brazelton et al., 2000) (Mezey et al., 2000). Interestingly, under 
conditions of CNS damage such as stroke, cholinergic fiber degeneration, or motor 
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neuron injury, Priller and colleagues found that green fluorescent protein-labeled bone 
marrow cells could enter the CNS and take up a microglial phenotype (Priller et al., 
2001).  On other hand it was shown that bone-marrow derived cells do not contribute at 
all to the CD11b+/Iba-1+ population when the CNS was protected from irradiation, 
suggesting that proliferation of endogenous microglia is the most plausible explanation 
for the increase in Iba-1+ cell number (Mildner et al., 2007). This latter view could be 
further supported with citings that local microglia proliferate following lesioned CNS 
with intact blood-brain barrier (Priller et al., 2006) (Remington et al., 2007). 
 Microglia normally exist in a quiescent (resting) state in the healthy CNS, and are 
morphologically characterized by small soma and ramified processes.  However, upon 
“activation” in response to invading viruses or bacteria or CNS injury, microglia undergo 
morphological changes including shortening of cellular processes and enlargement of 
their soma (sometimes referred to as an “amoeboid” phenotype).  Activated microglia 
also up-regulate a myriad of cell surface activation antigens and produce innate cytokines 
and chemokines (discussed in detail below).  As the microglial lineage originates from 
peripheral myeloid precursor cells, it is helpful to consider the activation states of such 
peripheral innate immune cells to better understand the nature of microglial activation. 
 
1.4 Classical roles of peripheral innate immune cells 
It is now widely accepted that both innate and adaptive arms of the immune 
system play important roles in maintaining immune homeostasis.  However, little 
attention was paid to the evolutionarily much older innate immune system until the late 
Charlie Janeway proposed the involvement of innate mechanisms in vertebrate immunity.  
 
 
4 
 
 
 
Specifically, Janeway pioneered the idea that lymphocyte activation could be critically 
regulated by the evolutionarily ancient system of antigen clearance by phagocytic cells of 
myeloid origin.  Together with Ruslan Mezhitov, they originated the concept that these 
phagocytic innate immune cells recognize pathogen-associated molecular patterns 
(PAMPs) through pattern recognition receptors, the most notable examples being a set of 
phylogenetically conserved, germ-line encoded Toll-like receptors (TLRs, currently 11-
12 members, (Qureshi and Medzhitov, 2003) (Yamamoto et al., 2004) (Zhang et al., 
2002) (Tabeta et al., 2004), resulting in expression of cell-surface activation molecules 
[for example, major histocompatibility complex (MHC) class I and II, B7.1, B7.2, and 
CD40] and secretion of innate cytokines (e.g., tumor necrosis factor-α (TNF-α), 
interleukin (IL)-1, IL-6, IL-12, and IL-18 (Janeway and Medzhitov, 2002) (Medzhitov 
and Janeway, 2000a).   Once activated, the innate arm of the immune response calls 
adaptive immune cells into action, and both branches act in concert to promote 
neutralization and clearance of invading pathogens.  Thus, innate immune cells are able 
to discriminate “non-infectious self” from “infectious non-self” and thereby form the first 
line of defense against invading bacteria and viruses (for review see (Medzhitov and 
Janeway, 2000b) (Medzhitov and Janeway, 2002) (Medzhitov and Janeway, 2002) 
(Iwasaki and Medzhitov, 2004). 
 
1.4.1 The macrophage: prototypical phagocyte 
Macrophages (MΦs) are quintessential phagocytes whose primary role is to 
engulf pathogens such as invading bacteria and to remove debris and detritus, i.e., 
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remnants of apoptotic cells.   Tissue MΦs develop when blood monocytes enter into the 
various organs and tissues and differentiate into specialized, site-specific MΦs depending 
on their anatomical location, such as alveolar MΦs (lung), histiocytes (connective tissue), 
kupffer cells (liver), mesangial cells (kidney), osteoclasts (bone), or microglia (brain) 
(Goldsby et al., 2002).  Resting MΦs are both weak phagocytes and weak lymphocyte 
activators (Adler et al., 1994).  Upon activation however, for example in response to TLR 
stimulation by PAMPs, their phagocytic potential greatly enhances (Blander and 
Medzhitov, 2004) and they up-regulate cell-surface co-stimulatory molecules and 
produce pro-inflammatory innate cytokines as mentioned above.  Typically, engulfment 
of the pathogen by phagocytosis triggers a “respiratory burst” involving production of 
reactive oxygen species such as superoxide and peroxinitrite that kill the pathogen (Adler 
et al., 1994) (Forman and Torres, 2001).  In addition, activated MΦ up-regulate cell-
surface Fc receptors that aid in phagocytosis of pathogens opsonized by antibodies 
produced by plasma cells (Tsukada et al., 1994) (Blom et al., 2003).  On the other hand, 
in response to debris from apoptotic cells, the MΦ mounts a phagocytic response 
essentially in the absence of pro-inflammatory cytokines (Gregory and Devitt, 2004).  
The most likely reason for this anti-inflammatory phagocytic response is that pro-
inflammatory cytokines such as TNF-α promote bystander injury which may further 
damage tissues in which the apoptotic cells reside.  Thus, MΦs are highly capable of 
“innate activation” characterized by a strong phagocytic response sometimes 
accompanied by pro-inflammatory cytokine production (for a review see (Fujiwara and 
Kobayashi, 2005). 
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 1.4.2 The dendritic cell: professional antigen presenting cell 
Whereas MΦs have limited ability to process and present antigen to T cells, 
dendritic cells (DCs) are considered professional antigen presenting cells (APCs).  DCs 
can be found under the epithelia and in most organs where they capture and process non-
self antigens, migrate to lymphoid organs, and present antigen in the context of MHC to 
CD4+ and CD8+ T lymphocytes.  With their many finger-like cellular processes, DCs are 
morphologically optimized to simultaneously display antigen to many T cells.  Like 
MΦs, DCs respond to invading pathogens by recognizing PAMPs through TLRs, and 
subsequently phagocytose and process antigen.  DCs then up-regulate cell-surface co-
stimulatory molecules and secrete innate cytokines and chemokines (typically at levels an 
order of magnitude higher than those secreted by MΦs) to promote recruitment and 
activation of CD4+ and/or CD8+ T lymphocytes.  There are three generally accepted 
classifications of DCs in mice: plasmacytoid (p) DCs (CD11clo, CD11blo, B220+, CD8-), 
lymphoid (l) DCs (CD11c+, CD11b-, CD8+), and myeloid (m) DCs (CD11c+, CD11b+, 
B220-, CD8-, there are several subtypes,) (Banchereau et al., 2000).  In humans, there are 
clearly two distinct subsets of DCs: pDCs (CD11c-, CD11b-, CD14-, CD45RA+) and 
monocyte DCs (CD11c+, CD11b+, CD14+, CD45RA-) (for a review see (Shortman and 
Liu, 2002).  DC classes differ from each other predominately in tissue distribution, 
production of specific cytokines, TLR expression, and ability to promote innate versus 
adaptive immune responses (for a review see (Iwasaki and Medzhitov, 2004).  For 
example, freshly isolated human pDCs express TLR7 and 9, whereas mDCs express 
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TLR1, 2, 3, 5, 6, and 8 (Hornung et al., 2002) (Jarrossay et al., 2001) (Kadowaki et al., 
2001).  Stimulation of human pDCs or monocytic DCs with synthetic TLR7 ligands 
induces the secretion of interferon (IFN)-α (important for anti-viral innate immunity) or 
IL-12 [a key inducer of the adaptive T helper (Th) type I response], respectively (Ito et 
al., 2002).  Similarly, stimulation of TLR9 via DNA containing unmethylated CpG motifs 
results in IFN-α secretion by pDCs and IL-12 production by murine mDCs (Hemmi et 
al., 2003).  Despite these relative differences between DC classes, the major role of DCs 
on the whole remains; they act as potent APCs capable of strongly activating T 
lymphocytes.  Their APC capacity is much stronger than that of MΦs, as DCs are able to 
directly activate naïve T cells whereas MΦs are not (Iwasaki and Medzhitov, 2004).   
Thus, by virtue of their ability to promote T cell activation responses, DCs are highly 
capable of “adaptive activation”.  Activation markers of phagocytosis and APC responses 
in various innate immune cells are presented in the Table 1. 
 
1.5 Microglial activation after toll-like receptor stimulation: a mixed response 
Recent evidence indicates that microglia, like their peripheral innate immune cell 
counterparts, express a wide array of TLRs, including mRNA for TLRs 1-9 in mice 
(Olson and Miller, 2004) and in humans (Bsibsi et al., 2002).  Furthermore, many of 
these TLRs have been shown to be functional, allowing microglial recognition of a 
variety of PAMPs.  For example, Kielian and coworkers found that heat-killed 
Staphylococcus aureus and its cell wall product peptidoglycan (PGN) are able to 
stimulate innate activation of microglia characterized by pro-inflammatory cytokine and 
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chemokine production (Kielian et al., 2002).  Those authors found that the effect of PGN 
was critically dependent on TLR2, as TLR2-deficient mice demonstrated reduced 
cytokine and chemokine production after PGN challenge (Kielian et al., 2005).  
Furthermore, murine microglia respond to the TLR9 agonist, unmethylated CpG-DNA, 
by secreting numerous pro-inflammatory innate cytokines (probably responsible for 
neurotoxicity in oganotypic brain slice cultures treated with CpG-DNA (Iliev et al., 
2004), by up-regulating co-stimulatory cell surface molecules, and by promoting adaptive 
activation by secreting IL-12 to affect T cell activation (Dalpke et al., 2002).  In two 
recent studies, murine microglial pro-inflammatory responses to bacterial 
lipopolysaccharide (LPS), a known TLR4 ligand, resulted in dramatic injury to cultured 
oligodendrocytes (Lehnardt et al., 2002) and neurons (Lehnardt et al., 2003), further  
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demonstrating microglial bystander injury after TLR stimulation (probably mediated by 
over-production of innate pro-inflammatory cytokines). It has recently been shown that 
microglia respond to poly I:C [a synthetic double-stranded (ds) RNA analog thought to 
be recognized by TLR3, (Alexopoulou et al., 2001)] by producing pro-inflammatory 
cytokines and chemokines (Jack et al., 2005), and microglial pro-inflammatory responses 
to dsRNA seem to be dependent on TLR3, as TLR3-deficient microglia have blunted 
innate cytokine responses in vitro and markedly reduced cell surface activation markers 
in brain after poly I:C stimulation (Town et al., submitted).   Finally, infection with West 
Nile virus, a retrovirus that produces dsRNA during its life cycle, results in profound 
microglial activation as assessed by pro-inflammatory cytokine production in vitro and 
cell surface activation markers in vivo, effects that are dramatically reduced in TLR3-
deficient animals (Wang et al., 2004).   
In peripheral innate immune cells, TLR responses to PAMPs seem to be 
dependent on at least four different TLR intracellular adapter molecules: MyD88 
(involved in TLR1, 2, 4, 6, 7, 8, and 9 signaling), TRIF/TICAM-1 (mediates TLR3 and 4 
signaling), TIRAP/Mal (involved in TLR1, 2, 4, and 6 responses) and 
TIRP/TRAM/TICAM-2 (mediates TLR4 signaling).  These adapter molecules bind to the 
intracellular leucine-rich repeat region of the TLR and promote recruitment of additional 
factors such as IRAKs and TRAF6 that allow for activation of transcription factors 
including IRF-3 and NF-κB, which are responsible for activation of numerous innate 
cytokines and cell-surface activation antigen genes (for review see (Vogel et al., 2003) 
(Hemmi and Akira, 2005). It is still unclear how different TLR responses in innate 
immune cells (i.e., promotion of innate versus adaptive responses) can be achieved when 
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many TLRs share intracellular signaling molecules.  While little work has been done on 
intracellular signaling following TLR stimulation in microglia, it is likely that microglia 
utilize the same signaling cascades described for MΦs and DCs. 
 
1.6 Adaptive response of activated microglia in demyelinating disease via CD40-
CD40 ligand interaction 
 
1.6.1 Brain inflammation in demyelinating disease 
Experimental autoimmune encephalomyelitis (EAE) is a mouse model of the 
human disease multiple sclerosis (MS), an autoimmune disease characterized by 
inflammatory CNS demyelinating lesions accompanied by motor disturbances.  EAE can 
be induced in different strains of mice by subcutaneous or intraperioteneal inoculation 
with adjuvant plus epitopes found in myelin such proteolipid protein, myelin basic 
protein, or myelin oligodendrocyte glycoprotein.  The disease is critically dependent on 
activation of pro-inflammatory CD4+ T helper type I (Th1) cells by APCs, and these 
auto-aggressive Th1 cells can be adoptively transferred to non-diseased recipient mice 
that subsequently develop disease.  EAE is characterized by paralysis, typically 
beginning in the tail and hind limbs and progressing to the fore limbs.  In the SJL mouse 
strain, animals develop a relapsing-remitting form of the disease while C57BL/6 mice 
manifest paralysis that progressively worsens until death.  Upon histopathological 
analysis, brains from EAE mice generally show infiltration of Th1 cells (and other 
lymphocytes including MΦs and DCs) and activation of microglia, typically in white 
matter regions where demyelinating lesions are found (for review see (Olsson, 1995) 
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(Swanborg, 1995) (Cornet et al., 1998).    
 
1.6.2 CD40-CD40 ligand interaction in experimental autoimmune encephalomyelitis 
Immune/inflammatory cells receiving a primary stimulus (i.e., MHC-T cell 
receptor interaction between APCs and T lymphocytes, respectively) typically require co-
stimulatory signals via other pairs of molecules in order to become activated [for 
instance, the B7-CD28 and/or CD40-CD40 ligand (L) dyads in APC/T-cell activation; 
(van Kooten and Banchereau, 2000)].  CD40L is a key immunoregulatory molecule that 
plays a co-stimulatory role in the activation of immune cells from both the innate and 
adaptive arms of the immune system, and is typically expressed by activated CD4+ and 
some CD8+ T cell subsets (Grewal and Flavell, 1998).  CD40 receptor, a member of TNF 
and nerve growth factor super-family, is expressed on many professional and non-
professional APCs, including dendritic cells, B cells, monocytes/macrophages and 
microglial cells (O'Keefe et al., 2002) (Carson et al., 1998) (Havenith et al., 1998) (Tan et 
al., 1999b) (Tan et al., 1999a).  Nearly 10 years ago, activated Th cells that expressed 
CD40 ligand (CD40L) were found in brains of MS patients, and these cells were found in 
close apposition to CD40-bearing cells in active demyelinating lesions (Gerritse et al., 
1996).  The authors determined that the CD40-expressing cells were either macrophages 
or microglia based on staining for acid phosphatase or CD11b. 
To evaluate whether the CD40-CD40L interaction was pathogenic in EAE, 
Gerritse and co-workers administered a CD40L neutralizing antibody to SJL mice that 
were given proteolipid protein with adjuvant to induce EAE.  Strikingly, EAE was 
prevented in a prophylactic treatment regimen of anti-CD40L, and, when EAE was 
 
 
13 
 
 
 
induced in another cohort of animals, CD40L antibody treatment significantly reduced 
disease severity in an active treatment paradigm (Gerritse et al., 1996).   It was later 
shown that genetic deficiency in CD40L (Grewal et al., 1996) or antibody-mediated 
blockade of CD40L (Howard et al., 1999) resulted in attenuation of Th1 differentiation 
and effector function, including marked inhibition of the Th1 cytokine IFN-γ and reduced 
numbers of encephalitogenic effector T cells.  In an effort to further understand the nature 
of the CD40-CD40L interaction responsible for promotion of EAE, Becher and 
colleagues used a bone marrow reconstitution system to determine which CD40-
expressing cells were responsible for promoting EAE (Becher et al., 2001).  In that 
report, the authors showed that CD40 expression by parenchymal microglia was 
responsible for recruitment/retention of encephalitogenic T cells in EAE.  Strikingly, 
treatment of microglia with a combination of granulocyte macrophage-colony stimulating 
factor and CD40L has been shown to promote differentiation of these cells into cells that 
(1) express the pan-DC marker CD11c, (2) morphologically resemble DCs, and (3) 
secrete the Th1-promoting cytokine IL-12 p70 (Fischer and Reichmann, 2001).  Such 
CD11c+ CD11b+ “DC-like” microglia were found in EAE brain lesions in inflammatory 
foci containing T cells, and exhibited potent stimulation of allogeneic T cell proliferation 
versus CD11c- CD11b+ microglia (Fischer and Reichmann, 2001).  Although their origin 
was not determined, it was recently shown that “CNS DCs” (possibly “DC-like” 
microglia) are responsible for activation of naïve T cells in response to endogenous 
myelin epitopes (termed “epitope spreading”), and this process was initiated in the CNS 
as opposed to the peripheral lymphoid organs (McMahon et al., 2005). Thus, in the 
context of EAE, CD40-CD40L interaction on microglia seems to promote adaptive 
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function of these cells, resulting in a “DC-like” activated microglia phenotype that 
promotes encephalitogenic Th1 cell differentiation and effector function. 
 
1.7 Activation of microglia after CD40 ligation in Alzheimer disease: a shift from 
innate to adaptive response 
 
1.7.1 Alzheimer disease and microglial responses to β-amyloid 
It has been suggested that activated microglia play a key role in AD pathogenesis 
as they secrete pro-inflammatory innate cytokines such as TNF-α and IL-1β, which have 
been shown to promote neuronal injury at high levels (Meda et al., 1995) (Barger and 
Harmon, 1997) (McGeer and McGeer, 1998).  Furthermore, there is a large body of 
evidence that non-steroidal anti-inflammatory drug (NSAID) use is associated with 
reduced risk for AD in humans (Shapshak et al., 2004) (in t' Veld et al., 2001) (Zandi et 
al., 2002), for a review see (Szekely et al., 2004), and NSAID treatment of AD mice 
results in reduced β-amyloid plaque burden concomitant with ameliorated microglial 
activation (Matsushima et al., 1994) (Matsushima et al., 1994) (Lim et al., 2001).   Work 
done in Maxfield’s laboratory showed that challenge of microglia with labeled Aβ 
peptides promotes phagocytosis but poor degradation of soluble or fibrillar Aβ via 
scavenger receptors (Paresce et al., 1996) (Paresce et al., 1997) (Chung et al., 1999).   
Using knockout mice, his laboratory showed that the class A scavenger receptor (type I 
and II) is the predominant scavenger receptor responsible for Aβ uptake by microglia, 
with other scavenger receptors playing a more minor role (including the class B 
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scavenger receptor CD36) (Chung et al., 1999). 
1.7.2 Microglial responses to β-amyloid in the context of CD40 ligation 
We previously showed that, while murine microglial challenge with soluble Aβ 
peptides alone does not elicit TNF-α secretion, co-stimulation provided in the form of 
CD40 ligation (either via CD40L or an agonistic CD40 antibody) results in TNF-α 
production being synergistically affected (Tan et al., 1999a).  Further, microglia cultured 
from AD mice deficient in CD40L demonstrate reduced TNF-α secretion versus CD40L-
sufficient AD mouse microglia.  This form of microglial activation in CD40L-sufficient 
AD mice is pathogenic, as CD40L-deficient AD mice demonstrate reduced activated 
(CD11b+) microglia, an effect that is associated with mitigated abnormal hyper-
phosphorylation of tau protein (a key indicator of neuronal stress) (Tan et al., 1999a).  
Furthermore, genetic ablation of CD40L or administration of a CD40L-neutralizing 
antibody markedly reduces β-amyloid plaques in mouse models of AD, effects that are 
associated with mitigated astrocytosis and microgliosis (Tan et al., 2002a), for review see 
(Town et al., 2001) (Tan et al., 2002b).  More recently, overproduction of microglia-
associated CD40 and of astrocyte-derived CD40L was found in and around β-amyloid 
plaques in AD patient brains (Togo et al., 2000) (Calingasan et al., 2002), raising the 
possibility that the CD40-CD40L interaction may contribute to AD pathogenesis by 
promoting brain inflammation.  
In order to better understand the form of microglial activation affected by Aβ plus 
CD40L stimulation, we examined innate and adaptive activation of murine microglia 
challenged with Aβ in the presence or absence of CD40L co-stimulation (Townsend et 
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al., 2005).   When microglia were challenged with fluorescent-tagged synthetic human 
Aβ alone, they mounted a time-dependent phagocytic response (from 15 min to 60 min) 
which could be enhanced by Fc receptor stimulation using an anti-human Aβ antibody.  
This phagocytic response to Aβ alone was not associated with production of the pro-
inflammatory innate cytokines TNF-α, IL-6, or IL-1β, a result similar to that seen when 
microglia are challenged with apoptotic cells and mount an anti-inflammatory, pro-
phagocytic innate response (Minghetti et al., 2005).  Importantly, CD40L treatment 
opposed this phagocytic response, as determined by measuring both cell-associated 
Aβ and free extracellular Aβ.  As mentioned above, Maxfield’s laboratory demonstrated 
that microglia slowly degrade phagocytosed Aβ peptides (Paresce et al., 1996) (Paresce 
et al., 1997) (Chung et al., 1999).  We examined the ability of microglia to degrade Aβ 
peptides by first pulsing them with Aβ and then chasing these cells after 1 hour of culture 
in the presence or absence of CD40L stimulation.  Using this experimental approach, we 
found that CD40L also retarded microglial clearance of the peptide.  We further assessed 
putative modulation of microglial Aβ phagocytosis by cytokines known to promote 
effector T cell function, and found that the pro-inflammatory Th1-type cytokines IFN-γ 
and TNF-α inhibited Aβ phagocytosis whereas the anti-inflammatory Th2-type cytokines 
IL-4 and IL-10 boosted this response.   
 
1.8 Immunotherapy and Alzheimer’s disease 
 Alzheimer’s disease is described by many pathological characteristics and 
yet the predominant theory of the disease process in the amyloid hypothesis. This 
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hypothesis suggests that Aβ deposition can directly through diffuse or compact plaques, 
or indirectly through inflammatory cascade, result in progressive synaptic and neuritic 
injury. This injury causes alterations in intracellular kinases functions that further 
contribute to tau protein hyperphosphorylation and the formation of neurofibrilary 
tangles. The combination of these events and their propagation is believed to contribute 
to neuronal dysfunction and loss which will contribute to dementia observed in 
Alzheimer’s disease (Hardy and Selkoe, 2002). Thus, methods developed to clear or 
prevent formation of Aβ in the brains of AD patients represent a possible treatment 
modality.  One promising approach involves utilization of “active” Aβ immunization 
strategies, which produce dramatic reductions in Aβ pathology in animal studies (Schenk 
et al., 1999).  However, a phase IIa clinical trial was abandoned after about 6% of Aβ-
immunized AD patients developed aseptic meningoencephalitis (Nicoll et al., 2003; 
Orgogozo et al., 2003) that appeared to involve brain inflammatory reactions mediated by 
T-cells and microglia (Monsonego et al., 2001; Schenk and Yednock, 2002; Greenberg et 
al., 2003; Monsonego et al., 2003a).  Interestingly, a 12 month post-vaccination period 
analysis revealed an inverse correlation between titers of amyloid plaque-reactive 
antibodies and rate of cognitive decline (Hock et al., 2003), suggesting clinical efficacy.  
Despite the discontinuation of the clinical trials, Aβ vaccination studies have continued in 
effort to identify an immunization approach that is both safe and effective.  Current 
approaches have focused on minimizing T-cell mediated inflammatory responses in 
efforts to prevent CNS invasion of auto-aggressive T-cells, while promoting Aβ 
antibody-mediated clearance mechanisms (Chackerian et al., 2006; Maier et al., 2006; 
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Okura et al., 2006; Nikolic et al., 2007). A possible avenue to both enhance Aβ clearance 
and down-regulate CNS inflammatory responses (including invasion of reactive T-cells) 
involves modulation of the CD40 receptor (CD40)-CD40 ligand (CD40L) system. In the 
periphery, a variety of innate immune cells known as antigen-presenting cells (APCs) 
express CD40, including dendritic cells, B-cells, and monocytes/macrophages.  In the 
CNS, CD40 is expressed by resident cells including microglia, neurons, and astrocytes, as 
well as by peripherally-derived APCs (Tan et al., 2002a; Town et al., 2005). Recently, the 
CD40-CD40L interaction was determined to play a central role in promoting and 
maintaining dendritic cell APC phenotype during infections (Straw et al., 2003).  In the 
context of CNS immunity, the CD40-CD40L interaction is required for microglial 
maturation into functional APCs (Ponomarev et al., 2006).  We have recently shown that 
CD40L treatment of primary cultures of microglia inhibits phagocytosis of Aβ antibody 
opsonized, as well as non-opsonized Aβ species (Townsend et al., 2005). A blockade of 
the CD40-CD40L system down-regulates T-cell/microglia-mediated injury in the context 
of experimental autoimmune encephalitis (EAE) (Howard et al., 1999; Howard et al., 
2002).  Altogether, these studies suggest that blockade of the CD40-CD40L interaction 
could enhance Aβ vaccination-mediated Aβ clearance mechanisms, while minimizing 
pro-inflammatory T-cell-mediated damage in the CNS. However, a complete blockade of 
CD40-40L interaction would lead to distortion of immune functioning and hence an 
autoimmunity would emerge. Therefore, the need for an immunomodulator that can 
partially block the CD40-40L interaction and yet still allow normal immune functioning 
would be needed. Human umbilical cord blood cells (HUCBC) have been shown to 
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oppose the pro-inflammatory T helper cell type 1 (Th1) response, as demonstrated in an 
animal model of stroke where HUCBC infusion promoted a strong anti-inflammatory T-
helper 2 (Th2) response (Vendrame et al., 2004).  Importantly, this effect was associated 
with reduced infarct volume and rescue of behavioral deficit (Vendrame et al., 2004).  
HUCBC infusion has also shown therapeutic benefit in other neuroinflammatory 
conditions including multiple sclerosis, amyotrophic lateral sclerosis, neurodegenerative 
macular degeneration, and Parkinson’s disease (El-Badri et al., 2006; Garbuzova-Davis et 
al., 2006; Henning et al., 2006).  In AD preclinical models, administration of these cells 
to the PSAPP mouse model of AD was associated with extension of lifespan, although 
high doses were administered in this paradigm (Ghorpade et al., 2001). So perhaps a 
proper immunomodulator together with active Aβ vaccine working in tangent could be a 
right step towards future Alzheimer’s disease treatment. 
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CHAPTER TWO 
PERIPHERALLY ADMINISTERED HUMAN UMBILICAL CORD BLOOD 
CELLS REDUCE PARENCHYMAL AND VASCULAR β-AMYLOID DEPOSITS 
AND SUPPRESS CD40-CD40L INTERACTION
 
2.1 Abstract 
 Modulation of immune/inflammatory responses by diverse strategies including 
amyloid-β (Aβ) immunization, non-steroidal anti-inflammatory drugs, and manipulation 
of microglial activation states has been shown to reduce Alzheimer’s disease (AD)-like 
pathology and cognitive deficits in AD transgenic mouse models.  Human cord blood 
cells (HUCBC) have unique immunomodulatory potential, and we wished to test whether 
these cells might alter AD-like pathology after infusion into the PSAPP mouse model of 
AD.  Here, we report a marked reduction of Aβ levels/β-amyloid plaques and associated 
astrocytosis following multiple low dose infusions of HUCBC.  HUCBC infusions also 
reduced cerebral vascular Aβ deposits in the Tg2576 AD mouse model.  Interestingly, 
these effects were associated with suppression of the CD40-CD40L interaction as 
evidenced by decreased circulating and brain soluble CD40L (sCD40L) and elevated 
systemic IgM levels, attenuated CD40L-induced inflammatory responses, and reduced 
surface expression of CD40 on microglia.  Importantly, deficiency of CD40 abolishes the 
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effect of HUCBC on elevated plasma Aβ levels.  Moreover, microglia isolated from 
HUCBC-infused PSAPP mice demonstrated increased phagocytosis of Aβ.  Further, sera 
from HUCBC-infused PSAPP mice significantly increased microglial phagocytosis of 
Aβ1-42 peptide while inhibiting IFN-γ-induced microglial CD40 expression.  Increased 
microglial phagocytic activity in this scenario was inhibited by addition of recombinant 
CD40L protein.  These data suggest that HUCBC infusion confers mitigation of AD-like 
pathology by disrupting CD40L activity. 
 
2.2 Introduction 
Alzheimer’s disease (AD) is the most common progressive dementia, and is 
pathologically characterized by deposition of amyloid-β-peptide (Aβ) in the brain 
parenchyma.  Aβ plaques are potent activators of both microglia and astrocytes, central 
nervous system (CNS)-resident immunocompetent cells that respond to cerebral 
amyloidosis by chronic, pro-inflammatory activation (Benzing et al., 1999).  While it was 
once thought that activation of microglia and astrocytes in the AD brain was an 
epiphenomenon and not a pathoetiological contributor to AD, more recent studies have 
suggested that the Aβ-mediated inflammatory cascade is an etiological perpetrator in AD.  
For example, therapeutic strategies aimed at manipulating this inflammatory cascade, 
including Aβ immunization (Schenk et al., 1999; Bard et al., 2000; Nicoll et al., 2003), 
non-steroidal anti-inflammatory drugs (NSAID) (Matsushima et al., 1994; in t' Veld et 
al., 2001; Szekely et al., 2004), and modulation of microglial activation (Tan et al., 
1999a; Town et al., 2001; Tan et al., 2002b; Todd Roach et al., 2004; Laporte et al., 
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2006), are able to reduce AD-like pathology and improve behavioral impairment in 
Alzheimer’s transgenic mouse models and, in some cases, reduce AD pathology in 
humans. 
We previously showed that the CD40-CD40 ligand (CD40L) interaction plays a 
critical role in Aβ-induced pro-inflammatory microglial activation (Tan et al., 1999a).  
Moreover, we have demonstrated that disruption of this signaling pathway reduces 
cerebral Aβ deposits in the Tg2576 mouse model of AD and improves cognitive deficits 
in PSAPP AD mice (Town et al., 2001; Tan et al., 2002a; Tan et al., 2002b; Todd Roach 
et al., 2004).  The implication of CD40-CD40L interaction in AD-associated brain 
inflammatory process is supported from studies demonstrating increased expression of 
CD40 and CD40L in and around β-amyloid plaques in AD brain (Togo et al., 2000; 
Calingasan et al., 2002).  Recently, Desideri and colleagues (Desideri et al., 2006) 
reported circulating soluble CD40L (sCD40L) levels are significantly increased in AD 
patients vs. healthy elderly controls, further supporting a role for this receptor/ligand dyad 
in the pathogenesis of AD. 
Human umbilical cord blood cells (HUCBC) have been shown to oppose the pro-
inflammatory T helper cell type 1 (Th1) response, as demonstrated in an animal model of 
stroke where HUCBC infusion promoted a strong anti-inflammatory T-helper 2 (Th2) 
response (Vendrame et al., 2004).  Importantly, this effect was associated with reduced 
infarct volume and rescue of behavioral deficit (Vendrame et al., 2004).  HUCBC 
infusion has also shown therapeutic benefit in other neuroinflammatory conditions 
including multiple sclerosis, amyotrophic lateral sclerosis, neurodegenerative macular 
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degeneration, and Parkinson’s disease (El-Badri et al., 2006; Garbuzova-Davis et al., 
2006; Henning et al., 2006).  In AD preclinical models, administration of these cells to 
the PSAPP mouse model of AD was associated with extension of lifespan, although high 
doses were administered in this paradigm (Ghorpade et al., 2001). 
Based on these lines of evidence, we investigated whether multiple low-dose 
administration of HUCBC to AD transgenic mouse models could reduce AD-like 
pathology through suppression of deleterious inflammatory responses involving the 
CD40 pathway.  To address this possibility, we infused both double transgenic PSAPP 
mice and Tg2576 AD mouse models with HUCBC and then examined cerebral 
parenchymal and vascular Aβ levels/deposits, astrocytosis, microgliosis, and CD40 
pathway-associated molecules. 
 
2.3 Materials and methods 
 
2.3.1 Animals and administration of human umbilical cord cells  
HUCBC (95-98% mononuclear cells) were provided by Saneron CCEL 
Therapeutics, Inc. (Tampa, FL).  Transgenic PSAPP (APPswe, PSEN1dE9) and Tg2576 
mice were obtained from the Jackson Laboratory (Jankowsky et al., 2001; Garcia-Alloza 
et al., 2006) and Taconic Inc. (Hsiao et al., 1996), respectively, and were intravenously 
(i.v.) treated with HUCBC (100,000 cells/mouse) or PBS bi-weekly for the first two 
months and monthly for the remaining four months (n = 10/group, 5♂/5♀).  Mice were 
treated starting at 7 months of age (after appreciable Aβ deposits), and blood was 
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collected by sub-mandibular bleeding at 0, 2, 4 and 6 months to monitor plasma 
cytokines, sCD40L and Aβ levels throughout the study.  We analyzed brains of these 
mice for Aβ deposits and gliosis at 13 months of age (when these mice manifest well-
established AD-like pathology, including Aβ deposits and gliosis).  For PSAPP mice 
deficient in CD40, we treated these mice and controls at 8 weeks of age (preliminary 
studies showed that we can clearly detect plasma Aβ levels at this age) with HUCBC.  
Blood samples were collected by sub-mandibular bleeding at the 2nd month after the 
treatment.  Animals were housed and maintained in the College of Medicine Animal 
Facility at the University of South Florida (USF), and all experiments were performed in 
compliance with protocols approved by USF Institutional Animal Care and Use 
Committee. 
 
2.3.2Immunohistochemistry analysis 
Mice were anesthetized with isofluorane and transcardially perfused with ice-cold 
physiological saline containing heparin (10 U/mL).  Brains were rapidly isolated and 
quartered using a mouse brain slicer (Muromachi Kikai, Tokyo, Japan). The first and 
second anterior quarters were homogenized for Western blot analysis, and the third and 
fourth posterior quarters were used for microtome or cryostat sectioning (Tan et al., 
2002a). Brains were then fixed in 4% paraformaldehyde in PBS at 4°C overnight and 
routinely processed in paraffin in a core facility at the Department of Pathology (USF 
College of Medicine).  Five coronal sections from each brain (5 µm thickness) were cut 
with a 150 µm interval [for cingulate cortex (CC) bregma -0.10 mm to -0.82 mm; for 
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entorhinal cortex (EC) and hippocampus (H), bregma -2.92 mm to -3.64 mm].  Sections 
were routinely deparaffinized and hydrated in a graded series of ethanol before 
preblocking for 30 min at ambient temperature with serum-free protein block (Dako 
Cytomation, Carpinteria, CA).  Aβ immunohistochemical staining was performed using 
anti-human amyloid-β antibody (4G8) in conjunction with the VectaStain Elite ABC kit 
(Vector Laboratories, Burlingame, CA) coupled with diaminobenzidine substrate. Congo 
red staining was done according to standard practice using 10% (w/v) filtered Congo red 
dye cleared with alkaline alcohol.  These sections were rinsed three times for 5 min each 
in 70% ethanol, hydrated for 5 min in PBS, and mounted in Vectashield fluorescence 
mounting media (Vector Laboratories).  β-amyloid plaques positive for 4G8 or Congo red 
were visualized under bright field using an Olympus BX-51 microscope.  Aβ burden was 
determined by quantitative image analysis.  Briefly, images of five 5-µm sections (150 
µm apart) through each anatomic region of interest (hippocampus and neocortex) were 
captured and a threshold optical density was obtained that discriminated staining form 
background.  Manual editing of each field was used to eliminate artifacts.  Data are 
reported as percentage of immunolabeled area captured (positive pixels divided by total 
pixels captured).  Quantitative image analysis was performed by a single examiner (TM) 
blinded to sample identities. 
 
2.3.3 Immunofluorescence analysis 
Double immunofluorescence for Aβ and CD40 was performed using rat anti-
mouse CD40 (1:1000; Pharmingen) and rabbit anti-pan Aβ (1:100; Biosource 
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International, Inc) with overnight incubation followed by incubation at ambient 
temperature with goat anti-rat IgG FITC (1:50; PharMingen) and donkey anti-rabbit 
Alexa Fluor555 (1:500; Invitrogen) for 45 min.  Double immunofluorescence for Aβ and 
activated astrocytes was performed using a biotinylated human amyloid-β monoclonal 
antibody (4G8; 1:100, Signet Laboratories, Dedham, MA) and GFAP polyclonal 
antibody (1:500, DAKO).  Normal rabbit, normal mouse serum (isotype control), or 
phosphate buffered saline (PBS, 0.1 M, pH 7.4) were used instead of primary antibody or 
ABC reagent as a negative control.  Quantitative image analysis was done based on a 
previous method (Tan et al., 2002a) with minor modifications.  Images were acquired as 
digitized tagged-image format files to retain maximum resolution using an Olympus 
BX60 microscope with an attached digital camera system (DP-70, Olympus, Tokyo, 
Japan), and digital images were routed into a Windows PC for quantitative analyses using 
SimplePCI software (Compix, Inc. Imaging Systems, Cranberry Township, PA).  The 
cingulate cortex region was captured from the image of the cortex adjacent to the sagittal 
fissure, and the entorhinal cortex region was captured from the image of the cortex 
ventral to the rhinal fissure.  In images from cingulate and entorhinal regions, the cortical 
edge was not included in order to capture the full anatomic region of interest.  The 
hippocampal region was captured from between a portion of the CA1 subfield of the 
pyramidal cell layer and the lacunosum molecular layer.  The anatomical locations and 
boundaries of the regions analyzed were based on those previously defined (Obregon et 
al., 2006).  Images of five 5 µm sections through each anatomic region of interest were 
captured, and a threshold optical density was obtained that discriminated staining from 
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background.  Each anatomic region of interest was manually edited to eliminate artifacts.  
For “burden” analyses, data are represented as percentage of immunolabeled area 
captured (positive pixels) relative to the full area captured (total pixels). 
 
2.3.4 Flow cytometric and Western blot analyses of CD40 expression 
For flow cytometric analysis of microglial CD40 expression, primary cultured 
microglial cells were plated in 6-well tissue culture plates at 5 x 105 cells/well and 
incubated with IFN-γ (100 ng/mL) in the presence or absence of serum derived from 
HUCBC- or PBS-infused individual PSAPP mice.  Twelve hours after incubation, 
microglial cells were washed with flow buffer [PBS containing 0.1% (w/v) sodium azide 
and 2% (v/v) FCS] and re-suspended in 250 µl of ice-cold flow buffer for fluorescence 
activated cell sorting (FACS) analysis, according to methods described previously (Tan et 
al., 1999d).  Briefly, cells were pre-incubated with anti-mouse CD16/CD32 monoclonal 
antibody (clone 2.4G2, PharMingen) for 10 min at 4°C to block non-specific binding to 
Fc receptors.  Cells were then centrifuged at 5,000 x g, washed 3 times with flow buffer, 
and then incubated in flow buffer with hamster anti-mouse CD40-FITC or isotype control 
antibody-FITC (1:100 dilution; PharMingen).  After 30 min incubation at room 
temperature, cells were washed twice with flow buffer, re-suspended in 250 µL of flow 
buffer and analyzed by a FACScanTM instrument (Becton Dickinson).  A minimum of 
10,000 cells were accepted for FACS analysis.  Cells were gated based on morphological 
characteristics using CellQuestTM software (Beckton Dickinson) such that apoptotic and 
necrotic cells were not accepted for FACS analysis.  Percentages of positive (CD40-
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expressing) cells were calculated as follows: for each treatment, the mean fluorescence 
value for the isotype-matched control antibody was subtracted from the mean 
fluorescence value for the CD40-specific antibody. 
For Western immunoblotting analysis of brain CD40 expression, mouse brain 
homogenates were prepared from HUCBC- and PBS-infused PSAPP mice as previously 
described (Tan et al., 2002a).  An aliquot corresponding to 100 µg of total protein of each 
sample was separated by SDS-PAGE and transferred electrophoretically to 
immunoblotting PVDF membranes.  Nonspecific antibody binding was blocked with 5% 
nonfat dry milk for 1 hr at room temperature in Tris-buffered saline (TBS; 20 mM Tris 
and 500 mM NaCl, pH 7.5).  Subsequently, membranes were first hybridized with rabbit 
anti-CD40 antibody (1:1,500 dilution; StressGen) for 2 hrs and then washed 3 times in 
TBS and immunoblotting was by an anti-rabbit HRP-conjugated IgG secondary antibody 
as a tracer.  The luminol reagent was used to develop the blots.  To demonstrate equal 
loading, the same membranes were then stripped with β-mercaptoethanol stripping 
solution (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 100 mM β-mercaptoethanol) and re-
probed with mouse monoclonal antibody to actin.  Densitometric analysis was done as 
previously described (Tan et al., 2002a) using a FluorS Multiimager with Quantity One™ 
software (BioRad). 
 
2.3.5 β and cytokine ELISAs 
Mouse brains were isolated under sterile conditions on ice and placed in ice cold 
lysis buffer as previously described (Tan et al., 2002a).  Brains were then sonicated on ice 
 
 
29 
 
 
 
for approximately 3 minutes, allowed to stand for 15 minutes at 4°C, and centrifuged at 
15,000 rpm for 15 minutes.  This fraction represented the detergent-soluble fraction.  
Detergent-insoluble Aβ1-40, 42 species were further subjected to acid extraction of brain 
homogenates in 5 M guanidine buffer (Johnson-Wood et al., 1997), followed by a 1:5 
dilution in lysis buffer.  Aβ1-40, 42 were detected in brain homogenates prepared with lysis 
buffer or in plasma samples at a 1:10 or 1:5 dilution, respectively, in dilution buffer (PBS 
+ 1% BSA + PMSF).  Aβ1-40, 42 was quantified in these samples using our own Aβ1-40, 42 
ELISA kits (Rezai-Zadeh et al., 2005) and further evaluated with commercially available 
Aβ1-40, 42 ELISA kits (IBL-America) in accordance with the manufacturer’s instructions, 
except that standards included 0.5 M guanidine buffer in some cases to facilitate Aβ 
aggregation. Aβ1-40, 42 were represented as pg/mL of plasma and pg/mg of total protein 
(mean ± SD). 
Cell suspensions of splenocytes from individual mice were prepared as previously 
described (Town et al., 2002) and passed in 0.5 mL aliquots into 24-well plates at 3 
×106/mL.  These cells were treated for 48 hrs with concanavalin A (Con A, 5 µg/mL).  
Supernatants were then collected and assayed by IL-10, TNF-α, and IL-12(p70) cytokine 
ELISA kits in strict accordance with the manufacturer's instruction (R&D Systems).  The 
Bio-Rad protein assay (Bio-Rad) was performed to measure total cellular protein from 
each of the cell groups under consideration just prior to quantification of cytokine release 
by ELISA, and cytokine secretion is expressed as pg/mg total cellular protein (mean ± 
SD).  To verify whether stimulation of splenocytes produced any between-groups 
differences on cell death that might account for altered cytokine profiles, LDH release 
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assay was carried out as described (Town et al., 2002), and LDH was not detected in any 
of the wells studied.  ELISAs for IgM and IgG antibodies were carried out as previously 
described (Nikolic et al., 2007).  Optical densities were determined by a microplate 
reader at 450 nm. The ratio of IgM to IgG was calculated using optical density values and 
then the average ratio for each group was determined (mean ± SD).  Brain tissue-derived 
(from the detergent-soluble brain homogenate fraction) and serum-derived (plasma) 
samples were analyzed for sCD40L (Bener MedSystems Burlingame, CA), IL-4, IL-10, 
IL-2, IFN-γ, TNF-α, IL-1β, IL-12 (p70), and TGF-β cytokines by Bioplex assays (Bio-
Rad Laboratories, Hercules, CA) according to the manufacturer’s protocol.   
 
2.3.6 Microglial phagocytosis assay 
Primary cultures of murine microglia were established as previously described 
(Tan et al., 1999a; Townsend et al., 2005).  For fluorometic analysis of FITC-Aβ1-42, 
primary murine microglia were seeded at 1 x 105 cells/well (n = 6 for each condition) in 
24-well tissue-culture plates containing 0.5 mL of complete RPMI 1640 medium.  These 
cells were treated for 60 min with “aged” Aβ1-42 conjugated with FITC (Biosource 
International) (Townsend et al., 2005).  In the presence of FITC-Aβ1-42, microglia were 
then co-treated with serum (1/200, 1/400, 1/800 dilution) derived from HUCBC- or PBS-
infused individual PSAPP mice in the presence or absence of CD40L protein (2 µg/mL).  
Microglia were rinsed 3 times in Aβ-free complete medium, and media were exchanged 
with fresh Aβ-free complete medium for 10 min both to allow for removal of non-
incorporated Aβ and to promote concentration of the Aβ into phagosomes.  Extracellular 
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and cell associated FITC-Aβ were quantified using an MSF reader (SpectraMax®, 
Molecular Devices) with an emission wavelength of 538 nm and an excitation 
wavelength of 485 nm.  A standard curve from 0 nM to 500 nM of FITC-Aβ was run for 
each plate.  Total cellular proteins were quantified using the Bio-Rad protein assay. The 
mean fluorescence values for each sample were determined by fluorometic analysis.  
Relative fold change values were calculated as the mean fluorescence value for each 
experimental sample over control.  In this manner, both extracellular and cell associated 
FITC-Aβ were quantified.  To determine the extent to which cell death might have 
influenced phagocytic activity in the various treatment groups, we performed LDH 
release assay, and no significant cell death was detected over the 3 h time-frame in any of 
the treatment groups (p > 0.05). 
Primary culture peripheral macrophages were collected from 3-month old wild 
type mice by infusing their peritoneal cavity with ice-cold PBS following a four day i.p. 
immunization with 1mL of 3% (w/v) brewer’s thyoglycollate resuspended in PBS.  Cells 
were pooled following the isolation in order to decrease the variables.  Further, they were 
plated in a culture medium (RPMI-1640; 10% fetal bovine serum and antibiotics) to give 
1.5 × 106 cells/well in 6 well plates. Cells were incubated overnight at 37 °C under 5% 
CO2 in a humidified incubator, and non-adherent cells were removed by washing twice 
with PBS at 37 °C.  Following the removal of non-adherent cells, the remaining cells 
were tested for Aβ phagocytosis as described above with the addition of 1:200, 1:400, 
and 1:800 dilution of sera derived from HUCBC-treated mice, sera derived from PBS-
treated mice, as well as supernatants from cultured HUCBC cells.  
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 2.3.7 Statistical Analysis 
Data are presented as mean ± SD.  All statistics were calculated using one-way 
analysis of variance (ANOVA) for multiple comparisons.  A p value of < 0.05 was 
considered significant.  The statistical package for the social sciences release 10.0.5 
(SPSS Inc., Chicago, Illinois) was used for all data analysis. 
 
2.4 Results 
 
2.4.1 Cerebral parenchymal and vascular β-amyloid plaques are reduced in AD 
transgenic mice peripherally infused with HUCBC 
Previous work in a mouse model of stroke has shown that HUCBC infusion 
results in significant reduction in infarct volume as well as rescue of behavioral deficits 
associated with decreased pro-inflammatory cytokine production (Vendrame et al., 2004).  
We sought to determine whether HUCBC (95-98% mononuclear cells) infusion could 
impact Aβ-associated pathology in PSAPP double transgenic mice.  These animals were 
intravenuously (i.v.) injected with HUCBC (100,000 cells/mouse) beginning at 7 months 
of age (when β-amyloid deposits have already accumulated).  At 13 months of age, mice 
were sacrificed and evaluated for changes in AD-like pathology.  We chose to administer 
multiple low doses of HUCBC because, in our pilot studies, we observed that this 
strategy was superior compared to a single high dose of HUCBC on reducing cerebral 
amyloidosis in Tg2576 mice (data not shown).  HUCBC infusion in PSAPP mice resulted 
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in marked reduction of cerebral β-amyloid pathology as assayed by Aβ antibody (4G8) 
immunohistochemistry (Figure 1A) and Congo red histochemistry (Figure 1C).  
Quantitative image analysis revealed statistically significant differences for each brain 
region examined (P < 0.001) between PSAPP mice infused with HUCBC 
(PSAPP/HUCBC) and PSAPP mice peripherally infused with PBS (PSAPP/PBS) for 
both Aβ antibody (Figure 1B) and Congo red staining (Figure 1D).  Furthermore, ELISA 
analysis of brain extracts showed that levels of both detergent-soluble and -insoluble Aβ1-
40, -42 peptides were reduced in PSAPP mice infused with HUCBC (by 62% and 70%, 
respectively; Figure 1E).  A t-test for independent samples revealed significant between-
groups differences for each group examined (P < 0.001). 
Given that peripheral administration of HUCBC reduces cerebral parenchymal 
Aβ deposits and brain Aβ levels in PSAPP mice, we wished to investigate the impact of 
HUCBC infusion on cerebral amyloid angiopathy (CAA), which is characterized by Aβ 
deposits in the cerebral vasculature and is known to occur in 83% of AD patients (Ellis et 
al., 1996).  For this analysis, we used the Tg2576 mouse model of AD, which is known to 
manifest copious Aβ deposits in cerebral vessels at 15 to 20 months of age (Kaul et al., 
2000; Christie et al., 2001; Li et al., 2003; Friedlich et al., 2004; Robbins et al., 2006).  
We peripherally infused these mice with HUCBC or controls (PBS vehicle treatment or 
no treatment) (n = 10, 5♂/5♀ per group) at 12 months of age using the identical 
procedure above.  Six months thereafter, these mice were sacrificed for analyses of 
cerebral parenchymal or vascular β-amyloid deposits by Congo red histochemistry.  As 
shown in Figure 1F, Tg2576 mice receiving HUCBC treatment demonstrated reduction 
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of both cerebral parenchymal and vascular Congo red deposits compared with controls.  
Quantitative image analysis revealed statistically significant differences between 
Tg2576/HUCBC and Tg2576/PBS or non-treated control groups when examining total 
(78%), vascular (86%), or parenchymal (74%) Congo red staining (P < 0.001; Figure 
1G).  No significant difference was revealed between Tg2576/PBS and non-treated 
Tg2576 control mice (P > 0.05).  In addition, we also analyzed cerebral Aβ levels/β-
amyloid deposits by Aβ ELISA and Aβ antibody immunohistochemistry, and we 
obtained statistically significant results similar to those observed in HUCBC-infused 
PSAPP mice (P < 0.001; data not shown).
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Figure 1 
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Figure 1. Cerebral Aβ/β-amyloid pathology is reduced in PSAPP and Tg2576 mice 
peripherally infused with HUCBC.  Mouse paraffin-embedded coronal brain sections 
from the cingulate cortex (CC), hippocampus (H), and entorhinal cortex (EC) were 
stained with monoclonal human Aβ antibody, (A) 4G8 or (C) Congo red.  Percentages 
(plaque area/total area) of (B) Aβ antibody-immunoreactive deposits or of (D) Congo 
red-stained deposits were calculated by quantitative image analysis (mean ± SD; n = 10, 
5♀/5♂ per group).  (E) Aβ ELISA analysis was carried out for both levels of detergent-
soluble Aβ1-40, 42 (top panel) or 5 M guanidine-extracted Aβ1-40, 42 (bottom panel).  Data 
are represented as mean ± SD of Aβ1-40, 42 (pg/mg protein).  Mouse paraffin-embedded 
coronal brain sections from hippocampal regions of Tg2576 mice were stained with (F) 
Congo red. Positions of the hippocampal subfields CA1, CA3, and dentate gyrus (DG) 
are indicated in the upper left panel.  Arrows indicate Aβ deposit-affected vessels.  (G) 
Percentages (% labeled area) of Congo red-stained plaques/vessels were quantified by 
image analysis (mean ± SD; n = 10, 5♀/5♂), and percentage reduction is indicated. 
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2.4.2 Reduced CD40-positive microglia and GFAP-positive astrocytes in PSAPP mice 
peripherally infused with HUCBC 
It has previously been suggested that brain inflammation resulting from activated 
microglia and astrocytes contributes to β-amyloid plaque formation (Frackowiak et al., 
1992; Potter et al., 2001), and we have previously shown that ligation of microglial CD40 
enables activation in response to Aβ peptides (Tan et al., 1999a; Tan et al., 1999b; Tan et 
al., 1999c).  To investigate whether HUCBC could inhibit brain inflammation, we 
examined co-localization of β-amyloid deposits with CD40-positive microglia [an in vivo 
microgliosis marker (Togo et al., 2000)] or reactive [glial fibrillary acidic protein 
(GFAP)-positive] astrocytes by immunohistochemistry and Western blot analyses in 
PSAPP mice.  As shown in Figure 2A, CD40-positive microglial cells were reduced in 
the PSAPP/HUCBC-infused group.  Quantitative image analysis revealed statistically 
significant reductions when comparing PSAPP/HUCBC-infused and PSAPP/PBS-
infused groups for both Aβ and CD40 staining in hippocampal dentate gyrus and CA1 
regions (**P < 0.001) (Figure 2B).  Western blot analysis of CD40 expression showed a 
statistically significant decrease in brain homogenates from HUCBC-infused PSAPP 
mice (P < 0.001) (Figure 2C).  Furthermore, immunohistochemistry/histochemistry and 
immunofluorescence analyses showed reductions in β-amyloid-associated astrocytosis in 
PSAPP/HUCBC mice vs. PSAPP/PBS-treated mice (Figure 2D), and morphometry 
revealed reductions for neocortex and hippocampus by 84% and 86%, respectively in 
PSAPP/HUCBC mice (P < 0.001) (Figure 2E). 
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Figure 2 
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Figure 2. β-amyloid associated microgliosis and astrocytosis are reduced in HUCBC 
infused-PSAPP mice.  (A) Immunofluorescence was performed on mouse brain coronal 
paraffin sections prepared from PSAPP mice infused with HUCBC or PBS.  Red signal 
indicates Aβ positive (top panels); green indicates CD40 positive (middle panels), and 
merged images (bottom panels) reveal co-localization of CD40 and Aβ. DAPI (blue) was 
used as a nuclear counterstain.  (B) Immunofluorescence intensity for Aβ and CD40 was 
determined.  (C) Western blot analysis shows reduced CD40 expression in brain 
homogenates from PSAPP/HUCBC vs. PSAPP/PBS mice as indicated (actin was used as 
an internal reference control).  Densitometry analysis shows the ratio of CD40 to actin as 
indicated below the figure.  (D) Immunohistochemistry analysis shows GFAP and Aβ 
double staining (top panel), and immunofluorescence (bottom panel) reveals co-
localization of GFAP (red signal) and Aβ (green signal).  (E) Morphometric analysis 
results (mean GFAP/β-amyloid double positive plaques per mouse ± SD) are shown for 
the neocortex and the hippocampus of PSAPP/HUCBC vs. PSAPP/PBS mice.  Percent 
reduction of plaques double positive for GFAP and Aβ in PSAPP/HUCBC mice is 
indicated. 
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2.4.3 Increased plasma Aβ levels correlate with decreased CD40-CD40L interaction in 
HUCBC-infused PSAPP mice 
We have previously shown that administration of neutralizing CD40L antibody to 
PSAPP mice results in increased levels of plasma Aβ concomitant with reduced cerebral 
Aβ/β-amyloid pathology, suggesting that depletion of CD40L promotes brain-to-blood 
clearance of Aβ  (Tan et al., 2002a).  It is well-known that the CD40-CD40L interaction 
promotes pro-inflammatory Th1 and opposes anti-inflammatory Th2 immune responses 
(Grewal and Flavell, 1998; Mackey et al., 1998).  In addition, HUCBC treatment has 
been shown to be an immunoregulator in an animal model of stroke (Vendrame et al., 
2004; Newman et al., 2006).  We investigated whether reduction of cerebral Aβ levels/β-
amyloid deposits in HUCBC-infused PSAPP mice might 1) result from increased brain-
to-blood clearance of Aβ,  and 2) be associated with suppression of the pro-inflammatory 
CD40-CD40L interaction.  We probed individual blood samples from PSAPP mice 
infused with HUCBC or PBS for Aβ1-40, 42 and soluble CD40L (sCD40L).  ELISA 
revealed increased plasma Aβ1-40, 42 levels in PSAPP/HUCBC mice which inversely 
correlated with decreased levels of plasma sCD40L in these animals (Figures 3A-C).  
One-way ANOVA followed by post hoc comparison revealed significant differences 
between PSAPP/HUCBC-infused and PSAPP/PBS-infused mice for plasma Aβ1−40, 42 
levels and plasma sCD40L levels at each time point indicated (Figures 3A-C) (**P 
<0.001).   It is well established that CD40-CD40L interaction on B cells is required for 
IgM to IgG antibody class switching.  Therefore, we went on to evaluate the functional 
consequence of HUCBC-mediated suppression of the CD40-CD40L interaction on IgM 
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and IgG titers in mouse blood samples obtained at the time of sacrifice.  ELISA data 
revealed a significantly increased ratio of IgM to IgG in PSAPP/HUCBC mice when 
compared to control (Figure 3D, *P < 0.05), suggesting that the CD40 signaling pathway 
is functionally suppressed in HUCBC-infused PSAPP mice.  It has been recently reported 
that CD40 deficiency in APP transgenic mice confers a decrease in Aβ/β-amyloid loads 
(Laporte et al., 2006).  Although to a lesser extent than PSAPP/CD40+/+ mice, we also 
found PSAPP/CD40-/- mice do clearly manifest β-amyloid deposits (data not shown), 
allowing us to test whether administration of HUCBC to PSAPP/CD40-/- mice resulted in 
further amelioration of amyloidosis in these animals.  Thus, we treated PSAPP/CD40-/- at 
8 weeks of age with HUCBC or PBS (control) and assayed circulating Aβ levels, which 
correlate with cerebral amyloid levels in transgenic AD mice (DeMattos et al., 2002a).  
Results indicate no further benefit of HUCBC in PSAPP/CD40-/- mice on enhanced Aβ 
plasma levels (Figures 3E and F; P > 0.05), a presumed indicator of Aβ brain-to-blood 
efflux.  These data suggest that HUCBC mediate beneficial effects on reduction of 
amyloidosis via reducing CD40 pathway bioactivity, and are consistent with our previous 
studies showing that genetic or pharmacologic ablation of CD40-CD40L interaction 
mitigates AD-like pathology in transgenic mice (Tan et al., 1999a; Tan et al., 2002a).   
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Figure 3 
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Figure 3. HUCBC infusion results in CD40-dependent increased plasma Aβ levels in 
PSAPP mice.  ELISA analysis results are shown from blood (plasma) for (A) Aβ1-40, (B) 
Aβ1-42, (C) sCD40L, and (D) IgM/IgG.  Data are presented as mean ± SD (n = 10) for 
Aβ1-40, Aβ1-42 or sCD40L (pg/mL plasma).  Arrows below the panels show the time for 
each peripheral infusion with HUCBC or PBS.  (D) data are presented a ratio of IgM to 
IgG in blood (plasma) from mice at the 6th month following the treatment.  Aβ ELISA 
analysis for (E) Aβ1-40 and (F) Aβ1-42 in blood (plasma) derived from PSAPP/CD40+/+ or 
PSAPP/CD40-/- mice at the 2nd month following the third HUCBC infusion.  Data in (E 
and F), are presented as mean ± SD (n = 4, 2 ♂/2♀) of Aβ1-40 or Aβ1-42 (pg/mL plasma). 
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We hypothesized that, if HUCBC mediated reduced amyloidosis by reducing 
CD40 pathway activity, this should be associated with a shift from pro- to anti-
inflammatory cytokines in HUCBC-infused PSAPP mice.  Consistent with this 
hypothesis, we found that plasma levels of the anti-inflammatory cytokines IL-4 and IL-
10 were increased in HUCBC-infused PSAPP mice (Figure 4A, **P < 0.001).  
Furthermore, primary splenocytes from HUCBC-infused PSAPP mice showed reduced 
pro-inflammatory TNF-α and IL-12 (p70) and increased anti-inflammatory IL-10 
secretion.  We also analyzed brain cytokine levels by ELISA, and results showed 
statistically significant increases in anti-inflammatory TGF-β1 and IL-10 levels in 
PSAPP/HUCBC-infused mouse brain homogenates (Figures 4B and C; **P < 0.001).  
Consistent with our data showing reduction in circulating sCD40L after HUCBC 
treatment, we also measured sCD40L in brain homogenates and found a significant 
decrease in PSAPP/HUCBC mice compared to control (Figure 4D, **P < 0.001). 
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Figure 4 
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Figure 4. HUCBC infusion promotes anti-inflammatory/Th2 responses and decreases 
sCD40L in the CNS.  ELISA results are shown for (A) plasma-derived, (B) splenocyte 
culture-derived, (C) brain tissue derived cytokines, and (D) brain tissue derived sCD40L.  
Data are presented as mean ± SD (n = 10) values of cytokines (pg/mL plasma or medium) 
(D and E), or fold increase of cytokines over control (untreated) mice (C and D). 
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2.4.4 HUCBC inhibit microglial CD40 expression and enhance in vitro phagocytosis of 
Aβ peptides 
We and others have previously shown that microglial CD40 expression is 
important for CNS inflammatory responses (Tan et al., 1999a; Tan et al., 1999b; Tan et 
al., 1999c; Togo et al., 2000; Calingasan et al., 2002; Tan et al., 2002a; Tan et al., 2002b), 
and IFN-γ is a strong inducer of microglial CD40 expression (Carson et al., 1998; Tan et 
al., 2000; Sokol et al., 2006).  In order to investigate whether a soluble factor secreted 
following HUCBC infusion could modulate microglial expression of CD40, we treated 
primary microglial cells with serum from HUCBC- or PBS-infused individual PSAPP 
mice in the presence of IFN-γ (100 ng/mL) for 8 hrs.  We then examined CD40 
expression by FACS analysis.  As shown in Figure 5A, sera derived from HUCBC-
infused PSAPP mice significantly inhibited IFN-γ-induced microglial CD40 expression 
compared to controls (P < 0.001).  However, this effect was not directly mediated by 
HUCBC or human adult mononuclear cells (HAMNC), but was rather due to a soluble 
circulating factor produced by HUCBC-infused PSAPP mice (Figure 5A). 
We and others have shown that stimulation of microglial CD40 results in 
impaired Aβ phagocytic activity (Townsend et al., 2005) and promotion of microgial 
neurotoxic inflammatory responses (Ponomarev et al., 2006).  Thus, we wished to 
examine whether HUCBC could enhance microglial phagocytosis of Aβ peptide.  We 
prepared primary cultures of adult microglia from HUCBC- and PBS-infused PSAPP 
mice according to previously described methods (Lue and Walker, 2002), and then 
subjected these cells to Aβ phagocytosis assay using native or Aβ antibody-opsonized 
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fluorescent-tagged Aβ1-42 (FITC-Aβ1-42) according to our previously described methods 
(Townsend et al., 2005).  As shown in Figure 5B, when measuring FITC-tagged Aβ1-42 in 
cell supernatants or lysates, one-way ANOVA followed by post-hoc comparison showed 
a significant increase in Aβ uptake by microglia derived from HUCBC- vs. PBS-infused 
PSAPP mice (**P < 0.001).  Interestingly, the presence of Aβ IgG [2.5 
µg/mL;(Townsend et al., 2005)] significantly enhanced Aβ uptake by PSAPP/HUCBC- 
vs. PSAPP/PBS-derived microglial cells (##P < 0.001).  Given that sera from HUCBC-
infused PSAPP mice suppressed IFN-γ-induced microglial CD40 expression, we wished 
to test if the sera could increase microglial Aβ phagocytosis.  We incubated primary 
cultures of neonatal microglia with serum from individual PSAPP/HUCBC- vs. 
PSAPP/PBS mice at 1:200, 1:400, and 1:800 dilutions in the presence of FITC-Aβ1-42.  
We found that sera at the 1:200 dilution markedly enhanced microglial phagocytosis of 
Aβ1-42 peptide, which was opposed by the presence of recombinant mouse CD40L 
protein at 2 µg/mL (Figure 5C). 
In addition, we wished to test if sera-derived HUCBC-treated mice could increase 
peripheral macrophage phagocytic activity.  We incubated both sera derived from 
HUCBC and PBS-treated animals at 1:200, 1:400, and 1:800 dilutions with primary 
macrophage cells from wild-type mice in six-well tissue-culture plates in the presence of 
300 nM FITC-Aβ1-42 as described above.  We found that sera at the 1:200 dilution 
significantly enhanced macrophage phagocytosis of Aβ1-42 peptide (Figure 5D) (**P < 
0.01 with n = 4 for each mouse group presented).  However these effects were not 
observed in cultured HUCBC media (data not shown). 
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Figure 5 
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Figure 5. HUCBC modulate microglial CD40 expression and promote Aβ 
microglial/macrophage phagocytic activity.  (A) FACS analysis for CD40 expression in 
primary wild-type neonatal microglial cells treated with cultured medium from HUCBC 
or human adult mononuclear cells (HAMNC), or serum from individual PSAPP/HUCBC 
or PSAPP/PBS mice following IFN-γ challenge.  Data are presented as percentage of 
CD40 expressing cells (mean ± SD; n = 5).  (B,C,D) Microglial/macrophage 
phagocytosis assay results for extracellular and cell-associated FITC-Aβ1-42, which was 
detected using a fluorometer.  Data are represented as the relative fold of mean (± SD) 
fluorescence over control for each sample (n = 4 for each condition presented).  Primary 
microglial cells from (B) adult PSAPP/HUCBC or PSAPP/PBS mice, (C) wild-type 
neonatal microglia, and (D) primary peripheral macrophage. 
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2.5 Discussion 
Based on genetic, biochemical, and post-mortem evidence, Aβ peptides are key 
etiological contributors to AD pathogenesis (Hardy and Selkoe, 2002).  In addition to 
parenchymal Aβ deposits, deposition of Aβ in the cerebral vasculature (known as CAA) 
is a pathological feature of AD, and occurs with 83% frequency in AD patients (Ellis et 
al., 1996; Hardy and Selkoe, 2002; Jellinger, 2002; Green et al., 2005). Aβ has been 
shown to mediate pro-inflammatory and neurodegenerative changes, and oligomeric 
forms of the peptide are neurotoxic (Malinin et al., 2005). It is well-documented that 
brain inflammatory mechanisms mediated by reactive glia are activated in response to Aβ 
plaques (Benzing et al., 1999; Eikelenboom and van Gool, 2004; Rozemuller et al., 2005; 
Townsend et al., 2005).  Expression profiles of two such pro-inflammatory molecules, 
CD40 and CD40L, are markedly increased in and around Aβ plaques in AD patients and 
in mouse models of the disease (Togo et al., 2000; Calingasan et al., 2002), and genetic 
or pharmacologic blockade of CD40-CD40L interaction reduces AD-like pathology in 
transgenic AD mice (Tan et al., 2002a), suggesting an etiologic role of this 
receptor/ligand dyad in the disease (Town et al., 2001; Tan et al., 2002b).  In a recent 
clinical report, it was found that circulating sCD40L levels are significantly increased in 
AD patients (Desideri et al., 2006), suggesting that peripheral as well as brain 
dysregulation of the CD40 pathway occurs in AD.  We have previously shown that CD40 
ligation promotes pro-inflammatory activation of microglia and reduces microglial 
phagocytosis of Aβ peptide in vitro (Tan et al., 1999a; Townsend et al., 2005), supporting 
a mechanistic explanation for reduced AD-like pathology after blocking the CD40-
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CD40L interaction (Tan et al., 2002b). 
HUCBC have been shown to down-regulate pro-inflammatory Th1 response in an 
animal model of stroke (Vendrame et al., 2004), and have also shown therapeutic benefit 
in other neuroinflammatory/neurodegenerative conditions (El-Badri et al., 2006; 
Garbuzova-Davis et al., 2006; Henning et al., 2006).  Based on this evidence, we sought 
to examine their putative therapeutic value in mitigating AD-like pathology in transgenic 
mice.  After HUCBC infusion, treated mice exhibited diminished cerebral Aβ/β-amyloid 
pathology and down-regulation of pro-inflammatory responses in the brain and in the 
periphery.  Based on the conspicuous role of CD40-CD40L interaction in mediating brain 
pro-inflammatory response and exacerbating AD-like pathology, we investigated whether 
HUCBC-mediated reduction of AD-like pathology might be associated with alteration in 
this receptor/ligand dyad.  Our results show decreased expression of microglial CD40 and 
reduction in both CNS and peripheral sCD40L concomitant with HUCBC-induced 
diminished AD-like pathology, raising the possibility that disruption of CD40-CD40L 
interaction may be responsible for mitigation of AD-like pathology in this scenario.  To 
directly address this hypothesis, we treated PSAPP mice deficient for CD40 with 
HUCBC and assayed circulating Aβ levels as a marker of brain-to-blood Aβ efflux, and 
results showed no further benefit of HUCBC in these mice. 
Here, we demonstrate that infusion of the HUCBC mononuclear fraction into 
PSAPP and Tg2576 mice results in reduced levels of both soluble and insoluble brain 
Aβ1-40, 42 concomitant with increased plasma Aβ1-40, 42 levels.  Past studies have suggested 
brain-to-blood clearance mechanisms that selectively remove Aβ from the brain, 
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potentially reducing Aβ levels in normal as well as AD patient brains (Shibata et al., 
2000; DeMattos et al., 2002a; DeMattos et al., 2002b; Shiiki et al., 2004; Crossgrove et 
al., 2005).  Experiments in rat models demonstrating clearance of Aβ1-40 peptide from the 
brain via the blood-brain-barrier (BBB) support this notion (Shibata et al., 2000; Shiiki et 
al., 2004; Terasaki and Ohtsuki, 2005).  Vascular endothelial cells, which are important 
BBB constituents, express CD40 (Suo et al., 1998; Tan et al., 1999d; Town et al., 2001; 
Sokol et al., 2006), and we now show that sCD40L is reduced in blood plasma from 
HUCBC-treated PSAPP mice, raising the possibility that interruption of CD40-CD40L 
interaction at the level of cerebrovascular endothelial cells may promote brain-to-blood 
clearance of Aβ.  Further, reduced circulating sCD40L levels in HUCBC-treated PSAPP 
mice raises the possibility that inflammatory cytokines produced by CD40-CD40L 
interaction on endothelial cells are reduced, and this idea is consistent with our finding of 
a shift towards anti-inflammatory cytokines in the CNS after HUCBC infusion.  
Interestingly, we also demonstrate that CAA [which is present in 83% of AD patients 
(Ellis et al., 1996)] is reduced by 68% after HUCBC treatment in Tg2576 AD mice.  This 
result shows that reduction in parenchymal Aβ does not come at the cost of increased 
vascular Aβ deposits, unlike a model in which transforming growth factor-β1 
overexpression reduces parenchymal plaques but increases vascular Aβ deposits (Wyss-
Coray et al., 1997; Wyss-Coray et al., 2001). 
In vitro HUCBC studies have shown that these cells secrete soluble factors that 
have beneficial effects (Vendrame et al., 2005; Newman et al., 2006).  For example, 
supernatants from cultured HUCBC promote survival of NT2 neural cells and peripheral 
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blood mononuclear cells cultured under conditions designed to induce cell stress and 
limit protein synthesis (El-Badri et al., 2006).  Additionally, HUCBC have been shown to 
produce a number of neurotrophic factors and cytokines that modulate inflammatory 
responses, including nerve growth factor, colony stimulating factor-1, thrombopoietin, 
and IL-11 (Suen et al., 1994; McGowan et al., 1999; Vendrame et al., 2004).  Previous 
reports have shown that HUCBC entry into the brain is not required to promote 
neuroprotection (Borlongan et al., 2004), and that recovery following brain injury is 
mediated through peripheral responses (Townsend et al., 2005).  We did not detect 
infiltration of HUCBCs into brain parenchyma, either at 4 hrs after HUCBC 
administration or at the time of mouse sacrifice (data not shown), making it unlikely that 
these cells were directly involved in ameliorating cerebral amyloidosis.  Therefore, we 
hypothesized that a soluble factor produced after HUCBC infusion in the periphery was 
responsible for reduced AD-like pathology and inflammatory response.  To test this, we 
1) measured cytokines in blood plasma, spleen, and brains from HUCBC- or PBS-treated 
PSAPP mice, 2) evaluated the impact of sera from these treated mice on IFN-γ-induced 
microglial CD40 expression, and 3) assayed Aβ phagocytosis in vitro in neonatal 
microglia treated with sera from HUCBC/PSAPP or PBS/PSAPP mice and in adult 
microglial cultures derived from these mice.  Results generally show a shift from pro-
inflammatory Th1-type cytokines towards anti-inflammatory Th2 cytokines in tissues 
from HUCBC-treated PSAPP mice.  Further, sera from HUCBC-treated mice are able to 
reduce microglial CD40 expression and enhance Aβ phagocytosis by these cells.  Finally, 
adult microglia from HUCBC-treated PSAPP mice have increased capacity to 
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phagocytose Aβ.   
When taken together, the above results suggest that, in addition to promoting 
brain-to-blood Aβ efflux, HUCBC infusion promotes production of a peripheral anti-
inflammatory soluble factor that is likely able to cross the BBB and affect microglial Aβ 
clearance.  Previous reports have show that soluble factors, including heat-shock proteins 
and pro-inflammatory cytokines, are capable of modulating Aβ phagocytosis by 
microglia (Kakimura et al., 2002; Koenigsknecht-Talboo and Landreth, 2005), and our 
previous work has shown that microglial CD40-CD40L interaction retards Aβ 
phagocytosis/clearance (Townsend et al., 2005).  Non-saturable BBB transport 
mechanisms have been described for a number of cytokines including TNF-α (which is 
transported via TNF receptors) and IL-1, and other soluble factors such as leukemia 
inhibitory factor, chemoattractant-1, and epithelial growth factor (Quan and Banks, 
2007).  Thus, it remains possible that soluble factors produced by the host in response to 
HUCBC treatment gain access to the brain via the BBB and encounter microglia.  
Ultimately, we propose that infused HUCBCs exert their effect on reducing cerebral 
amyloidosis by causing the host to secrete a soluble factor that acts by reducing sCD40L-
CD40 interaction on microglia, which then promotes microglial clearance of Aβ.  This 
mechanism is supported by our observations of 1) reduced brain levels of sCD40L in 
HUCBC-infused PSAPP mice, 2) reduced CD40 expression on microglia cultured in the 
presence of HUCBC-infused PSAPP mouse sera, 3) increased Aβ phagocytosis/removal 
by microglia cultured in the presence of HUCBC-infused PSAPP mouse sera or cultured 
from adult PSAPP/HUCBC mice, and 4) our previous observations that microglial CD40 
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ligation shifts these cells away from a Aβ phagocytic phenotype and towards a pro-
inflammatory response (32). Future studies designed to identify this soluble factor are 
warranted, and may yield additional pharmacotherapeutic target(s).  Additionally, our 
observation of no further therapeutic benefit of HUCBCs when administered to 
PSAPP/CD40-/- mice establishes a CD40 pathway-dependent mechanism for HUCBC 
therapeutic benefit on reduction of cerebral amyloidosis.  These results dovetail with our 
previous studies showing that CD40-CD40L interaction mitigates AD-like pathology in 
transgenic mice (Tan et al., 1999a; Tan et al., 2002a). 
It was recently shown that peripheral macrophages are able to infiltrate the brain 
and limit cerebral amyloidosis in AD mice after irradiation, suggesting that 
hematogenously-derived macrophages are efficient at phagocytosing and clearing Aβ 
deposits (Simard et al., 2006).  However, earlier studies have shown that brain-resident 
microglia are also able to phagocytose/clear Aβ (Paresce et al., 1996; Paresce et al., 1997; 
Chung et al., 1999).  We did not detect the presence of brain infiltrating macrophages in 
the current experimental paradigm.  Specifically, we stained for CD40 (a marker for both 
macrophages and microglia), and noted the presence of process-bearing cells that 
morphologically resembled microglia in and around Aβ plaques (see Figure 2A).  Also, 
we did not observe vascular “cuffing” that would suggest the presence of infiltrating 
macrophages that are frequently observed in other CNS inflammatory conditions such as 
experimental autoimmune encephalomyelitis (Imrich and Harzer, 2001).  Furthermore, 
our results provide evidence that both primary culture microglia and macrophages posses 
the ability for enhanced Aβ phagocytosis following in vitro stimulation with sera derived 
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from HUCBC-treated animals.   This too is consistent with peripheral immunomodulation 
of CD40-CD40L interaction by HUCBC treatment.  Additionally, given the difficulties 
inherent to discriminating macrophages from microglia, and the ability of peripheral 
macrophages to engraft into the CNS and take up a microglial phenotype after brain 
injury (Priller et al., 2001), it remains possible that peripheral macrophages may 
contribute to reduced cerebral amyloidosis after HUCBC treatment. 
In this report, we have shown that HUCBC infusion ameliorates AD-like 
pathology, including reductions in 1) cerebral Aβ levels/β-amyloid pathology, 2) CAA, 
and 3) brain inflammation including CD40-positive activated microglia and GFAP-
positive activated astrocytes.  These effects of HUCBCs were associated with increased 
brain-to-blood efflux of Aβ and a shift from pro-inflammatory Th1 to anti-inflammatory 
Th2 cytokines both in the brain and in the periphery, similar to what we observed after 
Aβ immunization (Town et al., 2002; Town et al., 2005a; Town et al., 2005b).  Further, 
HUCBC infusion of PSAPP mice reduces both CNS and circulating sCD40L levels, and 
sera from these mice is able to promote microglial Aβ phagocytosis.  When taken 
together, our results provide the basis for a novel immunomodulatory strategy for AD 
using HUCBC. 
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3.1 Abstract 
Amyloid-β (Aβ) immunization efficiently reduces amyloid plaque load and 
memory impairment in transgenic mouse models of Alzheimer’s disease (AD) (Schenk et 
al., 1999; Morgan et al., 2000).  Active Aβ immunization has also yielded favorable 
results in a subset of AD patients (Hock et al., 2003).  However, a small percentage of 
patients developed severe aseptic meningoencephalitis associated with brain 
inflammation and infiltration of T-cells (Nicoll et al., 2003; Orgogozo et al., 2003).  We 
and others have shown that blocking the CD40-CD40 ligand (L) interaction mitigates 
Aβ-induced inflammatory responses and enhances Aβ clearance (Tan et al., 2002b; 
Townsend et al., 2005).  Here, we utilized genetic and pharmacologic approaches to test 
whether CD40-CD40L blockade could enhance the efficacy of Aβ1-42 immunization, 
while limiting potentially damaging inflammatory responses.  We show that genetic or 
pharmacologic interruption of CD40-CD40L interaction enhanced Aβ1-42 immunization 
efficacy to reduce cerebral amyloidosis in the PSAPP and Tg2576 mouse models of AD.  
Potentially deleterious pro-inflammatory immune responses, cerebral amyloid angiopathy 
(CAA) and cerebral microhemorrhage were reduced or absent in these combined 
approaches. Pharmacologic blockade of CD40L decreased T-cell neurotoxicity to Aβ-
producing neurons.   Further reduction of cerebral amyloidosis in Aβ-immunized PSAPP 
mice completely deficient for CD40 occurred in the absence of Aβ immunoglobulin G 
(IgG) antibodies or efflux of Aβ from brain to blood, but was rather correlated with anti-
inflammatory cytokine profiles and reduced plasma soluble CD40L.  These results 
suggest CD40-CD40L blockade promotes anti-inflammatory cellular immune responses, 
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likely resulting in promotion of microglial phagocytic activity and Aβ clearance while 
precluding generation of neurotoxic Aβ-reactive T-cells.  Thus, combined approaches of 
Aβ immunotherapy and CD40-CD40L blockade may provide for safer and more 
effective Aβ vaccine. 
 
3.2 Introduction 
Amyloid-β (Aβ), a proteolytic product of amyloid precursor protein (APP),  is a 
key molecule in the pathogenesis and progression of Alzheimer’s disease (AD) (Blennow 
et al., 2006).  Overproduction of soluble and aggregated Aβ species drives cerebral 
amyloidosis including β-amyloid plaque formation, a hallmark pathological feature of 
AD.  Thus, methods developed to clear or prevent formation of Aβ in the brains of AD 
patients represent a possible treatment modality.  One promising approach involves 
utilization of “active” Aβ immunization strategies, which produce dramatic reductions in 
Aβ pathology in animal studies (Schenk et al., 1999).  However, a phase IIa clinical trial 
was abandoned after about 6% of Aβ-immunized AD patients developed aseptic 
meningoencephalitis (Nicoll et al., 2003; Orgogozo et al., 2003) that appeared to involve 
brain inflammatory reactions mediated by T-cells and microglia (Monsonego et al., 2001; 
Schenk and Yednock, 2002; Greenberg et al., 2003; Monsonego et al., 2003).  
Interestingly, a 12 month post-vaccination period analysis revealed an inverse correlation 
between titers of amyloid plaque-reactive antibodies and rate of cognitive decline (Hock 
et al., 2003), suggesting clinical efficacy.  Despite the discontinuation of the clinical 
trials, Aβ vaccination studies have continued in effort to identify an immunization 
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approach that is both safe and effective.  Current approaches have focused on minimizing 
T-cell mediated inflammatory responses in efforts to prevent CNS invasion of auto-
aggressive T-cells, while promoting Aβ antibody-mediated clearance mechanisms 
(Chackerian et al., 2006; Maier et al., 2006; Okura et al., 2006; Nikolic et al., 2007). 
A possible avenue to both enhance Aβ clearance and down-regulate CNS inflammatory 
responses (including invasion of reactive T-cells) involves modulation of the CD40 
receptor (CD40)-CD40 ligand (CD40L) system.  CD40 is a ~ 45-50 kDa cell surface 
molecule, which is a member of the tumor necrosis factor-α (TNF-α)/nerve growth factor 
(NGF) receptor super-family.  In the periphery, a variety of innate immune cells known 
as antigen-presenting cells (APCs) express CD40, including dendritic cells, B-cells, and 
monocytes/macrophages.  In the CNS, CD40 is expressed by resident cells including 
microglia, neurons, and astrocytes, as well as by peripherally-derived APCs (Tan et al., 
2002a; Town et al., 2005).  CD40L (also known as CD154), is expressed as a membrane-
anchored molecule by activated T-cells and astrocytes, and can also be secreted as a 
smaller soluble protein (van Kooten and Banchereau, 2000).  The CD40-CD40L 
interaction acts as an accessory co-stimulatory pathway involved in key immune cell 
processes including: activation, maturation/differentiation, growth/proliferation, and 
regulation of apoptosis (Town et al., 2001a).   
We have previously shown that CD40 ligation is a molecular trigger for pro-
inflammatory microglial activation in response to Aβ peptides (Tan et al., 1999).  
Further, genetic or pharmacologic blockade of the CD40-CD40L interaction reduces β-
amyloid pathology in the brains of transgenic mouse models of AD (Tan et al., 1999; Tan 
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et al., 2002a). Increased CD40 and CD40L immunoreactivity has been found in and 
around β-amyloid plaques in AD brain (Togo et al., 2000; Calingasan et al., 2002), 
further suggesting that CD40-CD40L interaction may contribute to Aβ and β-amyloid 
plaque pathology.  
Recently, the CD40-CD40L interaction was determined to play a central role in 
promoting and maintaining dendritic cell APC phenotype during infections (Straw et al., 
2003).  In the context of CNS immunity, the CD40-CD40L interaction is required for 
microglial maturation into functional APCs (Ponomarev et al., 2006).  We have recently 
shown that CD40L treatment of primary cultures of microglia inhibits phagocytosis of 
Aβ antibody opsonized, as well as non-opsonized Aβ species (Townsend et al., 2005). 
Associated with reduced Aβ phagocytic capacity, CD40L treatment up-regulated cell 
surface markers indicative of an APC phenotype including CD45, CD86, MHC II, and 
promoted the release of pro-inflammatory molecules including interleukin (IL)-1β and 
TNF-α (Townsend et al., 2005).  Thus, CD40-CD40L interaction may act as a molecular 
switch necessary to drive pro-inflammatory microglial APC phenotype maturation at the 
cost of reducing phagocytosis (Townsend et al., 2005; Ponomarev et al., 2006).  
Additionally, blockade of the CD40-CD40L system down-regulates T-cell/microglia-
mediated injury in the context of experimental autoimmune encephalitis (EAE) (Howard 
et al., 1999; Howard et al., 2002).  Altogether, these studies suggest that blockade of the 
CD40-CD40L interaction could enhance Aβ vaccination-mediated Aβ clearance 
mechanisms, while minimizing pro-inflammatory T-cell-mediated damage in the CNS.   
To investigate this hypothesis, we studied transgenic “PSAPP” mice overexpressing 
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mutant human presenilin-1 (DeltaE9), and “Swedish” mutant human APP (APPSwe), 
which develop AD-like pathology (Jankowsky et al., 2001).  We took a genetic approach 
to CD40 blockade by crossing these mice with CD40-/- mice to yield: CD40 wild-type 
(PSAPP), CD40 heterozygous deficient (PSAPP/CD40+/-), and CD40 homozygous 
deficient (PSAPP/CD40-/-) animals.  We then vaccinated these mice over a course of 4 
months utilizing aggregated Aβ1-42 peptide or vehicle.  We also took a pharmacologic 
approach by administering CD40L neutralizing antibody to Aβ1-42-vaccinated PSAPP 
mice.  Results from both strategies showed enhanced reduction of cerebral amyloidosis as 
evidenced by reductions in Aβ load, β-amyloid plaque burden, and cerebral amyloid 
angiopathy (CAA).  Moreover, we report reduced cerebral microhemorrhage and 
inflammatory immune responses as measured by cytokine analysis and T-cell induced 
neurotoxicity to Aβ producing neurons.  These results were associated with inhibition of 
microglial APC phenotype.  Interestingly, homozygous CD40 deficient Aβ1-42-
immunized PSAPP mice displayed reduced cerebral amyloidosis in the absence of 
immunoglobulin G (IgG) antibodies or efflux of Aβ from brain to blood.  These effects 
were correlated with reduced plasma CD40 ligand (CD40L) and increased anti-
inflammatory cytokine levels.  Altogether these data suggest that disruption of the CD40-
CD40L interaction enhances Aβ1-42-immunization mediated Aβ clearance mechanisms by 
promoting anti-inflammatory cellular immunity to support microglial clearance of Aβ.  
 
3.3 Materials and methods 
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3.3.1 Reagents 
Anti-human Aβ monoclonal antibody (4G8) was purchased from Signet 
Laboratories.  Aβ1-42 peptide was obtained from Biosource International (Camarillo, CA). 
Aβ1-42 peptide was added to 0.9% saline (4 mg/mL), vortexed, and incubated for 24 h at 
37º C.  This solution was aliquoted, frozen and stored at −80º C.  Immediately prior to 
use, Aβ1-42 aliquots were thawed and then mixed with adjuvant or PBS at 1:1 (v/v). 
Complete and incomplete Freund's adjuvant were purchased from Sigma.  DuoSetTM 
enzyme-linked ELISA kits (including TNF-α, transforming growth factor-β1 (TGF-β1), 
IL-1β, and IL-10) were obtained from R&D Systems (Minneapolis, MN).  Purified rat 
anti-mouse MHC class II antibody was obtained from PharMingen (San Diego, CA).  
Congo red and concanavalin A (Con A) were obtained from Sigma.  Aβ1-40 and Aβ1-42 
ELISA kits were purchased from IBL-America (Minneapolis, MN).  Murine IgG and 
HRP-conjugated goat anti-mouse IgG were obtained from Pierce Biotechnology, Inc. 
(Rockford, IL).  Goat anti-mouse IgM peroxidase conjugate antibody (A8786) was 
obtained from Sigma.    
 
3.3.2 Mice 
Wild-type C57BL/6, PSAPP mice (APPSwe, PSEN1dE9) and CD40 deficient 
(CD40-/-) mice were all obtained from Jackson Laboratories (Bar Harbor, ME).  We 
crossed CD40-/- mice with PSAPP mice and characterized offspring by polymerase chain 
reaction-based genotyping for the mutant APP construct and mutant presenilin1 (PS1) 
gene (to examine PSAPP status) and neomycin selection vector (to type for CD40 
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deficiency), followed by Western blot for brain APP and splenic CD40 protein, 
respectively.  Animals were housed and maintained under specific pathogen-free 
conditions in the College of Medicine Animal Facility at the University of South Florida, 
and all experiments were in compliance with protocols approved by the University of 
South Florida Institutional Animal Care and Use Committee.  The animals that we 
studied were PSAPP/CD40+/+, PSAPP/CD40+/-, PSAPP/CD40-/-, CD40-/-, and their 
littermates.  All of the mice included did not develop infections or neoplasms during the 
duration of this study. 
 
3.3.3 Immunization strategies 
For our genetic approach to CD40-CD40L blockade, we crossed PSAPP and 
CD40-/- mice and, at 8 months of age, divided them into groups consisting of Aβ1-42 or 
vehicle (PBS)-vaccinated CD40-/- and wild-type mice (n = 8 for each group, 4♂/4♀), or 
PSAPP/CD40+/+ (PSAPP/CD40+/+/Aβ1-42, PSAPP/CD40+/+/PBS), PSAPP/CD40+/- 
(PSAPP/CD40+/-/Aβ1-42, PSAPP/CD40+/-/PBS), or PSAPP/CD40-/- (PSAPP/CD40-/-/Aβ1-
42, PSAPP/CD40-/-/PBS) mice (n = 16 for each group, 8♂/8♀).  Immunization of these 
mice was performed at regular time intervals in a similar fashion to the methods 
described by Schenk et al. (Schenk et al., 1999).  Briefly, 8 month-old mice were injected 
with Aβ1-42 (100 µg/mouse) or PBS emulsified in monophosphoryl lipid A (detoxified 
endotoxin) from S. minnesota (MPL) and synthetic trehalose dicorynomycolate (TDM) 
biweekly until 9 months of age, and monthly injection with Aβ1-42 or PBS alone was 
performed thereafter.   
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For our pharmacologic approach to CD40-CD40L blockade, we studied 8 month-
old PSAPP mice divided into five groups (n = 16 for each group, 8♂/8♀) as follows: 
PBS-treated Aβ1-42 immunized PSAPP mice (PSAPP/Aβ1-42/PBS), CD40L antibody-
treated Aβ1-42 immunized PSAPP mice (PSAPP/Aβ1-42/CD40L antibody), Isotype control 
IgG-treated Aβ1-42 immunized PSAPP mice (PSAPP/Aβ1-42/IgG antibody), or CD40L 
antibody-treated non- Aβ1-42 immunized PSAPP mice (PSAPP/CD40L antibody).  We 
immunized these mice with Aβ1-42 as described above and treated them with CD40L 
antibody (200 µg/mouse) based on our previous report (Tan et al., 2002a).  For all mice, 
blood samples were collected from the sub-mandibular vein just before immunization and 
then on a monthly basis thereafter 1-2 days prior to the succeeding monthly injection 
(except the final collection, which was taken one month after the final injection) 
throughout the course of immunization, and mice were sacrificed at 12 months of age.  
 
3.3.4 Measurement of plasma IgG and IgM Aβ antibodies by ELISA 
Aβ antibodies in individual mouse plasma and brain homogenates were measured 
in duplicate according to previously described methods (Maier et al., 2005).  Briefly, 
human Aβ1-42 peptide was coated at 1 µg/mL in 50 mM carbonate buffer, pH 9.6 (coating 
buffer) on 96-well immunoassay plates overnight at 4º C.  The plates were washed with 
0.05% Tween 20 in PBS (washing buffer) five times and blocked with blocking buffer 
(PBS with 1% BSA, 5% horse serum) for 2 hrs at room temperature.  Murine IgG or IgM 
was serially diluted in coating buffer (1,000-0 µg/mL) to generate a standard curve.  
Mouse plasma and brain homogenate samples were diluted in blocking buffer at 
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concentrations ranging from 1:400 to 1:102,400, added to the plates, and incubated for 2 
hrs at room temperature.  After 3 washes with washing buffer, a detection antibody 
(HRP-conjugated goat anti-mouse IgG, or HRP-conjugated goat anti-mouse IgM was 
diluted  at 1:4,000), added to the plates and incubated for 1 hr at 37º C.  Following 4 
washes, tetramethylbenzidine substrate was added to the plates and incubated for 15 min 
at room temperature.  Fifty µL of stop solution (2 N H2SO4) was added to each well of 
the plates.  The optical density of each well was immediately determined by a microplate 
reader at 450 nm.  Aβ antibody data are reported as µg per mL of plasma (mean ± SD).   
 
3.3.5 Measurement of Aβ species from plasma and brain homogenates by ELISA 
Mouse brains were isolated under sterile conditions on ice and placed in ice-cold 
lysis buffer (containing 20 mM Tris, pH 7.5, 150 mM NaCl, 1mM EDTA, 1 mM EGTA, 
1% v/v Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM 
Na3VO4, 1 µg/mL leupeptin, 1 mM PMSF) as previously described (Rezai-Zadeh et al., 
2005).  Brains were then sonicated on ice for approximately 3 min, allowed to stand for 
15 min at 4°C, and centrifuged at 15,000 rpm for 15 min.  Aβ1-40 and Aβ1-42 species were 
detected by a 2-step extraction protocol, similar to previously published methods 
(Johnson-Wood et al., 1997; Rezai-Zadeh et al., 2005).  Detergent-soluble Aβ1-40 and 
Aβ1-42 were directly detected in plasma and brain homogenates prepared with lysis buffer 
described above by a 1:4 or 1:10 dilution, respectively.  Total Aβ1-40 and Aβ1-42 species 
were detected by acid extraction of brain homogenates in 5 M guanidine buffer, followed 
by a 1:10 dilution in lysis buffer.    Aβ1-40 and Aβ1-42 were quantified in individual 
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samples in duplicate using Aβ1-40 and Aβ1-42 ELISA kits in accordance with the 
manufacturer’s instructions (IBL-America), except that standards included 0.5 M 
guanidine buffer in some cases.  Aβ1-40 and Aβ1-42 are represented as pg per mL of plasma 
or pg per mg of total protein (mean ± SD). 
 
3.3.6 Brain and plasma cytokine analysis 
Enzyme-linked immunoabsorbance assay (ELISA) for detection of IL-1β, IL-10, 
TGF-β1, or TNF-α was carried out for measurement of cytokines in mouse blood plasma, 
or brain.  Tissues were obtained at the time of sacrifice, and were diluted in PBS and 
assayed using the kits described above in strict accordance with the manufacturer's 
instruction (R&D Systems).  The Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, 
CA) was performed to measure total cellular protein from each sample prior to 
quantification of cytokine release by ELISA, and cytokine secretion is expressed in 
pg/mg total protein.  
 
3.3.7 Histology 
Mice were anesthetized with isofluorane and transcardially perfused with ice-cold 
physiological saline containing heparin (10 U/ml). Brains were rapidly isolated and 
quartered using a mouse brain slicer (Muromachi Kikai, Tokyo, Japan).  The first and 
second anterior quarters were homogenized for Western blot analysis, and the third and 
fourth posterior quarters were used for microtome or cryostat sectioning as previously 
described (Tan et al., 2002a).  Brains were then fixed in 4% paraformaldehyde in 0.9% 
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saline at 4°C overnight and routinely processed in paraffin in a core facility at the 
Department of Pathology (University of South Florida College of Medicine).  Five 
coronal sections from each brain (5 µm thickness) were cut with a 150 µm interval.  
Paraffin sections were routinely deparaffinized and hydrated in a graded series of ethanol.  
All sections were pre-blockading for 30 min at ambient temperature with serum-free 
protein block (Dako Cytomation, Carpinteria, CA).  
Aβ immunohistochemical staining was performed using anti-human amyloid-β 
antibody (clone 4G8; 1:100; Signet Laboratories) in conjunction with the VectaStain Elite 
ABC kit (Vector Laboratories, Burlingame, CA) coupled with the diaminobenzidine 
substrate.  For microglia/macrophage immunostaining (MHC II, Iba, and CD45), sections 
were prepared as described above.  Following pre-blocking, sections were treated 
overnight with anti-mouse MHC II (1:500) Iba (1:100) or CD45 (1:500) antibodies 
diluted in PBS  (obtained from Santa Cruz (O'Keefe et al., 2002)), incubated with HRP-
conjugated anti-mouse IgG, and developed.  For congo red histochemistry, sections were 
routinely deparaffinized and rinsed in 70% (v/v) ethanol before staining with fresh-
filtered 1% (w/v) congo red diluted in 70% ethanol for 5 min. These sections were rinsed 
three times for 5 min each in 70% ethanol, hydrated for 5 min in 0.9% saline, and 
mounted. β-amyloid plaques and reactive microglia were visualized using an Olympus 
BX-51 microscope (Olympus, Tokyo, Japan). 
Quantitative image analysis was performed for 4G8 immunohistochemistry and 
congo red histochemistry.  Images were obtained using an Olympus BX-51 microscope 
and digitized using an attached MagnaFire™ imaging system (Olympus, Tokyo, Japan).  
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Briefly, images of five 5-µm sections (150 µm apart) through each anatomic region of 
interest (hippocampus or cortical areas) were captured and a threshold optical density was 
obtained that discriminated staining form background.  Manual editing of each field was 
used to eliminate artifacts.  Data are reported as percentage of immunolabeled area 
captured (positive pixels) divided by the full area captured (total pixels).  Quantitative 
image analysis was performed by a single examiner (TM) blinded to sample identities.   
 
3.3.8 Splenocyte cultures 
Cell suspensions of splenocytes from individual mice were prepared as previously 
described (Town et al., 2001b; Town et al., 2002) and passed in 0.5 mL aliquots into 24-
well plates at 3 × 106 cells/mL.  These cells were cultured for 48 h in the presence or 
absence of Con A (5 µg/mL), or Aβ1-42 (20 µg/mL).  Supernatants were then collected 
and assayed by IFN-γ, IL-2, and IL-4 cytokine ELISA kits in strict accordance with the 
manufacturer's instruction (R&D Systems).  The Bio-Rad protein assay (Bio-Rad 
Laboratories, Hercules, CA) was performed to measure total cellular protein from each 
well prior to quantification of cytokine release by ELISA, and cytokine secretion is 
expressed in pg/mg total cellular protein (mean ± SD).  To verify whether stimulation of 
splenocytes produced any between-groups differences on cell death that might account 
for altered cytokine profiles, LDH release assay was carried out as described (Townsend 
et al., 2005) and LDH was not detected in any of the wells studied. 
 
3.3.9 Aβ-specific lymphocyte neurotoxicity assay 
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Primary cultured neuronal cells were used as target cells in 51Cr release assay for 
Aβ-specific lymphocyte neurotoxicity (Tan et al., 1999).  We co-cultured primary 
neuronal cells from PSAPP mice or their littermates with CD3+ T-cells (including CD4+ 
and CD8+ T-cells) isolated from primary cultures of splenocytes derived from Aβ1-42/IgG- 
or Aβ1-42/CD40L antibody-treated PSAPP mice as described above.  As in our previous 
studies (Tan et al., 1999; Town et al., 2002), primary neuronal cells were labeled with 
51Cr as target cells and co-cultured with T-cells as effectors.  Four hour-51Cr release assay 
was then carried out.  Total release represents the radioactivity released after lysis of 
target cells with 5% Triton X-100.     
 
3.3.10 Statistical analysis 
All data were normally distributed; therefore, in instances of single mean 
comparisons, Levene’s test for equality of variances followed by t-test for independent 
samples was used to assess significance.  In instances of multiple mean comparisons, 
analysis of variance (ANOVA) was used, followed by post-hoc comparison using 
Bonferroni’s method.  Alpha levels were set at 0.05 for all analyses.  The statistical 
package for the social sciences release 10.0.5 (SPSS Inc., Chicago, Illinois) was used for 
all data analysis.           
 
3.4 Results 
 
3.4.1 CD40 deficiency modulates Aβ antibody production after Aβ vaccination 
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It is well-established that B-cells require CD40 engagement by T-cell-derived 
CD40L to produce IgG antibodies in response to vaccination (Kawabe et al., 1994; 
Bishop and Hostager, 2003).  To determine the effects of Aβ1-42 vaccination on Aβ 
antibody production in the absence of CD40 expression, strain- and gender-matched 
CD40 deficient (CD40-/-) and wild type mice (n = 8 per group, 4♂/4♀) were immunized.  
We employed a four-month vaccination strategy according to modified previous methods 
(Schenk et al., 1999) utilizing synthetic aggregated Aβ1-42 peptide or PBS with 
MPL/TDM as adjuvant.  Mouse plasma samples were collected monthly over this four-
month vaccination period and subjected to ELISA for measurement of Aβ antibodies.  
Results indicated potent Aβ IgG production in wild-type mice, whereas CD40-/- mice 
produced no detectable Aβ IgG (Figure 6A, top panel).  While CD40-/- mice did not 
produce detectable Aβ IgG, they did produce Aβ IgM that was not significantly different 
from wild-type mice [98.56 ± SD 7.45 vs. 86.98 ± SD 12.09 (µg/mL at 1 month after the 
first immunization). 
To investigate the impact of CD40 deficiency on Aβ1-42 vaccination-induced 
humoral immune responses in a  mouse model of AD, we vaccinated 8 month-old PSAPP 
mice  with three CD40 genotypes  (PSAPP/CD40+/+, PSAPP/CD40+/-, and PSAPP/CD40-
/-) with either Aβ1-42 or vehicle (PBS).  Blood samples from all mice were individually 
collected once monthly over the four month vaccination period.  As expected, Aβ1-42 
vaccinated PSAPP/CD40-/- mice demonstrated no detectable Aβ IgG, whereas 
PSAPP/CD40+/- and PSAPP/CD40+/+ mice produced similar increases in Aβ antibodies 
throughout the four-month Aβ1-42 vaccination program (Figure 6A, bottom panel).    
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3.4.2 Increased plasma Aβ1-40 and Aβ1-42 in heterozygous CD40 deficient PSAPP mice 
after Aβ vaccination  
Activation of Aβ efflux from the CNS to the systemic circulatory system is a 
well-recognized clearance mechanism underlying Aβ vaccination in AD mouse models 
(Sigurdsson et al., 2002; Lemere et al., 2003).  To determine the effect of partial or 
complete CD40 deficiency on activation of Aβ efflux after Aβ1-42 vaccination, we 
separately measured plasma Aβ1-40 and Aβ1-42 species by ELISA monthly over the four-
month vaccination period.  Importantly, PSAPP/CD40+/-/Aβ1-42 mice exhibited 
dramatically increased plasma Aβ1-40 and Aβ1-42 compared to PSAPP/CD40-/-/Aβ1-42 
animals at the time points analyzed (Figure 6B, P < 0.001), pointing to a shift in Aβ load 
from the CNS to the systemic circulation in this group.  PSAPP/CD40-/-/Aβ1-42 mice 
displayed very low levels of plasma Aβ species, similar to unvaccinated mouse groups. 
The lack of elevated Aβ plasma levels in PSAPP/CD40-/-/Aβ1-42 mice can most likely be 
explained by the absence of Aβ IgG in this mouse group, as homozygous CD40 
deficiency conferred absence of Aβ IgG production to either Aβ species (Figure 6A, 
bottom panel).  Interestingly, PSAPP/CD40+/-/Aβ1-42 mice displayed similarly elevated 
plasma levels of Aβ1-40 and Aβ1-42 when compared with the PSAPP/CD40+/+/Aβ1-42 mouse 
group (P > 0.05).  These data further suggest that Aβ IgG production may be required for 
Aβ efflux from the CNS to the periphery in this vaccination paradigm.   
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Figure 6 
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Figure 6.  Evaluation of the effects of CD40 deficiency on Aβ antibody generation and 
Aβ efflux in Aβ1-42-immunized mice.  Peripheral blood samples were collected monthly 
throughout the four-month Aβ immunization course.  (A) The graph shows antibody 
levels for wild-type vs. CD40-/- mice (top panel) and PSAPP mice deficient for CD40 vs. 
appropriate controls as indicated (bottom panel) following Aβ1-42 vaccination.  
PSAPP/CD40+/+/Aβ1-42 and PSAPP/CD40+/-/Aβ1-42  mice produced similar elevations in 
Aβ IgG antibodies, in contrast to PSAPP/CD40-/-/Aβ1-42, PSAPP/CD40+/+/PBS, 
PSAPP/CD40+/-/PBS, and PSAPP/CD40-/-/PBS mice that produced undetectable levels of 
Aβ IgG antibodies.  Data are presented as mean ± SD of plasma Aβ antibodies (µg/mL).  
(B)  Plasma Aβ1-40 and Aβ1-42 peptides were measured separately by ELISA.  Data are 
represented as mean ± SD of Aβ1-40 (top panel) or Aβ1-42 (bottom panel). 
PSAPP/CD40+/+/Aβ1-42 and PSAPP/CD40+/-/Aβ1-42 mice produced similar elevations in 
plasma Aβ1-40 and Aβ1-42, in contrast to PSAPP/CD40-/-/Aβ1-42, PSAPP/CD40+/+/PBS, 
PSAPP/CD40+/-/PBS, and PSAPP/CD40-/-/PBS mice that produced minimal levels of 
plasma Aβ1-40 and Aβ1-42. 
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3.4.3 Reduced cerebral Aβ1-40 and Aβ1-42 in heterozygous CD40 deficient PSAPP mice 
vaccinated with Aβ1-42
As shown in Figure 7, results revealed that Aβ1-42 vaccination of mice completely 
(PSAPP/CD40-/-) and partially (PSAPP/CD40+/-) deficient for CD40 yielded decreased 
amounts of soluble (top panels) and insoluble (bottom panels) Aβ1-40 and Aβ1-42 in brain 
homogenates as measured by ELISA.  Most importantly, a significantly greater reduction 
in both soluble and insoluble Aβ1-40 and Aβ1-42 levels was evident in the PSAPP/CD40+/-
/Aβ1-42 group compared to either PSAPP/CD40+/+/Aβ1-42 or PSAPP/CD40-/-/Aβ1-42 
groups (*P < 0.05; **P < 0.001).  We further observed that β-amyloid histopathology 
was also markedly reduced in the PSAPP/CD40+/-/Aβ1-42 group as determined by Aβ 
antibody immunohistochemical analysis (Figure 8A), and congo red staining (Figure 8B) 
of mouse coronal brain sections from Aβ vaccinated mice.  Quantitative analysis of 
results revealed significantly reduced Aβ antibody- and congo red-positive β-amyloid 
plaque burden in each brain region examined from PSAPP/CD40+/-/Aβ1-42 mice as 
compared to either PSAPP/CD40+/+/Aβ1-42 or PSAPP/CD40-/-/Aβ1-42 groups (Figure 8C, 
**P < 0.001).  Together, these data indicate that CD40 heterozygosity confers the 
greatest reduction in Aβ load in PSAPP mice when compared to all other groups 
following Aβ1-42 vaccination, and suggest that partial disruption of CD40 signaling could 
maximize Aβ1-42 vaccination efficacy.
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Figure 7
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Figure 7.  Cerebral Aβ levels are significantly reduced in Aβ1-42-immunized PSAPP 
mice heterozygous for CD40.  Detergent-soluble Aβ1-40 and Aβ1-42 (A) and insoluble (5M 
guanidine-soluble) Aβ1-40 and Aβ1-42 peptides (B) were measured separately in brain 
homogenates by ELISA.  Data are presented as mean ± SD of Aβ1-40 or Aβ1-42 (pg/mg 
protein).  
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 Figure 8 
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Figure 8.  β-amyloid pathology is reduced in Aβ1-42-immunized PSAPP mice 
heterozygous for CD40.  Mouse coronal brain sections were embedded in paraffin and 
stained with monoclonal human Aβ antibody (A), or were stained with congo red (B), 
and the hippocampus is shown.  (C) Percentages [plaque area/total area; mean ± SD with 
n = 16 mice (8♂/8♀)] of Aβ antibody-immunoreactive Aβ plaques (top panel) and congo 
red-positive Aβ deposits (bottom panel) were calculated by quantitative image analysis 
for each brain region (CC/H: cingulate cortex and hippocampus; EC: entorhinal cortex) 
as indicated. 
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Interestingly, Aβ plaque reduction in PSAPP/CD40-/-/Aβ1-42 mice was 
significantly reduced when compared to PSAPP/CD40+/+/Aβ1-42, or PSAPP/CD40-/-/PBS 
groups (Figure 8C, *P < 0.05).  These data are additionally supported by ELISA analyses 
of both soluble and insoluble Aβ1-40 and Aβ1-42 in brain homogenates (Figure 7), and 
suggest other mechanisms besides Aβ IgG production, such as cellular immune 
responses, might be involved in the observed reductions of cerebral Aβ/β-amyloid in 
PSAPP mice after Aβ1-42 vaccination.  
 
3.4.4 Aβ1-42 vaccination results in markedly increased anti-inflammatory cytokines and 
reduced plasma soluble CD40L in PSAPP/CD40-/- mice 
Due to the observed lack of Aβ IgG antibodies in PSAPP/CD40-/- mice following 
Aβ1-42 vaccination, we wished to investigate whether cellular immune responses could be 
involved in the reductions of cerebral Aβ and β-amyloid deposits in these animals.  To 
test this hypothesis, we performed ELISA to examine anti-inflammatory cytokine profiles 
in brain homogenates from PSAPP/CD40+/+, PSAPP/CD40+/-, and PSAPP/CD40-/- mice 
vaccinated with either Aβ1-42 or vehicle (PBS).  As shown in Figure 9A, analysis of data 
revealed significantly (**P <0.001) elevated expression of brain IL-10 from either 
PSAPP/CD40-/-/Aβ1-42 or PSAPP/CD40-/+/Aβ1-42 mice compared to PSAPP/CD40+/+/Aβ1-
42  mice, but not for IL-1β ( P >0.05).  Moreover, we found a significant decrease in 
plasma soluble CD40L (sCD40L) when comparing PSAPP/CD40-/-/Aβ1-42 to either 
PSAPP/CD40+/+/Aβ1-42 or PSAPP/CD40-/-/PBS mice (**P <0.001, Figure 9B).  Reduced 
sCD40L in PSAPP/CD40-/-/Aβ1-42 compared to PSAPP/CD40+/+/Aβ1-42 mice occurred in 
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the absence of significantly different levels of Aβ IgM antibodies (data not shown).  
These data indicate that reductions in cerebral Aβ after Aβ1-42 vaccination of 
PSAPP/CD40-/-/PBS mice is associated with a rise in the anti-inflammatory cytokines IL-
4, IL-10 and TGF-β1, and a decrease in plasma sCD40L levels.   
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Figure 9 
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Figure 9.  PSAPP/CD40-/- mice have increased anti-inflammatory IL-10 cytokine and 
decreased plasma soluble CD40L (sCD40L) after Aβ1-42 vaccination.  (A) ELISA 
analysis of cytokine levels in brain homogenates from the indicated mouse groups.  Data 
are presented as mean ± SD of each cytokine (pg/mg total protein).  (B) ELISA for 
plasma sCD40L levels in the indicated mouse groups.  Data are presented as mean ± SD 
of plasma sCD40L protein (pg/mL). 
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3.4.5 Neutralizing CD40L antibody increases circulating Aβ1-40 and Aβ1-42 levels and 
reduces cerebral amyloidosis in Aβ1-42 vaccinated PSAPP and Tg2576 mice 
To determine whether pharmacologic inhibition of CD40-CD40L interaction 
might produce a similar effect as genetic disruption on enhancing Aβ1-42 vaccination 
efficacy, we administered neutralizing CD40L antibody to PSAPP mice in combination 
with active Aβ1-42 vaccination described in “Materials and Methods.”  Blood samples 
were individually collected from all mice at a monthly time interval.  Similar to the 
effects observed in Aβ1-42 vaccinated PSAPP/CD40+/- mice, Aβ1-42 vaccinated PSAPP 
mice treated with CD40L antibody displayed elevations in plasma levels of Aβ1-40 and 
Aβ1-42 and Aβ IgG antibodies that did not significantly differ from Aβ1-42 vaccinated 
PSAPP mice injected with an isotype-matched IgG control antibody (Figure 10A, top to 
bottom, respectively).  The PSAPP/Aβ1-42/CD40L antibody and PSAPP/Aβ1-42/IgG 
groups produced greater plasma levels of Aβ1-40 and Aβ1-42 species and Aβ antibodies 
than either PSAPP mice receiving PBS or treatment with CD40L antibody alone, 
confirming that 1) immunization of this cohort of animals was successful and 2) 
neutralizing CD40L did not hamper Aβ antibody production (Figure 10A).  Additionally, 
no significant differences were revealed for either plasma Aβ1-40 and Aβ1-42 levels or Aβ 
antibodies when comparing PSAPP/Aβ1-42/IgG to PSAPP/Aβ1-42 groups (P > 0.05; data 
not shown). 
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 Figure 10 
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Figure 10.  Peripheral and cerebral Aβ levels are reduced in Aβ1-42-immunized PSAPP 
mice treated with CD40L neutralizing antibody.  (A) ELISA analysis for plasma levels of 
Aβ1-40 and Aβ1-42 and Aβ antibodies.  Plasma Aβ1-40 (top panel) and Aβ1-42 (middle panel) 
were measured separately by ELISA.  PSAPP/Aβ1-42/CD40L antibody and PSAPP/Aβ1-
42/IgG mice produced similar elevations in plasma Aβ1-40 and Aβ1-42, in contrast to 
PSAPP/CD40L antibody and PSAPP/PBS mice which produced minimal levels of 
plasma Aβ1-40 and Aβ1-42.  Data are represented as mean ± SD of Aβ1-40 or Aβ1-42 (pg/mL) 
in plasma.  Aβ antibody levels (bottom panel) were measured by ELISA.  PSAPP/Aβ1-
42/CD40L antibody and PSAPP/Aβ1-42/IgG mice produced similar elevations in plasma 
Aβ IgG antibodies in contrast to PSAPP/CD40L antibody and PSAPP/PBS mice which 
had undetectable levels of plasma Aβ IgG antibodies.  Data are presented as mean ± SD 
of Aβ antibodies (µg/mL) in plasma.  No significant difference in Aβ antibody levels 
between PSAPP/Aβ1-42/CD40L antibody and PSAPP/Aβ1-42/IgG mice (P > 0.05) was 
observed.  (B) Soluble Aβ1-40 and Aβ1-42 peptides (top panel) and insoluble Aβ1-40 and 
Aβ1-42 (bottom panel) in brain homogenates were measured separately by ELISA.  Data 
are presented as mean ± SD of Aβ1-40 or Aβ1-42 peptides normalized to total protein 
(pg/mg). 
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tivity could reduce CAA following Aβ vaccination in the Tg2576 mouse model 
of AD.  Since Tg2576 mice are known to produce CAA pathology at 15 to 20 months of 
age (Christie et al., 2001; Li et al., 2003; Friedlich et al., 2004; Kim et al., 2007), we 
initiated i.p. injection of these mice with CD40L antibody at 12 months of age (n = 16, 
8♂/8♀) in conjunction with active Aβ1-42 immunization using an identical procedure as 
described above.  Four months later, we sacrificed these mice and examined CAA.  As 
We next examined the effect of neutralizing CD40L antibody on cerebral Aβ 
levels in PSAPP mice vaccinated with Aβ1-42.  ELISA analysis revealed that PSAPP/Aβ1-
42/CD40L antibody mice display significantly reduced amounts of cerebral soluble and 
insoluble Aβ1-40 and Aβ1-42 peptides as compared with PSAPP/Aβ1-42/IgG, 
PSAPP/CD40L antibody, or PSAPP/PBS groups (**P < 0.001; Figure 10B).  
Furthermore, PSAPP/Aβ1-42/CD40L antibody mice showed a marked reduction in 
cerebral Aβ deposits compared to PSAPP/Aβ1-42/IgG mice or other control groups (**P < 
0.001; Figs. 11A –C).  These data show additional reduction in cerebral Aβ and β-
amyloid in the context of Aβ1-42 vaccination provided by pharmacologic blockade of 
CD40-CD40L interaction.   
Together, these data demonstrate that disruption of the CD40-CD40L interaction 
by 1) a genetic approach or 2) pharmacologic depletion of available CD40L by 
neutralizing antibody enhances reduction of cerebral amyloidosis after Aβ1-42 
vaccination.  Recent studies have show  CAA and cerebral microhemorrhage o en oc
in AD mice following intraperitoneal injection (i.p) active or passive Aβ vaccination 
(Wilcock et al., 2004; Wilcock et al., 2007).   Thus, we next investigated if disruptio
CD40L ac
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 shown nly 
β1-42/CD40L 
on, we also 
and 
0L 
1-42 
mpared to Aβ1-42-alone-immunized mice (P < 0.001; data 
not sho
in Figs. 11D – E, disruption of CD40L activity by the depleting antibody not o
promotes additional reduction in total congo red after Aβ1-42 vaccination, but also further 
reduces vascular congo red signal.  This was confirmed by statistical analysis, which 
revealed significant differences between Tg2576/Aβ1-42/IgG and Tg2576/A
antibody groups (**P < 0.001) for both total and vascular congo red.  In additi
analyzed cerebral Aβ levels/β-amyloid deposits in these two groups by Aβ ELISA 
immunochemistry.  Similar to the effects observed in Aβ1-42/CD40L antibody-vaccinated 
PSAPP mice, Tg2576 mice receiving both Aβ1-42 immunization and depleting CD4
antibody displayed a marked decrease in cerebral soluble and insoluble Aβ1-40 and Aβ
levels and β-amyloid load co
wn).        
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Figure 11 
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Figure 11.  Cerebral β-amyloid deposits and cerebral amyloid angiopathy are reduced in 
Aβ1-42-immunized PSAPP or Tg2576 mice treated with CD40L neutralizing antibody.  
Mouse paraffin-embedded coronal brain sections from were stained with rabbit Pan-β-
amyloid antibody (A) or with congo red (B), and the hippocampus is shown.  (C) 
Percentages (plaque area/total area; mean ± SD) of Aβ antibody-immunoreactive deposits 
(top panel) or of congo red-stained sections (bottom panel) were calculated by 
quantitative image analysis.  (D) Tg2576 received Aβ1-42 vaccination plus neutralizing 
CD40L antibody or isotype-matched control IgG both Aβ1-42, and brain sections were 
stained with congo red (hippocampus is shown).  Positions of the hippocampal subfields 
CA1, CA3, and DG (dentate gyrus) are indicated in the upper left panel.  Arrows indicate 
Aβ deposit-affected vessels.  (E)  Percentages (% of area) of congo red-stained plaques 
were quantified by image analysis [mean ± SD with (n = 16, 8♂/8♀)]. 
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mitigated APC-like microglia, we fluorescently labeled brain sections with MHC II and 
CD45 antibodies.  As shown in Figure 12C, Iba1 positive microglial cells were largely 
positive for CD45 and MHC II in Aβ1-42/IgG immunized PSAPP mice, but not in Aβ1-42 
and CD40L antibody co-immunized PSAPP mice.  These data indicate that depletion of 
functional CD40L results in decreased pro-inflammatory APC-like microglial activation 
in PSAPP/Aβ1-42/CD40L antibody mice.  It should be noted that Iba1 immunostaining 
does not distinguish resident microglia from peripherally-derived monocytes that may 
migrate to the CNS and take up a microglial phenotype.  
3.4.6 CD40 pathway blockade decreases MHC II and CD45-positive microglia and 
increases anti-inflammatory cytokines in Aβ1-42 immunized PSAPP mice 
To evaluate the effects of CD40/CD40L blockade on pro-inflammatory APC-lik
microglial activation in the Aβ1-42 vaccination paradigm, we first stained brain sec
from PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody mice with Iba1 antibody 
(Figure 12A).  We quantified Iba1 positive microglia/macrophages with/withou
spindle-shaped morphology, as it has been previously reported that microglial cells 
become spindle-shaped when exposed to stimuli including LPS and Con A that promot
the pro-inflammatory APC phenotype (Washington et al., 1996; Bernhardi and Nicholls, 
1999).  Interestingly, disruption of CD40L activity significantly reduced spindle-shaped 
microglia/macrophages by morphologic analysis (**P < 0.001), but did not alter non-
spindle-shaped cells (Figure 12B).  To further evaluate whether CD40L
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Figure 12. CD40L blockade inhibits APC-like microglial activation in Aβ1-42 vaccinated 
PSAPP mice and promotes anti-inflammatory cellular immunity.  (A) Representative 
hippocampal sections from PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody 
mouse brains were stained with Iba1 antibody to illustrate both microglial load and 
morphology. (B) Quantitative image analysis of microglial load (Iba1 positive) and 
percentage of spindle-shaped Iba1 positive microglia is shown.  (C) Representative 
hippocampal sections from PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody 
mouse brains were stained with Iba1 together with MHC II or CD45 antibodies to 
illustrate microglial load and activation status (DAPI was used as a nuclear counterstain).  
(D) Th1 and Th2 cytokine analysis by ELISA was conducted on mouse brain 
homogenates from PSAPP, PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody 
mice.  Data are represented as mean ± SD of each cytokine in brain homogenates (pg/mg 
total protein) from PSAPP, PSAPP/Aβ1-42/CD40L antibody or PSAPP/Aβ1-42/IgG mice. 
 ro-
0 
/IgG 
 other 
 or IL-1β.  
ory 
 
3.4.7  Aβ1-42-immunized PSAPP mice treated with CD40L neutralizing antibody exhibit 
increases in anti-inflammatory cytokines and decreases in neurotoxic inflammatory 
responses in vitro 
To investigate Aβ-specific T-cell immune responses after Aβ1-42 immunization 
plus neutralizing CD40L antibody treatment, we established primary cultures of 
splenocytes from: PSAPP/Aβ1-42/IgG, PSAPP/Aβ1-42/CD40L antibody, PSAPP/CD40L 
antibody, and PSAPP/PBS mice.  We then quantified key cytokines produced by 
activated T-cells (IFN-γ, IL-2, and IL-4) in supernatants by ELISA.  Both non-specific 
To further determine the consequences of this phenomenon in terms of 
inflammatory responses, we analyzed brain homogenates from PSAPP/Aβ1-42/CD40L 
antibody, PSAPP/Aβ1-42/IgG, and other control groups by ELISA for expression of p
inflammatory and anti-inflammatory cytokines.  Analysis of results revealed a 
significantly (**P <0.001) greater expression of anti-inflammatory TGF-β1 and IL-1
cytokines from PSAPP/Aβ1-42/CD40L antibody mice compared to the PSAPP/Aβ1-42
mice (Figure 12D).  Moreover, PSAPP/Aβ1-42/CD40L antibody mice also produced 
significantly (P <0.001) greater expression of TGF-β1 and IL-10 when compared to
controls including PSAPP/IgG and PSAPP/Aβ1-42/PBS mice (data not shown).  No 
significant between-groups differences were revealed when considering TNF-α
These data indicate that CD40L blockade correlates with a rise in the anti-inflammat
cytokines TGF-β1 and IL-10, without affecting the pro-inflammatory cytokines TNF-α 
and IL-1β. 
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nes (**P < 0.001) after in vitro Aβ1-42 challenge.  Of note, there were 
gnificant differences within mouse groups between IL-4 and either IFN-γ or IL-2 after 
β1-
se groups (P > 0.05; data not shown).    
g 
 mice 
 
) and specific recall stimulation of primary cultured splenocytes with Aβ
resulted in increases in the pro-inflammatory T-cell cytokines, IFN-γ and IL-2, in both 
PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody groups compared to the 
PSAPP/CD40L antibody group (Figure 13A).  However, these pro-inflammator
cytokines were reduced in the PSAPP/Aβ1-42/CD40L antibody group versus PSAPP/Aβ
42/IgG mice.  Moreover, PSAPP/Aβ1-42/CD40L antibody mice demonstrated increased 
anti-inflammatory T helper type 2 cytokine IL-4 when compared to PSAPP/Aβ1-42/Ig
mice.   These data indicate that disruption of CD40L activity in Aβ1-42 vaccinated mice 
reduces pro-inflammatory Aβ-specific T-cell immune responses in favor of an anti-
inflammatory response.  One-way ANOVA followed by post hoc comparison revealed 
significant differences when comparing PSAPP/Aβ1-42/CD40L antibody to  
PSAPP/CD40L antibody or PSAPP/Aβ1-42/IgG mouse groups for levels of each of the 
three cytoki
si
Aβ1-42 recall challenge (##P < 0.001).  Following challenge, no significant difference in 
cytokine release was observed from splenocytes between PSAPP/PBS and PSAPP/A
42/IgG control mou
To determine whether CD40L neutralization could mitigate potentially damagin
effects of Aβ-specific T-cells, we co-cultured primary neuronal cells from PSAPP
or their littermates with CD3+ T-cells (including CD4+ and CD8+ T-cells) isolated from 
the primary cultured splenocytes derived from PSAPP/Aβ1-42/IgG or PSAPP/Aβ1-
42/CD40L antibody mice as described above.  Per our previous reports (Tan et al., 2000;
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CD40L activity. 
Tan et al., 2002a; Town et al., 2002), we labeled primary neuronal cells with 51Cr as
target cells and co-cultured them with T-cells as effectors, and carried out four-hour 51C
release assay.  ANOVA showed main effects of effector:target ratio for Aβ1-42 va
PSAPP mouse-derived T-cells (effectors) and PSAPP mouse-derived neuronal cells 
(target cells) (**P <0.001; n = 8 mice for PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L 
antibody groups; n = 5 mice for both control groups) (Figure 13B), but not when 
unvaccinated PSAPP mouse-derived T-cells were used (control 1) or when cont l 
littermate (non-transgenic mouse)-derived neuronal cells (control 2) were used (P > 
0.05).  ANOVA followed by post-hoc comparison revealed a significant difference across 
ratios between PSAPP/Aβ1-42/IgG and PSAPP/Aβ1-42/CD40L antibody T-cells (**P < 
0.001), indicating an overall decrease in percentage of cell lysis as a result of disrupting 
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Figure 13. Aβ-specific neurotoxic inflammatory responses are reduced in Aβ1-42-
immunized PSAPP mice deficient for CD40.  (A) Splenocytes were individually isolated 
and cultured from mice as indicated after Aβ1-42 immunization and either CD40L 
antibody treatment or PBS injection (control).  These cells were stimulated with Con A (5 
µg/mL) or Aβ1-42 (20 µg/mL) for 48 hrs.  Cultured supernatants were collected from these 
cells for IFN-γ, IL-2, and IL-4 cytokine analyses by ELISA.  Data are represented as 
mean ± SD (n = 10) of each cytokine in supernatants (pg/mg total intracellular protein).  
(B) Aβ specific T cell-mediated neuronal cell injury was determined by 51Cr release 
assay.  Data are reported as mean 51Cr release values ± SD, and n = 8 for each condition 
presented.  PSAPP/Aβ1-42/IgG mouse group, effectors: Aβ1-42/IgG-immunized PSAPP 
mouse-derived T cells; target cells: PSAPP-mouse-derived primary neuronal cells.  
PSAPP/Aβ1-42/CD40L antibody mouse group, effectors: Aβ1-42/CD40L antibody-
immunized PSAPP mouse-derived T cells; target cells: PSAPP-mouse-derived primary 
neuronal cells.  Control 1, effectors: unvaccinated PSAPP mouse-derived T cells; target 
cells: PSAPP mouse-derived neuronal cells.  Control 2, effectors: Aβ1-42-immunized 
PSAPP mouse-derived T cells; target cells: non-transgenic mouse-derived primary 
neuronal cells. 
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ard et al., 2000), and microglial Fc receptor (i.e., microglial phagocytosis 
of Aβ antibody-opsonized deposits) is not required for brain Aβ clearance (Das et al., 
2003).  Thus, we suggest that the combination of blocking the microglial CD40 pathway 
and Aβ immunotherapy further enhances microglial Abeta clearance. 
Previous clinical investigation has revealed that active immunization with Aβ in 
humans confers the unacceptable risk of aseptic meningoencephalitis associated with T-
3.5 Discussion 
We have previously shown the CD40-CD40L interaction enhances pro-
inflammatory microglial activation triggered by cerebral Aβ deposits (Tan et al., 1
This form of microglial activation is deleterious, as both genetic ablation of CD40L and 
CD40L neutralizing antibody reduce brain levels of several neurotoxic inflammatory 
cytokines and mitigate cerebral amyloidosis in AD mouse models (Tan et al., 2002a).
establish a possible mechanism to explain these results, we previously quantified 
microglial phagocytic activity in CD40 deficient versus CD40 sufficient AD mice.  W
observed inhibition of microglial Aβ phagocytosis upon CD40 ligation.  This coincided 
with increased microglial co-localization of MHC class II with non-opsonized 
Aβ peptide.  Moreover, this APC phenotype was accompanied by upregulation of pr
inflammato  Th1 cytokines such as TNF-α, IL-1β, IL-2, and IFN-γ (Townsend e
2005).  These data suggest that CD40 pathway blockade induces “switching” of the 
microglial phenotype from a pro-inflammatory APC state to an anti-inflammatory, pro-
phagocytic state (Townsend et al., 2005).  Interestingly, brain Aβ clearance in the Aβ
immunotherapy paradigm has previously been suggested to rely on microglial 
phagocytosis (B
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 gliosis, and associated rise in CNS pro-inflammatory mediators (Schenk 
et al., 1 ta and our 
40 
ever, 
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groups 
cell infiltration, 
999; Schenk and Yednock, 2002; Nicoll et al., 2003).  Based on these da
work on the CD40-CD40L association with brain Aβ levels, we investigated whether 
CD40 blockade could reduce cerebral Aβ deposits without the undesirable inflammatory 
events in the CNS.    
First, we tested whether active Aβ1-42 vaccination of CD40 deficient mice could 
produce significant levels of Aβ antibodies.  Consistent with the requirement of CD
signaling for IgM to IgG class switching (Kawabe et al., 1994), homozygous CD40 
deficient mice vaccinated with Aβ1-42 did not produce detectable Aβ IgG antibodies, but 
had slightly increased levels of Aβ IgM antibodies vs. wild-type controls.  How
active Aβ1-  vaccination of PSAPP/CD40+/- mice produced elevated plasma anti-Aβ Ig
antibodies comparable to CD40 sufficient PSAPP mice which are consistent with a gen
dose-effect (Figure 6A).   Interestingly, further reduction in cerebral amyloidosis in A
vaccinated PSAPP/CD40-/- occurred essentially in the absence of Aβ IgG antibodies.  It 
well known that the CD40 pathway is essential for antibody isotype switching from Ig
to IgG, and this result suggests that the additional therapeutic benefit from bloc
CD40 pathway is independent of IgG in our system.  However, given 1) the requirement 
of CD40 signaling for a diverse set of immunological responses and 2) that we did not 
use IgG deficient mice, this conclusion should be taken with caveats. 
Next, we quantified plasma levels of Aβ1-40 and Aβ1-42 species 
of Aβ-immunized PSAPP mice in an attempt to determine the relationship 
between IgG, IgM, and efflux of Aβ from the brain to the periphery.  Similar elevations 
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 β1-40, 42 species (Figure 6B).  This lack of elevated plasma Aβ1-40, 
42 corre
tinct 
 
 
1-42  resulted in 
reduced IFN-  and IL-2 production in the PSAPP/A 1-42/CD40L antibody  mouse group 
compared to PSAPP/Aβ1-42/IgG mice (Figure 13A).  Further, PSAPP/CD40 /Aβ1-42 mice 
of plasma Aβ1-40, 42 species between CD40 heterozygous deficient or CD40 sufficient 
PSAPP mice were observed (Figure 6B).  Thus, we suggest that Aβ IgG-mediated brain 
to blood efflux was operating similarly in CD40 heterozygous and CD40 sufficient 
PSAPP mice.  By contrast, Aβ1-42 vaccinated PSAPP/CD40-/- mice did not exhibit 
elevations in plasma A
lated positively with the lack of Aβ IgG antibody production in the homozygous 
CD40 deficient PSAPP mice.  This is consistent with a lack of brain-to-blood efflux of 
Aβ via the peripheral sink hypothesis (DeMattos et al., 2001), and suggests that a dis
mechanism is operating in these PSAPP/CD40-/- mice. While CD40 deficient mice do 
produce normal levels of Aβ IgM antibodies, no detectable elevation in peripheral Aβ
was observed.  This, too, is in accord with the notion that Aβ IgG is required for brain to 
blood efflux of Aβ (DeMattos et al., 2001).  As pharmacotherapeutic “proof of 
principle”, we administered CD40L neutralizing antibody to Aβ1-42 vaccinated PSAPP 
mice, and confirmed greater reductions in cerebral amyloidosis compared to Aβ1-42 
vaccinated PSAPP mice given control IgG.  This experimental approach was performed 
to offset the possibility that genetic ablation, in and of itself, does not confer 
developmental changes that would result in modulation of Aβ loads.   
We next went on to test T-cell specific immune responses against Aβ and found
that recall stimulation of primary cultured splenocytes with Aβ peptide
γ β
+/-
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Previously, we showed that CD40 ligation shifts microglial response to Aβ from an anti-
inflammatory phagocytic phenotype to a pro-inflammatory APC response  (Town et al., 
exhibited an increase in the anti-inflammatory Th2 cytokine, IL-10, and produced less 
circulating soluble CD40L (sCD40L) compared to PSAPP/CD40+/+/Aβ1-42 mice (Figure 
9).  Taken together, these findings suggest partial CD40 pathway inhibition reduces 
inflammatory but increases anti-inflammatory T-cell immune responses to Aβ chal
This is particularly attractive as these results raise the possibility that 50% 
pharmacological inhibition of CD40 might be of benefit in the attenuation of the pro-
inflammatory meningoencephalitis associated with active Aβ vaccination in humans, 
while still allowing for production of Aβ IgG antibodies.   
In addition to developing parenchymal Aβ deposits and associated elevated 
inflammatory cytokines seen in the PSAPP model, the Tg2576 mouse model of AD als
develops cerebrovascular Aβ deposits not unlike cerebral amyloid angiopathy (CAA), 
which is observed in the majority of AD patients (Nicoll et al., 2003; Wilcock et
2004; Wilcock et al., 2007).   To determine if reducing available CD40L might also 
mitigate CAA, we administered neutralizing CD40L antibody to Aβ vaccinated Tg2576 
mice.  Indeed blockade of the CD40L with neutralizing antibody in combination with Aβ
vaccination produced the highest therapeutic effect (reduction of parenchyma
the most minimal CAA-like pathology as measured by parenchymal an
g respectively (Figs. 11D – E).  These results suggest CD40L antibody 
neutralization not only improves the cerebral amyloid reducing effect of Aβ vaccination, 
but also confers a reduction in undesirable CAA-like pathology in Tg2657 mice. 
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2002; Townsend et al., 2005).  In accord, here we observed downregulation of microgli
APC morphology in situ (Figs. 12A – B), and reduction in CD45 and MHC II-positive 
microglia from Aβ1-42 vaccinated PSAPP mice treated with CD40L neutralizing antibody
(Figure 12C).  Indeed, reduction in MHC II expression, a measure of microglial APC 
phenotype, correlated with elevated brain levels of anti-inflammatory Th2 c
TGF-β1 and IL-10 (Figure 12D).  Although NK cell-mediated activation of microglia
bypass MHC and T cell receptors to produce a vaccine immune response, infiltration o
NK cells into the CNS has not been reported in the Aβ vacc
ely.    
Another possibility is that so-called “anti-ergotypic” responses, defined as an 
immune response to the vaccine-activated host immune cells, could play a role in 
enhanced efficacy of Aβ immunotherapy in conjunction with CD40 blockade.  Short-
term anti-ergotypic lines isolated from vaccinated Multiple Sclerosis (MS) patients 
demonstrate a mixed phenotype (both CD4+ and CD8+ cells).  These cells secrete IFN-γ 
and TNF-α, but not TGF-β1 (Correale et al., 1997; Hellings et al., 2004).  Although we 
can not fully rule out this mechanism in our studies of CD40 blockade enhancement of 
reduced cerebral amyloidosis after Aβ vaccination, it is interesting to note that our re
in the CNS and in splenocytes show the converse: a reduction in IFN-γ and TN
an increase in TGF-β (Figure 12D and Figure 13A), suggesting the involvement of a 
different mechanism.  
Given our previous observation CD40 ligation induces “switching” of the 
microglial phenotype from a pro-phagocytic state endorsing Aβ phagocytosis to a pro-
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hus, complete systemic blockade of CD40-CD40L would likely 
have de y 
inflammatory APC state (Townsend et al., 2005), we propose that combined CD40 
blockade and Aβ vaccination promotes microglial phagocytosis/clearance of Aβ from th
CNS. Additionally, T-cells derived from neutralizing CD40L antibody-treated Aβ1-42 
vaccinated PSAPP were dramatically less neurotoxic to Aβ producing neurons ex vivo
(Figure 13B), suggesting further benefit afforded by combining these therapeutic 
approaches.  However, it is worth noting that this latter result needs to be interpreted with 
the caveat that standard active Aβ vaccination of AD mouse models (unless modified 
with the addition of pertussis toxin) (Furlan et al., 2003) does not produce appreciable 
brain infiltrate
 in AD patients (Nicoll et al., 2003; Town et al., 2005). 
CD40-CD154 interaction is essential for initiating the adaptive immune res
as demonstrated by immune deficits observed in patients with mutations in the CD40 o
CD40L genes.  These patients develop type 1 hyper IgM immunodeficiency syndrom
(HIGM1) that is characterized by recurrent bacterial and opportunistic infections 
(Durandy 2001; Fuleihan 2001; Levy et al., 1997a).  Patients with homozygous mutation
in the CD40 gene have a severe immunodeficiency termed HIGM3.  Its clinical 
phenotype overlaps with that of HIGM1 and is characterized by defective generation of 
secondary antibodies and severe opportunistic infections, (Ferrari et al., 2001; Kutukcule
et al., 2003) particularly Cryptosporidium enteritis and Pneumocystis carinii pneumonia 
(Levy et al., 1997b).  T
leterious immunosuppressive side effects. For this reason, pharmacotherap
would need to be titrated such that the CD40-CD154 pathway was partially inhibited.   
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Interestingly, as we have shown in our proof-of-concept paradigm in transgenic mic
even a 50% blockade of CD40 is enough to increase the efficacy of the Abeta vaccine on 
reduction of cerebral amyloidosis. 
Our observations suggest that partial blockade of CD40 signaling, either by 
genetic or by pharmacologic means, increases the effectiveness of Aβ1-42 vaccinati
further reducing cerebral amyloidosis and simultaneously promoting anti-inflammatory 
cellular immune processes in the brain and in the periphery.  If the benefit afforded by 
CD40 pathway blockade to Aβ1-42 vaccinated AD mouse models can translate to the 
clinical syndrome, then pharmacotherapy aimed at reducing CD40 signaling in 
conjunction with Aβ vaccination may represent an approach tha
e in humans.  Future studies will be required to isolate CD40-CD40L downstream 
signaling involved in reduced efficacy of Aβ vaccination, as this may uncover additional
targets for pharmacologic intervention. 
 
 
 
 
135 
 
 
 K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Lieberburg, I., 
., Vasquez, N., Weiss, K., Welch, B., Seubert, P., 
Schenk, D., Yednock, T., 2000.  Peripherally administered antibodies against amyloid 
beta-pe l of 
Alzheimer disease. Nat Med. 6(8), 916-9. 
Bernhardi, R. V., Nicholls, J. G., 1999. Transformation of leech microglial cell 
tissue. J Exp Biol. 202 (Pt 6), 723-8. 
Bishop, G. A., Hostager, B. S., 2003. The CD40-CD154 interaction in B cell-T cell 
 
368, 387-
er's disease induce antibody responses against 
l responses. Vaccine. 24, 6321-31. 
hen, K., Iribarren, P., Hu, J., Chen, J., Gong, W., Cho, E. H., Lockett, S., Dunlop, N. 
M., Wa g, J. M., 2006. Activation of Toll-like receptor 2 on microglia promotes cell 
uptake of Alzheimer disease-associated amyloid beta peptide. J Biol Chem. 281, 3651-9. 
 
Christie, R., Yamada, M., Moskowitz, M., Hyman, B., 2001. Structural and functional 
disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid 
angiopathy. Am J Pathol. 158, 1065-71. 
 
Correale, J., McMillan, M., Li, S., McCarthy, K., Le, T., Weiner, L. P., 1997.  Antigen 
presentation by autoreactive proteolipid protein peptide-specific T cell clones from 
chronic progressive multiple sclerosis patients: roles of co-stimulatory B7 molecules and 
IL-12.  J Neuroimmunol. 72, 27-43. 
 
Das, P., Howard, V., Loosbrock, N., Dickson, D., Murphy, M. P., Golde, T. E., 2003.   
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- 
knock-out mice. J Neurosci. 23(24), 8532-8. 
 
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C., Paul, S. M., Holtzman, D. 
M., 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and 
3.6 References 
Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., Guido, T., Hu, 
Motter, R., Nguyen, M., Soriano, F
ptide enter the central nervous system and reduce pathology in a mouse mode
 
morphology and properties following co-culture with injured central nervous system 
 
liaisons. Cytokine Growth Factor Rev. 14, 297-309. 
Blennow, K., de Leon, M. J., Zetterberg, H., 2006. Alzheimer's disease. Lancet. 
403. 
 
Calingasan, N. Y., Erdely, H. A., Altar, C. A., 2002. Identification of CD40 ligand in 
Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. 
Neurobiol Aging. 23, 31-9. 
 
Chackerian, B., Rangel, M., Hunter, Z., Peabody, D. S., 2006. Virus and virus-like 
particle-based immunogens for Alzheim
amyloid-beta without concomitant T cel
 
C
n
 
 
136 
 
 
  beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad 
Sci U S A. 98, 8850-5. 
., Ugazio, A. G., Levy, Y., Catalan, N., 
urandy, A., Tbakhi, A., Notarangelo, L. D., Plebani, A., 2001.  Mutations of CD40 gene 
Natl 
riedlich, A. L., Lee, J. Y., van Groen, T., Cherny, R. A., Volitakis, I., Cole, T. B., 
 
an animal model of Alzheimer's 
isease. J Neurosci. 24, 3453-9. 
an, R. L., 2001. The hyper IgM syndrome. Curr Allergy Asthma Rep.  1, 445-50. 
eview. 
mi, G., Martino, G., 2003. Vaccination with amyloid-beta 
eptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain. 126(Pt 2), 285-
ouble-edged 
accine. Nat Med. 9, 389-90. 
ate 
a, A., Papassotiropoulos, A., Nitsch, R. M., 
003. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. 
s of immunotherapeutic intervention by anti-CD40L 
CD154) antibody in an animal model of multiple sclerosis. J Clin Invest. 103, 281-90. 
 therapeutic blockade of CD154-CD40 in 
xperimental autoimmune encephalomyelitis. J Clin Invest. 109, 233-41. 
, 
decreases brain A
 
Durandy, A., Honjo, T.,  2001.  Human genetic defects in class-switch recombination 
(hyper-IgM syndromes).  Curr Opin Immunol.  13, 543-8. Review. 
 
Ferrari, S., Giliani, S., Insalaco, A., Al-Ghonaium, A., Soresina, A. R., Loubser, M., 
Avanzini, M. A., Marconi, M., Badolato, R
D
cause an autosomal recessive form of immunodeficiency with hyper IgM.  Proc 
Acad Sci U S A. 2001 Oct 23;98(22):12614-9. 
 
F
Palmiter, R. D., Koh, J. Y., Bush, A. I., 2004. Neuronal zinc exchange with the blood
vessel wall promotes cerebral amyloid angiopathy in 
d
 
Fuleih
R
 
Furlan, R., Brambilla, E., Sanvito, F., Roccatagliata, L., Olivieri, S., Bergami, A., 
Pluchino, S., Uccelli, A., Co
p
91. 
 
Greenberg, S. M., Bacskai, B. J., Hyman, B. T., 2003. Alzheimer disease's d
v
 
Hellings, N., Raus, J., Stinissen, P., 2004.  T-cell vaccination in multiple sclerosis: upd
on clinical application and mode of action. Autoimmun Rev. 3(4), 267-75.  
 
Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Muller-Tillmanns, B., 
Lemke, U., Henke, K., Moritz, E., Garcia, E., Wollmer, M. A., Umbricht, D., de 
Quervain, D. J., Hofmann, M., Maddalen
2
Neuron. 38, 547-54. 
 
Howard, L. M., Miga, A. J., Vanderlugt, C. L., Dal Canto, M. C., Laman, J. D., Noelle, 
R. J., Miller, S. D., 1999. Mechanism
(
 
Howard, L. M., Ostrovidov, S., Smith, C. E., Dal Canto, M. C., Miller, S. D., 2002. 
Normal Th1 development following long-term
e
 
Jankowsky, J. L., Slunt, H. H., Ratovitski, T., Jenkins, N. A., Copeland, N. G., Borchelt
 
 
137 
 
 
 17, 157-65. 
t, P., McConlogue, 
., 1997. Amyloid precursor protein processing and A beta42 deposition in a transgenic 
erminal center formation. Immunity. 1, 
67-78. 
., 
ci. 
saccharide-induced inflammation exacerbates tau pathology by a cyclin-
ependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J 
 
otarangelo, L. D., 2003.  Disseminated cryptosporidium infection in an infant with 
yper-IgM syndrome caused by CD40 deficiency. 
emere, C. A., Spooner, E. T., LaFrancois, J., Malester, B., Mori, C., Leverone, J. F., 
 protein 
llowing chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis. 14, 10-8. 
nick, I., 
., 
, E., Sanal, O., Peitsch, M. C., Notarangelo, L. D., 1997.  Clinical 
pectrum of X-linked hyper-IgM syndrome.  J Pediatr.  131, 47-54. 
 
lzheimer's disease. Am J Pathol. 163, 2155-64. 
ryl lipid A 
MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). Vaccine. 23, 
D. R., 2001. Co-expression of multiple transgenes in mouse CNS: a comparison of 
strategies. Biomol Eng. 
 
Johnson-Wood, K., Lee, M., Motter, R., Hu, K., Gordon, G., Barbour, R., Khan, K., 
Gordon, M., Tan, H., Games, D., Lieberburg, I., Schenk, D., Seuber
L
mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 94, 1550-5. 
 
Kawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H., Suematsu, S., Yoshida, N., 
Kishimoto, T., Kikutani, H., 1994. The immune responses in CD40-deficient mice: 
impaired immunoglobulin class switching and g
1
 
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W
Golde, T., McGowan, E., 2007. Abeta40 inhibits amyloid deposition in vivo. J Neuros
27, 627-33. 
 
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., LaFerla, F. M., 2005. 
Lipopoly
d
Neurosci. 25, 8843-53. 
 
Kutukculer, N., Moratto, D., Aydinok, Y., Lougaris, V., Aksoylar, S., Plebani, A., Genel,
F., N
h
J Pediatr.  142, 194-6. 
 
L
Matsuoka, Y., Taylor, J. W., DeMattos, R. B., Holtzman, D. M., Clements, J. D., Selkoe, 
D. J., Duff, K. E., 2003. Evidence for peripheral clearance of cerebral Abeta
fo
 
Levy, J., Espanol-Boren, T., Thomas, C., Fischer, A., Tovo, P., Bordigoni, P., Res
Fasth, A., Baer, M., Gomez, L., Sanders, E. A., Tabone, M. D., Plantaz, D., Etzioni, A
Monafo, V., Abinun, M., Hammarstrom, L., Abrahamsen, T., Jones, A., Finn, A., 
Klemola, T., DeVries
s
 
Li, L., Cao, D., Garber, D. W., Kim, H., Fukuchi, K., 2003. Association of aortic 
atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of
A
 
Maier, M., Seabrook, T. J., Lemere, C. A., 2005. Modulation of the humoral and cellular 
immune response in Abeta immunotherapy by the adjuvants monophospho
(
5149-59. 
 
 
138 
 
 
 D., Jiang, L., Das, P., Janus, C., Lemere, C. A., 
006. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning 
, K., 
arbinian, N., Darekar, P., Mihaly, L., Khalili, K., 2006. Beta-amyloid deposition and 
onsiveness to amyloid beta-peptide in amyloid precursor protein transgenic 
ice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl 
A., Imitola, J., Zota, V., Oida, T., Weiner, H. L., 2003. Microglia-mediated 
itric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 
f, 
 G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., 
rendash, G. W., 2000. A beta peptide vaccination prevents memory loss in an animal 
 Markham, H., Weller, R. O., 2003. 
an Alzheimer disease after immunization with amyloid-beta 
eptide: a case report. Nat Med. 9, 448-52. 
icrohemorrhage. Proc Natl Acad Sci U S A. 104, 2507-12. 
s 
 
kura, Y., Miyakoshi, A., Kohyama, K., Park, I. K., Staufenbiel, M., Matsumoto, Y., 
 
rgogozo, J. M., Gilman, S., Dartigues, J. F., Laurent, B., Puel, M., Kirby, L. C., 
 
Maier, M., Seabrook, T. J., Lazo, N. 
2
deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific 
cellular immune response. J Neurosci. 26, 4717-28. 
 
Miklossy, J., Kis, A., Radenovic, A., Miller, L., Forro, L., Martins, R., Reiss
D
Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging. 27, 228-36. 
 
Monsonego, A., Maron, R., Zota, V., Selkoe, D. J., Weiner, H. L., 2001. Immune 
hyporesp
m
Acad Sci U S A. 98, 10273-8. 
 
Monsonego, 
n
cells. J Immunol. 171, 2216-24. 
 
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duf
K., Jantzen, P., DiCarlo,
A
model of Alzheimer's disease. Nature. 408, 982-5. 
 
Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P.,
Neuropathology of hum
p
 
Nikolic, W. V., Bai, Y., Obregon, D., Hou, H., Mori, T., Zeng, J., Ehrhart, J., Shytle, R. 
D., Giunta, B., Morgan, D., Town, T., Tan, J., 2007. Transcutaneous beta-amyloid 
immunization reduces cerebral beta-amyloid deposits without T cell infiltration and 
m
 
O'Keefe, G. M., Nguyen, V. T., Benveniste, E. N., 2002. Regulation and function of clas
II major histocompatibility complex, CD40, and B7 expression in macrophages and
microglia: Implications in neurological diseases. J Neurovirol. 8, 496-512. 
 
O
2006. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term
effects and safety. Proc Natl Acad Sci U S A. 103, 9619-24. 
 
O
Jouanny, P., Dubois, B., Eisner, L., Flitman, S., Michel, B. F., Boada, M., Frank, A., 
Hock, C., 2003. Subacute meningoencephalitis in a subset of patients with AD after 
Abeta42 immunization. Neurology. 61, 46-54. 
 
 
 
139 
 
 
 onomarev, E. D., Shriver, L. P., Dittel, B. N., 2006. CD40 expression by microglial 
., Kulhanek, D., Eckenstein, F., 
003. Inflammation and cerebral amyloidosis are disconnected in an animal model of 
, Westendorp, R. G., 2001. Patients with Alzheimer's disease display a pro-
n, D., Hardy, J., Town, T., Tan, J., 2005. Green tea 
pigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and 
., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, 
, Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., 
3-
r 
heng, J. G., Bora, S. H., Xu, G., Borchelt, D. R., Price, D. L., Koliatsos, V. E., 2003. 
igurdsson, E. M., Wisniewski, T., Frangione, B., 2002. A safer vaccine for Alzheimer's 
 plays a 
entral role in regulating dendritic cell activation during infections that induce Th1 or 
attson, M. P., Flavell, R. 
., Mullan, M., 1999. Microglial activation resulting from CD40-CD40L interaction after 
ation 
 pathway. J Biol Chem. 275, 37224-31. 
P
cells is required for their completion of a two-step activation process during central 
nervous system autoimmune inflammation. J Immunol. 176, 1402-10. 
 
Quinn, J., Montine, T., Morrow, J., Woodward, W. R
2
Alzheimer's disease. J Neuroimmunol. 137, 32-41. 
 
Remarque, E. J., Bollen, E. L., Weverling-Rijnsburger, A. W., Laterveer, J. C., Blauw, G. 
J.
inflammatory phenotype. Exp Gerontol. 36, 171-6. 
 
Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., 
Townsend, K., Zeng, J., Morga
e
reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci. 25, 8807-14. 
 
Schenk, D., Barbour, R., Dunn, W
J.
Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., 
Wogulis, M., Yednock, T., Games, D., Seubert, P., 1999. Immunization with amyloid-
beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400, 17
7. 
 
Schenk, D. B., Yednock, T., 2002. The role of microglia in Alzheimer's disease: friend o
foe? Neurobiol Aging. 23, 677-9; discussion 683-4. 
 
S
Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of 
amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. 
Neurobiol Dis. 14, 133-45. 
 
S
disease? Neurobiol Aging. 23, 1001-8. 
 
Straw, A. D., MacDonald, A. S., Denkers, E. Y., Pearce, E. J., 2003. CD154
c
Th2 responses. J Immunol. 170, 727-34. 
 
Tan, J., Town, T., Paris, D., Mori, T., Suo, Z., Crawford, F., M
A
beta-amyloid stimulation. Science. 286, 2352-5. 
 
Tan, J., Town, T., Mullan, M., 2000. CD45 inhibits CD40L-induced microglial activ
via negative regulation of the Src/p44/42 MAPK
 
 
 
140 
 
 
 ., 
ic 
e. 
ogo, T., Akiyama, H., Kondo, H., Ikeda, K., Kato, M., Iseki, E., Kosaka, K., 2000. 
own, T., Tan, J., Mullan, M., 2001a. CD40 signaling and Alzheimer's disease 
1-
2. Neurosci Lett. 307, 101-4. 
., 
own, T., Tan, J., Flavell, R. A., Mullan, M., 2005. T-cells in Alzheimer's disease. 
ownsend, K. P., Town, T., Mori, T., Lue, L. F., Shytle, D., Sanberg, P. R., Morgan, D., 
ve 
, J., 2000. CD40-CD40 ligand. J Leukoc Biol. 67, 2-17. 
kinase plasminogen-activator receptor in cultured 
uman central nervous system microglia. J Neurosci Res. 45, 392-9. 
N., 
y against Abeta in aged APP-transgenic mice 
verses cognitive deficits and depletes parenchymal amyloid deposits in spite of 
., Gordon, M. N., 2007. Amyloid-beta 
accination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases 
Tan, J., Town, T., Crawford, F., Mori, T., DelleDonne, A., Crescentini, R., Obregon, D
Flavell, R. A., Mullan, M. J., 2002a. Role of CD40 ligand in amyloidosis in transgen
Alzheimer's mice. Nat Neurosci. 5, 1288-93. 
 
Tan, J., Town, T., Mullan, M., 2002b. CD40-CD40L interaction in Alzheimer's diseas
Curr Opin Pharmacol. 2, 445-51. 
 
T
Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. 
Brain Res. 885, 117-21. 
 
T
pathogenesis. Neurochem Int. 39, 371-80. 
 
Town, T., Tan, J., Sansone, N., Obregon, D., Klein, T., Mullan, M., 2001b. 
Characterization of murine immunoglobulin G antibodies against human amyloid-beta
4
 
Town, T., Vendrame, M., Patel, A., Poetter, D., DelleDonne, A., Mori, T., Smeed, R
Crawford, F., Klein, T., Tan, J., Mullan, M., 2002. Reduced Th1 and enhanced Th2 
immunity after immunization with Alzheimer's beta-amyloid(1-42). J Neuroimmunol. 
132, 49-59. 
 
T
Neuromolecular Med. 7, 255-64. 
 
T
Fernandez, F., Flavell, R. A., Tan, J., 2005. CD40 signaling regulates innate and adapti
activation of microglia in response to amyloid beta-peptide. Eur J Immunol. 35, 901-10. 
 
van Kooten, C., Banchereau
 
Washington, R. A., Becher, B., Balabanov, R., Antel, J., Dore-Duffy, P., 1996. 
Expression of the activation marker uro
h
 
Wilcock, D. M., Rojiani, A., Rosenthal, A., Subbarao, S., Freeman, M. J., Gordon, M. 
Morgan, D., 2004. Passive immunotherap
re
increased vascular amyloid and microhemorrhage. J Neuroinflammation. 1, 24. 
 
Wilcock, D. M., Jantzen, P. T., Li, Q., Morgan, D
v
vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. 
Neuroscience. 144, 950-60. 
 
 
 
141 
 
 
  
 
 
CHAPTER FOUR 
ZHEIMER’S MICE RESULTS IN REDUCED CEREBRAL AΒ DEPOSITS IN 
RATION AND MICROHEMORRHAGE 
-
 
ts are lacking.  We have developed a novel 
e skin 
ion in 
TRANSCUTANEOUS AΒ PEPTIDE IMMUNIZATION OF TRANSGENIC 
AL
THE ABSENCE OF T-CELL INFILT
 
4.1 Abstract 
Alzheimer’s disease (AD) immunotherapy accomplished by vaccination with β
amyloid peptide (Aβ) has proved efficacious in AD mouse models.  However, “active”
Aβ vaccination strategies for the treatment of cerebral amyloidosis without concurrent 
nduction of detrimental side effeci
 transcutaneous (t.c.) Aβ vaccination approach and have evaluated efficacy and 
onitored for deleterious side effects, including meningoencephalitis and m
microhemorrhage, in wild-type mice and in a transgenic mouse model of AD.  We 
demonstrate that t.c. immunization of wild-type mice with aggregated Aβ1-42 plus the 
djuvant cholera toxin (CT) results in high-titer Aβ antibodies (mainly of the a
immunoglobulin G1 class) and Aβ1-42-specific splenocyte immune responses.  Confocal 
microscopy of the t.c. immunization site revealed Langerhans cells in areas of th
containing the Aβ1-42 immunogen, suggesting that these unique innate immune cells 
participate in Aβ1-42 antigen processing.  To evaluate the efficacy of t.c. immunizat
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 reducing cerebral amyloidosis, transgenic PSAPP (APPsw, PSEN1dE9) mice were 
immunized with aggregated Aβ1-42 peptide plus CT.  Similar to wild-type mice, PSAPP 
mice showed high Aβ antibody titers.  Most importantly, t.c. immunization with Aβ1-42 
plus CT resulted in significant decr 40, 42 levels coincident with 
incr
br
t.c. immunization constitutes a novel, effecti ent strategy for 
 
ngles” and 
s (Selkoe 
eal 
s 
this 
 
eases in cerebral Aβ1-
eased circulating levels of Aβ1-40, 42, suggesting brain-to-blood efflux of Aβ.  
Reduction in cerebral amyloidosis was not associated with deleterious side-effects of 
ain T-cell infiltration or cerebral microhemorrhage.  Together, these data suggest that 
ve and potentially safe treatm
AD.   
4.2 Introduction  
Alzheimer’s disease (AD) is the most common dementing illness and is 
pathologically characterized by the presence of intracellular neurofibrillary “ta
extracellular senile plaques primarily composed of 40-42 amino acid Aβ peptide
2001).  In a seminal report, Schenk and colleagues showed that intraperiton
vaccination of the PDAPP transgenic mouse model of AD with Aβ1-42 plus Freund’
adjuvant resulted in dramatic reduction of cerebral amyloidosis (Schenk et al. 1999).  
This therapeutic approach is clearly highly efficacious; however, the safety of 
strategy has become an important concern.  In a recent clinical trial, patients were 
administered a synthetic Aβ peptide (AN-1792) plus adjuvant and approximately 6% of
these patients developed aseptic meningoencephalitis, most likely mediated by brain-
infiltrating activated T-cells (Hock et al. 2003; Bayer et al. 2005).  This serious side-
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 e 
t possible meningoencephalitis resulting from Aβ vaccination, various strategies 
ave been attempted.  Interestingly, recent works suggest that Aβ-derived peptides 
l tissues (with adjuvant) results in effective 
clearan ls of AD.  
t of Aβ 
 Such 
 safe 
effect led to suspension of the clinical trial.  Furthermore, passive transfer of Aβ 
antibodies to transgenic AD mice results in cerebral microhemorrhage, a potentially 
adverse side-effect (Wilcock et al. 2004; Racke et al. 2005).  Uncovering of these advers
events has re-directed Aβ vaccination strategies towards the goal of developing an 
approach that is both safe and effective.   
Studies examining the brains of Aβ vaccinated patients developing 
meningoencephalitis implicate Aβ reactive T-cell subsets as major components of this 
deleterious response to active Aβ vaccination (Nicoll et al. 2003; Ferrer et al. 2004).  To 
subver
h
delivered intranasally to mucosal epithelia
ce of Aβ plaques and improvement of cognitive function in animal mode
Moreover, T-cell reactivity appeared to be considerably reduced compared with other 
active immunization strategies (Maier et al. 2005; Maier et al. 2006).  In other studies, 
differential T-cell responses were observed dependent upon the epitope/fragmen
peptide utilized for vaccination.  Specifically, portions of the Aβ peptide seemed to 
stimulate different T-cell responses, resulting in either pro-inflammatory T-helper cell 
type 1 (Th1) responses, or anti-inflammatory T-helper cell type 2 (Th2) responses. 
findings imply that Aβ vaccination is not only efficacious, but may also prove to be
and therefore a feasible strategy for AD therapy depending upon a number of factors 
including route of delivery, adjuvant choice, and Aβ epitope administered.  
The skin is a well-established effective route for vaccination, including delivery 
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 .  
s 
al 
hans cell (LC) precursors, known as migratory 
CD14+ rofessional” 
 
Keratinocyte-derived IL-10 serves to buffer harmful pro-inflammatory immune activation 
and therby preserves skin barrier integrity (Niizeki; Streilein 1997).   
Taken together, these lines of evidence led us to hypothesize that targeting Aβ 
immunotherapy to skin tissue may provide an immunotherapeutic approach that is both 
efficacious and safe.   To evaluate this hypothesis, we tested a t.c. Aβ immunization 
strategy using both wild-type and the transgenic PSAPP (APPsw, PSEN1dE9) mouse 
model of AD (Jankowsky et al. 2001).  We found that t.c. immunization of non-
transgenic C57BL/6 mice with aggregated Aβ1-42 peptide plus the adjuvant cholera toxin 
(CT) resulted in high Aβ antibody titers [mainly immunoglobulin (Ig) G1], and Aβ -
specific splenocyte immune responses after re-challenge with the peptide.  Confocal 
microscopy of the t.c. immunization site revealed CD207 and CD11c double-positive 
Langerhans cells in areas of the skin containing the Aβ  immunogen, suggesting that 
these unique innate immune cells participate in Aβ  antigen processing.  Further, 
of peptide-based vaccines (Beignon et al. 2005; Itoh; Celis 2005; Dell et al. 2006)
Strong humoral and cellular immune responses have been elicited after transcutaneou
(t.c.) vaccination (Giudice; Campbell 2006), largely owing to the diverse populations of 
resident antigen presenting cells (APCs) and other immune cells in the various derm
layers.  Subsets of dermal-resident Langer
 LC precursors, are important immune regulators that demonstrate “p
APC capability including reducing T-cell stimulatory function by producing anti-
inflammatory cytokines (Larregina et al. 2001).  Also, skin-resident keratinocytes release
the anti-inflammatory cytokine interleukin (IL)-10 in response to certain stimuli.  
1-42
1-42
1-42
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l. 
r 
ately 
obtained from R&D Systems (Minneapolis, MN).  Aβ1-40 β1-42 ELISA kits were 
transgenic PSAPP mice t.c. immunized with aggregated Aβ1-42 peptide plus CT 
manifested effective immune responses against Aβ in concert with reduced cerebral Aβ
pathology, demonstrating the effectiveness of this approach.  These mice showed high 
Aβ antibody titers and increased circulating Aβ levels, suggesting brain-to-blood efflux
of Aβ.  Importantly, brain T-cell infiltration and cerebral microhemorrhage were not 
observed after t.c. immunization, indicating that this immunization strategy is potentially 
safe.   
 
4.3 Materials and methods 
 
4.3.1 Reagents. 
 Lyophilized cholera toxin (CT), CT antibody, concanavalin (Con A) and mouse
CD3 antibody were obtained from Sigma (St Louis, MO).  Aβ1-42 peptide was purchased
from U.S. peptides (Rancho Cucamonga, CA).  As previously described (Schenk et a
1999), Aβ1-42 peptide was added to 0.9% saline (4 mg/mL), vortexed, and incubated fo
24 h at 37º C.  This solution was aliquoted, frozen and stored at −80º C.  Immedi
prior to use, Aβ aliquots were thawed and then mixed with CT (reconstituted with 
distilled water to 0.5 mg/mL).  Antibody 4G8 directed against Aβ (amino acids 17-26) 
was purchased from Chemicon/Millipore (Billerica, MA).  Enzyme-linked 
immunoabsorbance assay (ELISA) kits for detection of IFN-γ, IL-2, and IL-4 were 
and A
purchased from IBL-American (Minneapolis, MN).  Murine IgG and HRP-conjugated 
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 L).  
es 
nimals  
 Wild-type C57BL/6 and PSAPP (APPsw, PSEN1dE9) mice were obtained from 
or, ME).  Animals were housed and maintained in the 
ollege of Medicine Animal Facility at the University of South Florida, and all 
e in compliance with protocols approved by the University of South 
Florida  
rr
β µg/m µ
µ µ
goat anti-mouse IgG were obtained from Pierce Biotechnology, Inc. (Rockford, I
Biotinylated anti-mouse IgG1, IgG2a and IgG2b were purchased from Zymed® 
Laboratories (South San Francisco, CA).  Alexa-Fluor™-conjugated secondary antibodi
(including Alexa-Fluor™488, 594, and 647) were purchased from Invitrogen (Carlsbad, CA).  
Lactate dehydrogenase (LDH) kit was obtained from Promega (Madison, WI).       
 
4.3.2 A
Jackson Laboratory (Bar Harb
C
experiments wer
 Institutional Animal Care and Use Committee.  Brain sections from mice induced
with experimental autoimmune encephalomyelitis were provided by Dr. Terrence Town 
and used as a positive control for CD3 staining.  Brain sections for positive 
microhemo hage staining from mice intraperitoneally passively given Aβ antibodies 
were provided by Dr. Dave Morgan (Wilcock et al. 2006).   
   
4.3.3 Transcutaneous (t.c.) immunization of mice  
 To test whether t.c. delivery of Aβ peptide could stimulate immune responses, we 
first t.c. immunized wild-type C57BL/6 mice.  These mice (n = 10, 5 male/5 female) 
were t.c. immunized with human A 1-42 peptide (200 ouse) and CT (10 g/mouse) 
or CT alone (10 g/mouse) in 100 L of 0.9% saline on a weekly basis for the first 
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 e bi-
ach 
munization, mice were anaesthetized.  A small lower back section (1-2 cm2) was 
extra precaution not to damage the skin.  The skin was then swabbed with 
acetone
n.  
ed 
as withdrawn 
or 
PP mice (n = 9, 4 male/5 
ale) at 4 months of age using the same procedure described above.  No mortality was 
nd none of the animals exhibited 
sympto
month.  Thereafter, these mice were continually t.c. immunized with Aβ1-42 (100 
µg/mouse) and CT (5 µg/mL) or CT alone (5 µg/mouse) in 100 µL of 0.9% salin
weekly for the following 12 weeks.  Transcutaneous immunization was performed 
according to a method described by Skelding and colleagues (Skelding et al. 2006) with 
minor changes.   To ensure mice immobility for the duration of administration for e
im
shaved with an 
 to remove surface oils and enhance penetration, allowed to air dry, and then re-
hydrated by swabbing with 0.9% saline.  The shaved edge was coated with a thin 
petroleum jelly layer to prevent unnecessary leakage of the immunization solutio
Lastly, 100 µL of Aβ1-42 in combination with CT or CT alone in 0.9% saline was plac
on the shaved region and allowed to be absorbed for 2 h.  At the end, the skin was 
washed with 0.9% saline and dried, so as to remove any remaining immunization 
solution.  Mice were cleaned thereafter and returned to their cages.  Blood w
on weeks 0 (immediately prior to the first immunization), 4, 8 and 16 (immediately pri
to the sacrifice of these mice).  We then t.c. immunized PSA
fem
observed over the course of the t.c. immunization a
ms causing their removal from the study. 
 
4.3.4 Splenocyte cultures.  
 Cell suspensions of splenocytes from individual mice were prepared as 
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 ll plates 
okine 
 
 
red 
nd 
 
207 
ti-mouse CD11c (1:50; Pierce 
iotechnology, Rockford, IL), and/or anti-human Aβ antibody (clone 4G8; 1:500; 
ica, MA) or rat anti-mouse CD3 antibodies (1:200; 
eBiosci njugated 
previously described (Town et al. 2002) and passed in 0.5 mL aliquots into 24-we
at 3 × 106/mL.  These cells were treated for 48 h with ConA (5 µg/mL), anti-CD3 (1 
µg/mL) or Aβ1-42 (20 µg/mL).  Supernatants were then collected and assayed by cyt
ELISA kits in strict accordance with the manufacturer's instruction (R&D Systems).  The
Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA) was performed to measure
total cellular protein from each of the cell groups under consideration just prior to 
quantification of cytokine release by ELISA, and cytokine secretion is expressed in 
pg/mg total cellular protein (mean ± SD).  To verify whether stimulation of splenocytes 
produced any between-groups differences on cell death that might account for alte
cytokine profiles, LDH release assay was carried out as described (Tan et al. 2000) a
LDH was not detected in any of the wells studied. 
 
4.3.5 Immunofluorescence staining.   
Non-transgenic C57BL/6 mice were transcutaneouslly treated with Aβ/CT, CT 
alone, or PBS for 18 h, as described above.  The dorsal skin was removed by careful 
razor slicing around pre-labeled regions (1.5 cm in diameter) where the vaccine was 
applied.  Skin or brain samples were routinely prepared for immunofluorescence staining. 
The staining was curried out using the following primary antibodies:  anti-mouse CD
(Langerin; 1:250; eBioscience San Diego, CA), an
B
Chemicon/Millipore, Biller
ence) overnight at 4°C, followed by appropriate secondary antibodies co
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 ng 
 
.6 (coating buffer) in 96-well 
munoassay plates overnight at 4º C.  The plates were washed with 0.05% Tween 20 in 
locked with blocking buffer (PBS with 1% BSA 
and 5%
in 
37º C.  
 and 
4) was 
with AlexaFluor488, -594, and/or -647 (1:500; Invitrogen) for 45 min. Sections were then 
washed 3 times in PBS, and mounted with fluorescence mounting media containing 
DAPI (Vector Laboratories, Inc., CA) to counter-stain cell nuclei, and then viewed under 
an Olympus BX-51 microscope or visualized in independent channels using a Zeiss 
LSM510 META confocal microscope equipped with a 2-photon laser that was used for 
exciting DAPI. 
 
4.3.6 Aβ antibody ELISA.   
Aβ antibodies in mouse plasma and brain homogenates were measured accordi
to previously described methods (Maier et al. 2005).  Briefly, human Aβ1-40 peptide was
coated at 2 µg/mL in 50 mM carbonate buffer, pH 9
im
PBS (washing buffer) five times and b
 horse serum) for 2 h at room temperature.  Murine IgG was serially diluted in 
coating buffer (1,000 - 0 ng/mL) to generate a standard curve.  Mouse plasma and bra
homogenate samples were diluted in blocking buffer at concentrations ranging from 
1:400 to 1:102,400, added to the plates, and incubated for 2 h at room temperature.  After 
5 washes with washing buffer, a detection antibody (HRP-conjugated goat anti-mouse 
IgG, 1 mg/mL) was diluted (1:4,000), added to the plates and incubated for 1 h at 
Following 8 washes, tetramethylbenzidine (TMB) substrate was added to the plates
incubated for 15 min at room temperature.  Fifty µL of stop solution (2 N N2SO
added to each well to terminate the reaction.  The optical density of each well was 
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 de 
wells were blocked with blocking buffer for 2 h at room temperature.  
ouse plasma was serially diluted in blocking buffer, added to each well, and incubated 
ashes, the plates were incubated in secondary antibodies 
(biotin
oom 
le 
immediately determined by a microplate reader at 450 nm.  Aβ antibodies were 
represented as ng per mL of plasma (mean ± SD).   
 ELISAs for Aβ antibody isotypes were carried out as previously described (Town 
et al. 2001; Lemere et al. 2002).  Ninety-six well plates were coated with Aβ1-40 pepti
(2 µg/mL) in coating buffer and incubated for 2 h at 37° C.  Following three washes in 
washing buffer, 
M
for 1 h at 37º C.  After five w
ylated anti-mouse IgG1, IgG2a or IgG2b) diluted at 1:1,000 in blocking buffer for 
1 h, followed by 30 min in streptevidin-HRP (1:200 in blocking buffer) at room 
temperature.  TMB substrate was added to the plates and incubated for 15 min at r
temperature.  Fifty µL of stop solution was added to each well to terminate the reaction.  
The optical density of each well was immediately determined by a microplate reader at 
450 nm.  The ratios of IgG1 to IgG2a or IgG1 to IgG2b were calculated for each time 
point from each mouse individually using optical density values and then average ratio 
for each group (mean ± SD).   
 
4.3.7 Aβ ELISA.  
 Mouse brains were isolated under sterile conditions on ice and placed in ice-cold 
lysis buffer as previously described (Rezai-Zadeh et al. 2005).  Brains were then 
sonicated on ice for approximately 3 min, allowed to stand for 15 min at 4°C, and 
centrifuged at 15,000 rpm for 15 min.  This fraction represented the detergent-solub
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 ogenates 
, followed by a 1:10 dilution in lysis 
 
 
on with the VectaStain Elite ABC kit (Vector 
aboratories, Burlingame, CA) coupled with diaminobenzidine substrate.  4G8-positive 
examined under bright field using an Olympus (Tokyo, Japan) BX-51 
micros
 diluted 
 70% 
fraction.  Aβ1-40, 42 species were further subjected to acid extraction of brain hom
in 5 M guanidine buffer (Johnson-Wood et al. 1997)
buffer.  Soluble Aβ1-40, 42 were directly detected in plasma and brain homogenates 
prepared with lysis buffer described above at a 1:4 or 1:10 dilution, respectively.  Aβ1-40,
42 was quantified in these samples using the Aβ1-40, 42 ELISA kits (IBL-America, 
Minneapolis, Minnesota) in accordance with the manufacturer’s instructions, except that 
standards included 0.5 M guanidine buffer in some cases.  Aβ1-40, 42 were represented as 
pg per mL of plasma and pg per mg of total protein (mean ± SD).       
 
4.3.8 Immunohistochemistry and image analysis.   
As previously described (Tan et al. 2002), five coronal sections from each brain 
(5 µm thickness) were cut with a 150 µm interval.  Sections were routinely deparaffinized
and hydrated in a graded series of ethanol before preblocking for 30 min at ambient 
temperature with serum-free protein block (Dako Cytomation, Carpinteria, CA).  Aβ 
immunohistochemical staining was performed using anti-human amyloid-β antibody 
(clone 4G8; 1:100) in conjuncti
L
Aβ deposits were 
cope.  For congo red histochemistry, sections were routinely deparaffinized and 
rinsed in 70% (v/v) ethanol before staining with fresh-filtered 1% (w/v) congo red
in 70% ethanol for 5 min.  These sections were rinsed three times for 5 min each in
ethanol, hydrated for 5 min in 0.9% saline, and mounted in Vectashield fluorescence 
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ith an 
(H
ain constant throughout the analysis session. We do not adjust thresholds for each 
to the estimation. Section-to-
section variability in immunostaining is 
software then corrects for heterogeneity in background illumination (blank field 
correction) and calculates the measurement parameters for the entire field. 
For quantitative image analysis of immunohistochemistry, we combined unbiased 
sampling of sections with the videodensitometric procedures we have used extensively in 
the past (Wilcock et al., 2004). All procedures were performed by an individual blind to 
the experimental condition of each specimen. Sample numbers were randomized before 
the start of the tissue processing, and code was broken only after completion of the 
analysis. We sampled every fifth section from the mouse brain, starting with a section 
between 1 and 5, identified by a random number generator. Frontal cortical 
mounting media (Vector Laboratories).  Congo red-positive β-amyloid plaques were 
visualized using an Olympus BX-51 microscope.  Quantitative image analysis was 
performed for both immunohistochemistry and Congo red-stained tissue sections w
Oncor V150 image analysis system. The software uses hue, saturation, and intensity 
SI) to segment objects in the image field. Operationally, thresholds for object 
segmentation are established by using a series of standard slides that have extremes of 
intensity for the stain being measured. Thresholds in HSI space are established that 
accurately identify objects on all standard slides, and these segmentation thresholds 
rem
section to avoid the introduction of experimenter bias in
minor, owing to rigid fixation and staining 
protocols. In most experiments using the same reaction product (e.g., DAB-peroxidase), 
the same thresholds settings can be used for different antibodies. After establishing the 
threshold parameters, the image field is digitized with a frame grabber. The computer 
 
 
153 
 
 
 uct. 
ea that 
e 
d by 
 
 
 washed 
a) for 15 
second
n 
VA) 
le 
-
measurements were performed on laminae II-VI of the most anterior portion of the 
cortex. Hippocampal measurements were performed by circumscribing the entire 
hippocampus or selected hippocampal subfields. Using the standard nomenclature, "Aβ 
load" is defined as percent of area in the measurement field occupied by reaction prod
Similarly, "Congo red staining" (or "amyloid load") refers to the percent of the ar
is stained with Congo red. All values from a single mouse were averaged to represent th
single value for that animal in statistical analyses. Statistical analyses were performe
using ANOVA followed by Fischer's LSD post hoc means comparison test (Statview
software from SAS). The numbers of animals, not numbers of sections, have been used
for statistical comparisons. 
 
4.3.9 Perl’s Prussian blue reaction for ferric ion-hemosiderin.  
 Sections were deparaffinized, hydrated through descending grades of ethanol, 
washed in distilled water, and incubated for 20 min in a solution containing 20% 
hydrochloric acid and 10% potassium ferrocyanide (VWR).  These sections were
3 X for 5 min with H20 and counterstained with hematoxylin solution (Sigm
s and then mounted (Wilcock et al. 2006). 
 
4.3.10 Statistical analysis.  
 Means and standard deviations were calculated according to standard practice.  I
instances of multiple comparisons of the means, one-way analysis of variance (ANO
was carried out with post-hoc comparison by Bonferroni’s method.  In instances of sing
mean comparisons, a t-test for independent samples was used to assess significance.  P
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 sed 
c., 
tion.  Twenty non-transgenic C57BL/6 mice at eight weeks 
f age were used for this experiment, and ten mice received aggregated Aβ1-42 peptide 
ice were t.c. immunized 
over a 16-w
β antibody isotypes were 
determined by an IgG isotyping assay using an isotype-specific secondary antibody 
(Town et al. 2001).  Aβ antibodies were first detected at week 4 in all immunized mice 
and dramatically increased thereafter [(Figure 14A) P <0.001].  Consistent with our 
previous studies that utilized an intraperitoneal route of administration of Aβ plus 
Fruend’s adjuvant (Town et al. 2002), Aβ antibodies of the IgG1 isotype were produced 
values less than 0.05 were considered to be statistically significant.  Data were analy
using the Statistical Package for the Social Sciences (SPSS), release 13.0 (SPSS In
Chicago, IL).   
 
4.4 Results 
 
4.4.1 Transcutaneous immunization of mice with Aβ1-42 peptide plus cholera toxin results 
in high Aβ antibody titers.   
We first sought to determine whether t.c. administration of Aβ1-42 to mice could 
result in Aβ antibody produc
o
with CT (Aβ/CT), while the remaining ten received CT alone.  M
eek time course; weekly for the first 4 weeks and bi-weekly for the following 
12 weeks.  To characterize the kinetics of the humoral immune response following 
immunization, blood samples were taken at week 0 (baseline, immediately prior to the 
first immunization), 4, 8 and 16 (immediately prior to the sacrifice of these mice).  
Plasma Aβ antibody titers were measured by ELISA.  A
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 re 
utaneous immunization was further evaluated by assaying CT antibody 
ters in plasma from these mice at weeks 0, 4, 8 and 16 following immunization.  A 
n of results was observed, albeit CT antibody titers were higher in plasma 
om mice t.c. immunized with either Aβ/CT compared with CT alone (data not shown).  
 we were unable to detect Aβ antibody titers in these 
animal
at the highest level, while IgG2a antibodies directed against Aβ were present in 
significantly lesser quantity (P <0.001).  Aβ IgG2b antibody was least detectable (Figu
14B, C).  Transc
ti
similar patter
fr
As an additional control group, we injected non-transgenic C57BL/6 mice with PBS 
alone (n = 10) in parallel, and
s, confirming the specificity of our titer assay (data not shown).                      
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Figure 14 
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 Figure 14.  Generation of immune responses in wild-type C57BL/6 mice t.c. immunized 
with aggregated Aβ1-42 peptide plus CT.  (A) Aβ antibody titers were measured by 
ELISA.  Data are presented as mean ± SD (n = 10) of Aβ antibodies (ng/mL plasma).  
One-way ANOVA followed by post hoc comparison revealed significant differences in 
anti-Aβ titers when comparing week 4 to weeks 8, 12, or 16 (**P < 0.001).  IgG isotypes 
were determined by an Ig isotyping assay and represented as ratios (mean ± SD; n = 10) 
of IgG1 to IgG2a (B) or IgG1 to IgG2b (C).  One-way ANOVA followed by post hoc 
comparison revealed significant differences between the ratio of IgG1 and IgG2a versus 
IgG1 and IgG2b at each week shown (**P < 0.001).  (D) Splenocytes were individually 
isolated and cultured from wild-type mice t.c. immunized with Aβ1-42/CT, CT alone, or 
PBS (control).  These cells were stimulated with Con A (5 µg/mL) or Aβ1−42 (20 µ L) 
for 48 h.  Cultured supernatants were collected from these cells for IFN-γ, IL-2 and IL-4 
cytokine analyses by ELISA.  Data are presented as relative fold mean ± SD (n = 10) of 
each cytokine over PBS control.  One-way ANOVA followed by post hoc comparison 
revealed significant differences between groups for levels of each of three cytokines 
[IFN-γ, IL-2 and IL-4 (**P <0.001)] following in vitro Aβ1-42 challenge.  As noted, there 
was also a significant difference in cytokine levels between IL-4 and either IFN-γ or IL-2 
following Aβ1-42 challenge (##P <0.001).   (E) To characterize the dermal immune 
responses to Aβ/CT t.c. immunization, skin tissues were prepared from non-transgenic 
C57BL/6 mice t.c. immunized for 18 h with PBS (control, top panels), CT alone (middle 
panels) or with Aβ/CT (bottom panels) as indicated and then analyzed by laser scanning 
confocal microscopy with the indicated antibodies (antibody 4G8 was used to reveal Aβ).  
g/m
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Note the presence of CD207+CD11c+ LCs in Aβ-positive regions in the Aβ/CT t.c. 
immunized group.  
Figure 15 
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Figure 15. Aβ/CT t.c. immunization resulted in LC recruitment into dermal layers. To 
characterize the dermal immune responses to Aβ/CT t.c. immunization, skin tissues were 
prepared from nontransgenic C57BL/6 mice treated with Aβ/CT (Left), CT alone 
(Center), or PBS (Right) as indicated for 18 h and then analyzed. Skin frozen sections 
were stained with anti-mouse CD207 antibody/FITC-labeled anti-rat IgG2a, rabbit anti-
human Aβ antibody/Alexa Fluor-555-labeled anti-rabbit IgG, and DAPI. As noted, blue 
staining indicates all nucleated cells, ande green indicates CD207 positive cells 
(presumed LC, ×40). 
 4.4.2 Aβ-specific immune responses in from mice transcutaneously 
immunized with Aβ plus cholera toxin. 
To further investigate splenocyte responses to Aβ, primary cultures of splenocytes 
were established from individual mice (non-transgenic C57BL/6) t.c. immunized with 
Aβ/CT, CT alone, or PBS only (control) and immune responses were compared.  We 
quantified key cytokines produced by activated T-cells [interferon-γ (IFN-γ), interleukin 
(IL)-2, IL-4] in splenocyte supernatants by ELISA as an indicator of immune 
responsiveness.  Non-specific mitogenic stimulation of cultured splenocytes with 
concanavalin A (Con A) resulted in over two-fold increases in IFN-γ, IL-2, and IL-4 
production in cells from mice immunized with Aβ/CT or CT versus PBS-immunized 
controls (Figure 14D).  No statistically significant difference was noted between Aβ/CT 
and CT alone groups for each cytokine (P >0.05).  Similar results were observed in 
cultured splenocytes stimulated with anti-CD3 (data not shown).  On the other hand, 
specific recall stimulation with Aβ1-42 peptide of primary cultured splenocytes from 
Aβ/CT-t.c. immunized mice resulted in significantly increased production of IFN-γ, IL-2 
and IL-4 compared to splenocytes cultured from mice immunized with CT alone (P 
<0.001, Figure 14D).  Importantly, regarding the anti-inflammatory cytokine IL-4, an 8-
fold increase in its secretion by splenocytes from Aβ/CT-immunized mice following Aβ1-
42 recall stimulation was observed (P < 0.001) (Figure 14D).  Taken together with the 
predominantly IgG1 Aβ-specific humoral response in Aβ/CT-t.c. immunized wild-type 
mice, this IL-4 result suggests an anti-inflammatory Th2-type immune response.     
 
splenocytes 
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4.4.3 Transcutaneous immunization with Aβ plus CT promotes recruitment of dermal 
Langerhans cells.   
Given that LCs often play a key role in skin immune responses, we asked whether 
LCs might be recruited to the site of t.c. Aβ/CT immunization.  Skin tissues and frozen 
sections were prepared from non-transgenic C57BL/6 mice 18 h after t.c. vaccination 
with Aβ/CT or CT alone, and they were co-stained with antibodies against mouse CD207 
antibody (Langerin, a pan-LC marker), mouse CD11c (a marker of an LC subset 
(Douillard et al. 2005) and/or rabbit anti-human Aβ.  Aβ/CT t.c. immunization resulted in 
LC recruitment into dermal layers compared with CT alone or PBS-immunized controls 
(Figure 14E and Figure 15), where dermal LCs were much less frequently observed.  
Furthermore, these LCs tended to be found in regions of the skin that stained positive for 
Aβ peptide by 4G8 Aβ antibody (Figure 14E).  These data show the migratory action of 
LCs in response to Aβ/CT t.c. stimulation and suggest that this effect is important in 
mediating the initial immune response to Aβ/CT t.c. immunization.   
 
4.4.4 Transcutaneous immunization of PSAPP mice with Aβ plus CT results in Aβ-
specific immune response and increased circulating Aβ.   
Having shown high Aβ antibody titers and cultured splenocyte immune responses 
to Aβ in Aβ/CT t.c. immunized non-transgenic C57BL/6 mice, we then asked whether 
this immunization strategy would reduce cerebral amyloidosis in a mouse model of AD.  
Eighteen double-transgenic (APPswe/PSEN1dE9) PSAPP mice, which overproduce 
human Aβ and develop significant amyloid deposits by 8 months of age (Jankowsky et 
  = 9) 
 CT, while the remaining half received CT alone.  
The 16
 
 
ce, Aβ 
PP 
t 
he 
.  
1-42 
rly 
al. 2001), were immunized at four months of age in this study.    Half of them (n
received aggregated Aβ1-42 peptide with
-week procedure that we employed was identical to that used above for non-
transgenic C57BL/6 mice.  Blood samples were taken at weeks 0, 4, 8 and 16 following
immunization.  Plasma Aβ antibody titers from these mice were measured by ELISA. 
Significant increases in Aβ antibody titers were observed in PSAPP mice t.c. immunized 
with Aβ/CT (P < 0.001) (Figure 16A).  Similar to non-transgenic C57BL/6 mi
antibodies were first detected at week four in plasma from Aβ/CT-immunized PSA
mice, and dramatically increased thereafter.  By contrast, these Aβ antibodies were no
detected in plasma from CT-vaccinated control mice (Figure 16A).  Two weeks after t
final immunization, primary splenocytes were isolated and cultured from individual mice
Recall stimulation of splenocytes from Aβ/CT-t.c. immunized PSAPP mice with Aβ
peptide resulted in significantly increased production of IFN-γ and IL-2, and particula
IL-4 (data not shown), similar to results from Aβ/CT-t.c. immunized non-transgenic 
C57BL/6 mice.
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Figure 16.  Increased systemic Aβ after Aβ1-42/CT t.c. immunization of PSAPP mice. 
For Aβ analysis, blood samples were individually collected from Aβ/CT or CT alone t.c.-
immunized PSAPP mice at the time points indicated.  (A) Plasma Aβ antibody titers
measured by ELISA.  Data are presented as mean ± SD (n = 9) of Aβ antibodies (pg/mL 
plasma).  ANOVA followed by post hoc comparison revealed significant differences 
between Aβ/CT and CT t.c.-immunized PSAPP mice for plasma Aβ antibody levels at 
each time point as indicated (**P <0.001).  Moreover, this analysis revealed significan
differences between time points within the Aβ/CT t.c. immunized group as indicated (#
<0.001).  (B and C) Plasma Aβ  peptides were measured separately by Aβ ELISA. 
Data are presented as mean ± SD (n = 9) of Aβ  or Aβ  (pg/mL plasma).  One-way 
ANOVA followed by post hoc comparison revealed significant differences between 
Aβ/CT and CT alone t.c.-immunized PSAPP mice for plasma Aβ  levels at each 
time point as indicated (*P <0.05; **P <0.001).  Arrows below the panels show each t.c. 
immunization with respect to time of blood sample collection.   
1-40, 42
1-40 1-42
1−40, 42
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It has been hypothesized that passively-administered Aβ antibodies create a 
“peripheral sink”; in essence, shifting the equilibrium of Aβ levels from the brain to the 
blood (DeMattos et al. 2001; Matsuoka et al. 2003).  To determine whether this 
phenomenon was occurring in the Aβ/CT-t.c. immunization paradigm, we quantified Aβ 
levels in the blood by ELISA.  In support of this hypothesis, we found significantly 
increased circulating Aβ1-40, 42 in PSAPP mice t.c. immunized with Aβ/CT as early as 4 
weeks after immunization (Figure 16B and C).  Importantly, plasma Aβ1−40, 42 levels 
increased rapidly to the highest values of 781 ± 118 pg/mL and 129 ± 46 pg/mL, 
respectively, by week 8 (two weeks after the third booster t.c. immunization).  Thereafter, 
plasma Aβ levels remained relatively constant through to the time of sacrifice following 
16 weeks of immunization. 
 
4.4.5 PSAPP mice transcutaneously immunized with Aβ plus cholera toxin show reduced 
cerebral amyloidosis in the absence of T-cell infiltrates or cerebral microhemorrhage. 
Having shown significantly increased circulating Aβ levels in PSAPP mice t.c. 
immunized with Aβ/CT, we sought to evaluate Aβ/β-amyloid pathology in these mice.  
Using a sandwich ELISA-based method, detergent-soluble Aβ1-40, 42 levels were reduced 
by approximately 53 and 48%, respectively (P <0.001) (Figure 17A).  Insoluble Aβ1-40, 42 
(prepared by acid extraction of detergent-insoluble material in 5 M guanidine and 
subsequent ELISA) levels were reduced by 50 and 54%, respectively, in Aβ/CT t.c.-
immunized PSAPP mice (P <0.001) (Figure 17B).  We further analyzed β-amyloid 
plaques in brains of mice that received t.c. immunization with Aβ/CT or CT alone by 
 sis 
 antibodies in brain 
homogenates from Aβ/CT-t.c. immunized PSAPP mice [18.87 ± 6.25 (mean ng/mg total 
protein ± SD)], while Aβ antibodies were undetectable in PSAPP mice t.c. immunized 
with CT-alone (data not shown).   Given the presence of these Aβ antibodies in the brain, 
it is possible that additional Aβ clearance mechanisms (i.e., mediated by the Fc receptor 
on phagocytic microglia) are operating.
4G8 immnunohistochemistry and congo red histochemistry (Figure 17D and F, 
respectively).  At 10 months of age, Aβ/CT-t.c. immunized PSAPP mice showed 42-58% 
(Figure 17E) and 61-65% (Figure 17G) reductions in 4G8 immunoreactive and congo 
red-positive Aβ deposits, respectively, across hippocampal and cortical brain regions 
examined.  Together, these results demonstrate that t.c. immunization with Aβ/CT is 
effective in reducing cerebral amyloidosis in PSAPP mice. 
As shown above, we found that peripheral levels of human Aβ1-40, 42 were 
increased in mice t.c. immunized with Aβ/CT.  To determine this systemic increase in 
human Aβ1-40, 42 was associated with a reduction in cerebral Aβ levels, we performed 
correlation analysis and noted an inverse correlation between plasma and brain soluble 
Aβ (Figure 17C and Figure 18), suggesting that circulating Aβ antibodies play an 
important role in clearance of Aβ from brain to blood via the “peripheral sink” hypothe
(DeMattos et al. 2001; Matsuoka et al. 2003).  This effect is likely not solely responsible 
for reduced cerebral amyloidosis, as, interestingly, we detect Aβ
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Figure 17.  Reduction of cerebral Aβ/β-amyloid pathology in PSAPP mice t.c. 
immunized with Aβ1-42/CT.  Detergent-soluble Aβ1-40, 42 peptides (A) and insoluble Aβ1-
40, 42 prepared from 5 M guanidine extraction (B) in brain homogenates were measured 
separately by ELISA.  Data are presented as mean ± SD (n = 9) of Aβ1-40 or Aβ1-42 
(pg/mg protein), and reductions for each group are indicated.  (A and B), A t test revealed 
a significant between-group difference for either soluble or insoluble Aβ1-40, 42 (P < 
0.001).  (C) A significant inverse correlation (P < 0.001) between plasma and brain 
soluble Aβ levels was revealed.  Plasma Aβ levels are presented as percentage mean ± 
SD (n = 9) of soluble circulating Aβ at 16 weeks following t.c. immunization of PSAPP 
mice with Aβ/CT over CT control mice.  (D) Mouse brain coronal paraffin sections were 
stained with monoclonal anti-human Aβ antibody 4G8.  Left, Aβ1-42/CT t.c. immunized 
PSAPP mice; right, CT t.c. immunized PSAPP mice.  The top panels are from the 
cingulate cortex (CC), the middle panels are from the hippocampus (H), and the bottom 
panels are from the entorhinal cortex (EC).  (E) Percentages (plaque “burden”, area 
plaque/total area) of Aβ antibody-immunoreactive Aβ plaques (mean ± SD; n = 9) were 
calculated by quantitative image analysis, and reductions for each mouse brain area 
analyzed are indicated.  (F) Mouse brain sections from the indicated regions were stained 
with congo red.  Left, Aβ1-42/CT t.c. immunized PSAPP mice; right, CT t.c. immunized 
PSAPP mice.  (G) Percentages of congo red-stained plaques (mean ± SD; n = 9) were 
quantified by image analysis, and reductions for each brain region are indicated.  (E and 
G) a t test for independent samples revealed significant differences (P < 0.001) between-
groups for each brain region examined. 
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Figure 18 
 
 by-Figure 18. Simultaneous analysis of plasma and brain soluble Aβ levels on a mouse-
mouse basis. Data are presented as percentage of circulating or brain soluble Aβ at 16 
weeks after Aβ/CT t.c. immunization of individual PSAPP mice (n = 9) relative to 
average Aβ levels of control mice t.c. immunized with CT alone. Each color bar 
represents plasma Aβ levels and brain-soluble Aβ levels from each individual mouse as 
indicated. 
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 In a recent clinical trial, patients β peptide (AN-
1792) plus adjuvant and approximately 6% of these patients developed aseptic 
meningoencephalitis, most likely mediated by brain-infiltrating activated T-cells (Hock et 
al. 2003; Bayer et al. 2005).  This serious complication led to suspension of the clinical 
trial.  We sought to investigate whether Aβ/CT t.c. immunization might induce T-cell 
infiltration into the brain.  We immunostained brain sections from mice immunized with 
Aβ/CT, CT alone, or, as a positive control, non-transgenic C57BL/6 mice subcutaneously 
injected with myelin oligodendrocyte protein emulsified in complete Freund’s adjuvant 
(brains were isolated 20 days after immunization, when copious amounts of T-cells have 
infiltrated the brain).  As shown in Figure 19A-C, we did not detect CD3-positive T-cells 
in brains from mice t.c. immunized with CT or Aβ/CT; however, this was not due to a 
technical issue as T-cells were detected in the positive control tissue (Figure 19A).  
Further, we also immunostained brain sections from the above mice with CD4 or CD8 
antibodies (which stain different subsets of T-cells) and did not detect T-cell infiltration 
in brains of mice t.c. immunized with CT or Aβ/CT, while such cells were detected in our 
positive control tissue (data not shown). 
It has been reported that mice receiving passive transfer of Aβ antibodies manifest 
cerebral microhemorrhage (Wilcock et al. 2004; Racke et al. 2005).  To investigate this 
potentially adverse side-effect of Aβ/CT t.c. immunization, we carried out 
microhemorrhage analysis via Perl’s Prussian blue stain (which can detect even minute 
amounts of deposited iron derived from blood (Wilcock et al. 2004; Racke et al. 2005).  
We did not detect positive staining using this method in either t.c. immunized group, but 
 were administered a synthetic A
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 tissues 
 that both the Prussian blue stain and apolipoprotein B analyses were negative 
in t.c. immunized PSAPP mice, suggesting that detection of Aβ antibodies in the brains 
of these mice (as mentioned above) was not due to poor perfusion efficiency or detectable 
breakdown of the blood-brain-barrier, but rather was likely due to “physiological” entry 
of Aβ antibodies into the brain parenchyma.   
did observe staining in our positive control tissue [in this case, from mice 
intraperitoneally passively given Aβ antibodies (Wilcock et al. 2006)] (Figure 19D-F). 
As an additional indicator of possible blood-brain-barrier breakdown, we analyzed 
apolipoprotein B (present in blood but not normally in brain) levels in these brain
by Western blot and it was undetectable in the t.c. immunized groups (Figure 20). It is 
noteworthy
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Figure 19 
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 /CT t.c. 
was 
 panel is the neocortex.  Magnification for 
CD3 staining is 10 X while it is 20 X for microhemorrhage. 
Figure 19.  Absence of T-cell infiltration or brain microhemorrhage in Aβ
immunized mice.  To characterize the safety of the vaccine, brain sections were stained 
for CD3 as an indicator of T-cell infiltration (top panels).  Staining for hemosiderin 
also performed to identify microhemorrhage (bottom panels) in mice immunized with 
Aβ/CT (B and E), or CT alone (C and F).  These stained sections were compared to 
positive controls.  For CD3 staining, the positive control consisted of CD3-positive brain 
sections from EAE mice (A).  For microhemorrhage, experimental sections were 
compared to sections from mouse brains suffering microhemorrhage (D).  Each panel is 
representative of staining repeated in triplicate for each brain section for either CD3 or 
hemosiderin.  The brain region shown for each
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Figure 20 
  
 
nd 
n 
Figure 20. Apolipoprotein B protein was undetectable in brain tissue homogenates
derived from both Aβ/CT and CT t.c.-immunized mice. Brain homogenates were 
prepared from PSAPP mice t.c.-immunized with Aβ/CT or CT, and an aliquot 
corresponding to 100 µg of total protein was electrophoretically separated by using 4%
SDS-polyacrylamide gels. In addition, a series of mouse plasma dilutions (100, 50, a
25 µg per lane) was loaded as positive controls. Western blot analysis by apolipoprotein 
B antibody (ab20737, Abcam, Inc, Cambridge, MA) shows apolipoprotein B100 i
plasma but not in brain homogenates as indicated. 
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4.5 Discussion 
To translate animal Aβ immunization approaches into successful clinical AD 
therapies, such strategies should not only be efficacious, but also be safe, including 
avoiding meningoencephalitic reactions to Aβ immunization previously observed in 
humans (Janus 2003; Monsonego et al. 2003).  Experimental and postmortem evidence 
suggests that such aseptic meningoencephalitis observed in AD patients after Aβ 
vaccination resulted from CNS invasion by Aβ reactive T-cells (Monsonego et al. 2003; 
Maier et al. 2006).  The requirement of Aβ-reactive T-cells for cerebral amyloid plaque 
clearance mediated by “active” Aβ vaccination strategies still remains unclear 
(Monsonego et al. 2003; Orgogozo et al. 2003; Ferrer et al. 2004).   A previous study 
utilizing intranasal delivery of short Aβ-derived peptides lacking T-cell reactive epitopes 
with a specific immune-modulating adjuvant (mutant Escherichia coli heat-labile 
enterotoxin; LT R192G), demonstrated the possibility of potentiating an effective 
humoral anti-Aβ response while minimizing Aβ reactive T-cells (Maier et al. 2006), 
suggesting that Aβ-reactive T-cells are not necessary for an effective Aβ antibody 
response.  If this proves to be true in humans, such an approach may represent reasonable 
therapeutic potential; however, it should be noted that anosmia/hyposmia may limit the 
usefulness of intranasal Aβ immunization.  Further evidence that Aβ-reactive T-cells are 
likely not required for Aβ immunotherapy efficacy comes from “passive” immunization 
studies, which have shown that humoral responses alone may be sufficient to effectively 
reduce cerebral amyloid burden, and thereby mitigate neurodegeneration (Dickstein et al. 
2006; Ma et al. 2006).     
  of 
 an 
y 
ositive for Aβ, showing that these LCs 
migrate to the t.c. immunization site and likely participate in antigen processing.  The 
skin immune environment has likely evolved over millennia, owing to constant 
bombardment of the skin with various antigenic stimuli, resulting in a delicate balance 
between immunogenic and tolerogenic responses.  It is noteworthy that 
transcutaneous/epicutaneous immunization has been successful in mitigating 
neurodegenerative disease in both induced and spontaneous forms of experimental 
autoimmune encephalomyelitis (EAE), mouse models of the demyelinating disease 
multiple sclerosis (Bynoe et al. 2003; Bynoe et al. 2005).   
To determine the ability of Aβ t.c. immunization to effectively produce Aβ 
antibodies, we began our investigation in non-transgenic C57BL/6 mice, where we 
measured the kinetics of Aβ-specific antibody titers.  Remarkably, the Aβ antibody 
response was observed as early as week four in all immunized mice and dramatically 
increased thereafter, remaining elevated through 16 weeks post-initial vaccination. 
Antibody isotype characterization demonstrated a predominantly IgG1 
Here, we investigated the potential of t.c. Aβ immunization for the treatment
AD-like cerebral amyloidosis in transgenic mice. Transcutaneous immunization is
attractive route of delivery, as it is convenient, relatively painless, and minimall
invasive. This strategy is also appealing because the epidermal and dermal immune 
systems provide a unique environment for immune stimulation due to LC antigen 
presentation (Rozis et al. 2005; Renn et al. 2006; Schiller et al. 2006; Strid et al. 2006).  
Indeed, following Aβ/CT t.c. immunization, we observed cells double-positive for 
CD207 and CD11c in dermal regions that stained p
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 gG2b) response in line with our previous report utilizing an 
intrape
as 
ly 
 
ion 
Notwithstanding the need for these critical studies, Aβ immunization appears to 
modulate immune responses based on three major criteria: 1) tissue route of delivery, 2) 
antigen epitope utilized for immunization, and 3) properties of the co-administered 
adjuvant.  Whether Th2 polarization in this study occurred due to route of delivery, CT 
adjuvant choice, or the genetic background of the C57BL/6 strain (Rosas et al. 2005; 
Fukushima et al. 2006) remains to be fully determined in future studies.  It has been 
reported that CT promotes an anti-inflammatory Th2 immune response (Eriksson et al. 
2003), and our data demonstrating IgG1 subtype antibodies produced in the greatest 
(IgG1>IgG2a>I
ritoneal route of Aβ vaccination plus Freund’s adjuvant (Town et al. 2002).  
Production of IgG1 and IgG2b are typically due to anti-inflammatory Th2 cytokine 
signaling, whereas IgG2a typically results from pro-inflammatory Th1 signaling (Abb
et al. 1996).  The Th2 cytokine profile is likely favorable for inducing antibody 
production and thus Aβ clearance without the overt pro-inflammatory (i.e., possib
contributing to auto-immune responses) Th1-type activation that typifies cellular immune
responses (Romagnani 2000; Schwarz et al. 2001; Town et al. 2002).  Accordingly, to 
circumvent meningoencephalitic reactions, many studies investigating vaccinat
methods for reducing cerebral amyloidosis in AD have attempted to bias Th cell 
responses towards Th2 profiles utilizing various strategies (Kim et al. 2005; Dasilva et al. 
2006; Ghochikyan et al. 2006).  The effectiveness and potential safety of these strategies 
seems promising, but further investigation is needed to confirm whether the link between 
Th cell responses and meningoencephalitis in AD patients is causitive.  
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 proport
 
e 
c 
ll 
nd 
ccination 
matory Th2-type 
he Aβ 
; 
β/CT t.c. 
immunization of non-transgenic C57BL/6 mice produces both Aβ-specific local LC 
immune response and systemic immune response characterized by high Aβ antibody 
titers that are sustained throughout the immunization protocol.  
To determine the potential therapeutic efficacy of Aβ t.c. immunization, 6 month-
old double-transgenic (APPsw, PSEN1dE9) PSAPP mice [which develop robust amyloid 
pathology at 8 months of age (Jankowsky et al. 2001)], were immunized against Aβ/CT 
ion (compared to IgG2a or IgG2b antibodies) supports this notion.  Of note, CT 
antibody titers were observed (data not shown), indicating an immunogenic response to
this adjuvant.  To confirm specific systemic versus local immune cell activation, w
analyzed primary cultures of isolated splenocytes from t.c. immunized non-transgeni
C57BL/6 mice and found that Aβ/CT t.c. immunization conferred Aβ-specific T-ce
response as measured by secretion of cytokines IFN-γ, IL-2 and IL-4 upon aggregated 
Aβ1-42 peptide recall challenge.  Importantly, there was a marked increase in IL-4 
secretion compared to IFN-γ or IL-2, further suggesting Th2 immune responses after 
Aβ/CT t.c. immunization.  This is in agreement with our previous study, where we fou
Th2-type cytokine responses both in vivo and ex vivo after intraperitoneal Aβ va
with Freund’s adjuvant (Town et al. 2002).  Further, the Th2-type response that we 
observed following Aβ/CT t.c. immunization is important as anti-inflam
immune responses are likely preferred to pro-inflammatory Th1-responses in t
vaccination paradigm, given that pro-inflammatory Th1 cells likely contributed to the 
aseptic meningoencephalitis in the human clinical trial of AN-1792 (Nicoll et al. 2003
Town et al. 2005).  When taken together, these findings show that A
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 β antibody 
oup.  
only 
nation, 
 
that Aβ/CT t.c. immunization is effective at mitigating cerebral amyloidosis and suggest 
activation of Aβ brain-to-blood clearance.  This “peripheral sink” mechanism has been 
reported by others following passive transfer of Aβ antibodies to AD transgenic mice 
(DeMattos et al. 2001; Matsuoka et al. 2003). 
In order for AD immunotherapy approaches to be useful, they must not only be 
efficacious, but such approaches must also be safe and well-tolerated.  Importantly, while 
we did observe peripheral Aβ-specific T-cell responses consistent with an anti-
β
ex vivo by IL-4 secretion after Aβ recall stimulation of splenocytes) after Aβ/CT t.c. 
or CT alone for 16 weeks.  Results showed consistently high and sustained A
titers throughout the 16 week immunization period only in the Aβ/CT immunized gr
Interestingly, the magnitude of Aβ antibody response in Aβ/CT t.c. immunized was 
about half of that in wild-type mice (compare Figure 14A with Figure 15A), supporting 
the notion that transgenic mouse models of AD are hypo-responsive to Aβ vacci
probably owing to overexpression of the human APP transgene throughout their lives
(Monsonego et al. 2001).    This humoral response correlated with high plasma levels of 
Aβ1-40, 42 peptides which peaked around eight weeks and remained relatively constant 
through to 16 weeks.  Immunohistological and histochemical analyses of Aβ 
immunoreactive plaques and congophilic plaques, respectively, in cortical and 
hippocampal brain sections showed reductions by approximately 50% compared to CT 
t.c. immunized PSAPP mice, and a negative correlation existed between brain Aβ and 
blood Aβ levels following Aβ/CT t.c. immunization. Taken together, these results show 
inflammatory Th2 response (characterized in vivo by IgG1 A  antibody production and 
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immunization, no signs of aseptic meningoencephalitis and/or cell-mediated immunity 
were observed in brains as evidenced by lack of CD3 positive T-cell infiltrates.  
However, we did observe evidence of humoral immunity in brain as demonstrated by
antibody titers in brain homogenates, similar to data from previous reports using other 
modes of Aβ immunotherapy (Bard et al. 2000; Bacskai et al. 2001), suggesting transp
of Aβ antibodies across the blood-brain-barrier.  This observation was not due to poor 
PBS perfusion at the time of sacrifice, as Perl’s stain (which normally detects even
amounts of iron which could be present due poor perfusion) results were consistently 
negative.  Finally, other investigators have reported that passive transfer of Aβ antibodies 
to transgenic AD mice results in cerebral microhemorrhage (Wilcock et al. 2004; Racke 
et al. 2005).  Importantly, Perl’s stain did not show this potentially adverse side-effe
mice t.c. immunized with Aβ/CT.  Thus, when taken together, t.c. immunization holds 
potential as a novel, effective, and safe potential treatment strategy for AD.                 
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zheimer’s disease is the most common progressive neurodegenerative disorder. 
mal 
β deposits, deposition of Aβ in the cerebral vasculature (known as CAA) is another 
lis et al., 
f 
 
 the neuroinflammatory response can be regarded as a central feature of AD 
CHAPTER FIVE 
DISCUSSION 
 
Al
Based on genetic, biochemical, and post-mortem evidence, Aβ peptides are key 
etiological contributors to AD pathogenesis (Selkoe, 2001).  In addition to parenchy
A
pathological feature of AD, and occurs with 83% frequency in AD patients (El
1996; Selkoe, 2001; Jellinger, 2002; Green et al., 2005). It is well know that there is a 
chronic activation of inflammatory pathways in AD brain, including the production o
proinflammatory cytokines and acute-phase reactants in and around Aβ plaques. In 
addition, a number of other molecules important in the proinflammatory acute-phase 
response are also found at high levels in AD brain, including the activated glial product 
S100 beta, the protease α-1-antichymotripsin and α-2-macroglobulin, the prostaglandin –
generating enzymes cyclooxygenases 1 and 2, and components of the classical protein 
complement cascade such as C1q and C3 (Akiyama et al., 2000; McGeer and McGeer,
2001). Thus,
brain. 
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5.1 Microglia and central nervous system 
 
like cells, it is becoming increasingly clear that reactive microglia play more 
verse roles in the CNS.  Microglial “activation” is often used to refer to a single 
phenotype; however, a continuum of microglial activation exists, with phagocytic 
response (innate activation) at one end and antigen presenting cell function (adaptive 
activation) at the other.  Where activated microglia fall in this spectrum seems to be 
highly dependent on the type of stimulation provided. 
Here, we suggest a model wherein microglial cells exist in at least two 
functionally discernable states once “activated”, namely a phagocytic phenotype (innate 
activation) or an antigen presenting phenotype (adaptive activation), as governed by their 
stimulatory environment.  When challenged with certain PAMPs (particularly CpG-
DNA), murine microglia seem to activate a “mixed” response characterized by enhanced 
phagocytosis and pro-inflammatory cytokine production as well as adaptive activation of 
T cells.  In the EAE model, murine microglia seem to largely support adaptive activation 
of encephalitogenic T cells in the presence of the CD40-CD40 ligand interaction.  In the 
context of Aβ challenge, CD40 ligation is able to shift activated microglia from innate to 
adaptive activation.  Further, it seems that the cytokine milieu that microglia are exposed 
to biases these cells to innate activation (i.e., anti-inflammatory Th2-associated cytokines 
such as IL-4, IL-10, TGF-β1) or an adaptive form of activation (i.e., pro-inflammatory 
Th1-associated cytokines such as IFN-γ, IL-6, and TNF-α; summarized in Fig. 21).  
Microglia are innate immune cells of myeloid origin that take up residence in the 
central nervous system (CNS) during embryogenesis.  While classically regarded as 
macrophage-
di
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 Figure 21 
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 microglial activation responses.  In the 
context
nting 
y 
roglia.  
ll; 
kin; IFN, interferon, TNF, tumor 
necrosi
Figure 21. Model for innate versus adaptive 
 of β-amyloid challenge, microglia activate a phagocytic response.  If co-
stimulated with CD40 ligand, a shift from innate activation to adaptive antigen-prese
cell response ensues.  Additionally, certain anti-inflammatory Th2-type cytokines shift 
this balance back towards innate phagocytic response, while some pro-inflammator
Th1-associated cytokines tip the balance further towards adaptive activation of mic
See the text and Table for references.  Abbreviations used: APC, antigen presenting ce
CD40L, CD40 ligand; Th1, CD4+ T helper cell type I response; Th2, Th type II 
response; TGF, transforming growth factor; IL, interleu
s factor. 
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 Not all forms of microglial activation a s, as activated microglia may serve a 
protective role as was shown in Aβ1-42-immunized mouse models of AD.    It seems that 
enhanced microglial phagocytosis of β-amyloid plaques is at least partly responsible for 
the therapeutic benefit in these animals, so perhaps stimulation of innate microglial 
activation contributes to these reported benefits.  In conclusion for microglial activation, 
if we can learn how to better harness microglia in order to produce specific forms of 
microglial activation, this could be key to turn a pathogenic cell into a therapeutic 
modality. 
 
5.2 Immunotherapy for Alzheimer disease 
In a seminal report, Schenk and colleagues showed that peripheral immunization 
of the PDAPP mouse model of AD with Aβ1-42 peptide resulted in high antibody titers, a 
small fraction of which (0.1%, (Bard et al., 2000) crossed the blood-brain-barrier and 
entered the brain parenchyma.  Most importantly, these authors found that Aβ1-42 
vaccination markedly diminished β-amyloid plaque burden (Schenk et al., 1999).  These 
authors also found evidence of cells in the brains of the Aβ1-42 immunization animals that 
contained Aβ.  Many of these cells stained for the activated microglia marker MHC II 
and phenotypically resembled activated microglia, suggesting that these cells were able to 
phagocytose Aβ deposits.  In a follow-up report, Bard and colleagues supported this 
hypothesis by showing ex vivo that certain antibodies against Aβ peptides could trigger 
microglial phagocytosis and subsequent clearance of Aβ through the Fc receptor (Bard et 
al., 2000) (Bard et al., 2003).  Clearance of brain β-amyloid deposits was beneficial, as 
re deleteriou
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  mouse 
d 
st-mortem brain of one patient who died as a consequence of this side-
effect of treatment, there was significant clearance of Aβ plaques in parts of the 
neocortex and, in other areas where plaques remained, Aβ-immunoreactivity was 
associated with microglia (Nicoll et al., 2003).  It is not yet clear whether this fulminate 
infiltration of T cells in AD patients who developed aseptic T cell meningoencephalitis 
was due to adaptive activation of microglia, but this is a distinct possibility given that 
microglia did seem to recognize antibody-opsonized Aβ (Nicoll et al., 2003) (Monsonego 
and Weiner, 2003).  These results indicate the potentially damaging and overwhelming 
effects of a full-blown T cell autoimmune response, which does not normally occur in 
AD, and which may have been mediated by adaptively activated microglia. Thus, to 
translate animal Aβ immunization approaches into successful clinical AD therapies, such 
strategies should not only be efficacious, but also be safe, including avoiding 
meningoencephalitic reactions to Aβ immunization previously observed in humans 
Aβ1-42-vaccinated mice had markedly reduced cognitive impairment as assayed by 
behavioral testing in AD mice (Janus et al., 2000) (Morgan et al., 2000).  Thus, in
models of AD, innate (phagocytic) microglial activation mediated by the Fc receptor in 
the presence of antibody-opsonized Aβ appears beneficial rather than deleterious. 
Based on the above-mentioned data, a human clinical trial was begun to 
peripherally administer a synthetic Aβ1–42 peptide (AN-1792) with an adjuvant to AD 
patients.  Unfortunately, the trial was halted when a small percentage of patients 
developed aseptic T cell meningoencephalitis.  This response most likely occurre
because of an immune reaction to Aβ mediated by infiltrating T cells (Pfeifer et al., 
2002).  In the po
 
 
201 
 
 
  et 
une 
ave been elicited after transcutaneous (t.c.) vaccination (Giudice and 
ampbell, 2006). Taken together, these lines of evidence led us to hypothesize that 
y provide an immunotherapeutic approach 
that is b
 
d 
o 
(Janus, 2003; Monsonego et al., 2003b).  
 
5.2.1. Immunotherapy: transcutaneous vaccination 
Transcutaneous (t.c.) vaccination is an attractive route of delivery, as it is 
convenient, relatively painless, and minimally invasive. The skin is a well-established 
effective route for vaccination, including delivery of peptide-based vaccines (Masliah
al., 1991; Tan et al., 2002a; Beignon et al., 2005).  Strong humoral and cellular imm
responses h
C
targeting Aβ immunotherapy to skin tissue ma
oth efficacious and safe. Here, we first found that t.c. immunization of non-
transgenic C57BL/6 mice with aggregated Aβ1-42 peptide plus the adjuvant cholera toxin 
(CT) resulted in high Aβ antibody titers [mainly immunoglobulin (Ig) G1], and Aβ1-42-
specific splenocyte immune responses after re-challenge with the peptide. Similar
response was observed in transgenic PSAPP mice and resulted in effective immune 
responses against Aβ in concert with reduced cerebral Aβ pathology, demonstrating the 
effectiveness of this approach. These mice showed high Aβ antibody titers and increase
circulating Aβ levels, suggesting brain-to-blood efflux of Aβ.  Importantly, brain T-cell 
infiltration and cerebral microhemorrhage were not observed after t.c. immunization, 
indicating that this immunization strategy is potentially safe. Aβ immunization appears t
modulate immune responses based on three major criteria: 1) tissue route of delivery, 2) 
antigen epitope utilized for immunization, and 3) properties of the co-administered 
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 CT 
t al., 
2003), test 
 T-cell 
ted 
e found 
ination 
 
 
l., 
. 
adjuvant.  Whether Th2 polarization in our study occurred due to route of delivery, 
adjuvant choice, or the genetic background of the C57BL/6 strain (Rosas et al., 2005; 
Fukushima et al., 2006) remains to be fully determined in future studies. It has been 
reported that CT promotes an anti-inflammatory Th2 immune response (Eriksson e
and our data demonstrating IgG1 subtype antibodies produced in the grea
proportion (compared to IgG2a or IgG2b antibodies) supports this notion. Further we 
showed that splenocytes isolated from t.c. immunized mice and found Aβ-specific
responses as measured by secretion of cytokines IFN-γ, IL-2 and IL-4 upon aggrega
Aβ1-42 peptide recall challenge. Importantly, there was a marked increase in IL-4 
secretion compared to IFN-γ or IL-2, further suggesting Th2 immune responses after 
Aβ/CT t.c. immunization.  This is in agreement with our previous study, where w
Th2-type cytokine responses both in vivo and ex vivo after intraperitoneal Aβ vacc
with Freund’s adjuvant (Town et al., 2002). Further, the Th2-type response that we 
observed following Aβ/CT t.c. immunization is important as anti-inflammatory Th2-type
immune responses are likely preferred to pro-inflammatory Th1-responses in the Aβ 
vaccination paradigm, given that pro-inflammatory Th1 cells likely contributed to the 
aseptic meningoencephalitis in the human clinical trial of AN-1792 (Nicoll et al., 2003; 
Town et al., 2005). Finally, other investigators have reported that passive transfer of Aβ
antibodies to transgenic AD mice results in cerebral microhemorrhage (Arendash et a
2001; Racke et al., 2005).  Importantly, Perl’s stain did not show this potentially adverse 
side-effect in mice t.c. immunized with Aβ/CT.  Thus, when taken together, t.c
immunization holds potential as a novel, effective, and safe prospective treatment 
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strategy for AD.  
 
e have previously shown the CD40-CD40L interaction enhances pro-
bral Aβ deposits (Tan et al., 1999a).  
This fo L and 
utilized 
 
40-
 
 
gic 
 
hese 
W
inflammatory microglial activation triggered by cere
rm of microglial activation is deleterious, as both genetic ablation of CD40
CD40L neutralizing antibody reduce brain levels of several neurotoxic inflammatory 
cytokines and mitigate cerebral amyloidosis in AD mouse models (Tan et al., 2002a). 
Blocking the CD40-CD40L interaction mitigates Aβ-induced inflammatory responses 
and enhances Aβ clearance (Tan et al., 2002b; Townsend et al., 2005).  Here, we 
genetic and pharmacologic approaches to test whether CD40-CD40L blockade could
enhance the efficacy of Aβ1-42 immunization, while limiting potentially damaging 
inflammatory responses.  We show that genetic or pharmacologic interruption of CD
CD40L interaction enhanced Aβ1-42 immunization efficacy to reduce cerebral amyloidosis
in the PSAPP and Tg2576 mouse models of AD.  Potentially deleterious pro-
inflammatory immune responses, cerebral amyloid angiopathy (CAA) and cerebral
microhemorrhage were reduced or absent in these combined approaches. Pharmacolo
blockade of CD40L decreased T-cell neurotoxicity to Aβ-producing neurons.   Further 
reduction of cerebral amyloidosis in Aβ-immunized PSAPP mice completely deficient 
for CD40 occurred in the absence of Aβ immunoglobulin G (IgG) antibodies or efflux of
Aβ from brain to blood, but was rather correlated with anti-inflammatory cytokine 
profiles and reduced plasma soluble CD40L. Recently soluble CD40L was reported to be 
significantly increased in AD patients vs. healthy elderly controls, further supporting a 
role for this receptor/ligand dyad in the pathogenesis of AD (Desideri et al., 2006). T
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 it 
fer 
ach 
 be 
r, 
. 
as 
results suggest CD40-CD40L blockade promotes anti-inflammatory cellular immune 
responses, likely resulting in promotion of microglial phagocytic activity and Aβ 
clearance while precluding generation of neurotoxic Aβ-reactive T-cells. If the benef
afforded by CD40 pathway blockade to Aβ1-42 vaccinated AD mouse models can 
translate to the clinical syndrome, then pharmacotherapy aimed at reducing CD40 
signaling in conjunction with Aβ vaccination may represent an approach that is both sa
and more effective in humans.  Future studies will be required to isolate CD40-CD40L 
downstream signaling involved in reduced efficacy of Aβ vaccination, as this may 
uncover additional targets for pharmacologic intervention. 
 
5.2.2. Immunotherapy: human umbilical cord blood cells 
Considering that inflammation plays a crucial role in propagation of Alzheimer’s 
disease, a second or parallel therapy would be desired. This alternative therapy appro
would mainly immunomodulate peripheral immunity such that desired anti-inflammatory 
Th2 responses would predominate, in other words an increased Th2/Th1 ration should
observed. A possible strategy would involve a partial blockade of CD40-40L. Howeve
it is rather challenging to partially block CD40-40L interaction with the use of CD40 
agonists or CD40L antagonists since it could lead to immunodeficiencies and hyper IgM 
syndrome. Human cord blood cells (HUCBC) have unique immunomodulatory potential
HUCBC have been shown to oppose the pro-inflammatory Th1 response, as 
demonstrated in an animal model of stroke where HUCBC infusion promoted a strong 
anti-inflammatory Th2 response (Vendrame et al., 2004).  Importantly, this effect w
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 duced infarct volume and rescue of behavioral deficit (Vendrame et al., 
2004). mmatory 
, 
o 
ly, 
 reduced 
s the 
a 
ant 
associated with re
 HUCBC infusion has also shown therapeutic benefit in other neuroinfla
conditions including multiple sclerosis, amyotrophic lateral sclerosis, age-related 
neuromacular degeneration, and Parkinson’s disease (El-Badri et al., 2006; Garbuzova-
Davis et al., 2006; Henning et al., 2006).  In AD preclinical models, administration of 
these cells to the PSAPP mouse model of AD was associated with extension of lifespan
although high doses were administered in this paradigm (Ghorpade et al., 2001). Here, 
we showed a marked reduction of Aβ levels/β-amyloid plaques and associated 
astrocytosis following multiple low dose infusions of HUCBC.  HUCBC infusions als
reduced cerebral vascular Aβ deposits in the Tg2576 AD mouse model.  Interesting
these effects were associated with suppression of the CD40-CD40L interaction as 
evidenced by decreased circulating and brain soluble CD40L (sCD40L) and elevated 
systemic IgM levels, attenuated CD40L-induced inflammatory responses, and
surface expression of CD40 on microglia.  Importantly, deficiency of CD40 abolishe
effect of HUCBC on elevated plasma Aβ levels.  Moreover, microglia isolated from 
HUCBC-infused PSAPP mice demonstrated increased phagocytosis of Aβ.  Further, ser
from HUCBC-infused PSAPP mice significantly increased microglial phagocytosis of 
Aβ1-42 peptide while inhibiting IFN-γ-induced microglial CD40 expression.  Increased 
microglial phagocytic activity in this scenario was inhibited by addition of recombin
CD40L protein.  Thus, the data suggests that HUCBC infusion confers mitigation of AD-
like pathology by disrupting CD40L activity. When taken together, our results provide 
the basis for a novel immunomodulatory strategy for AD using HUCBC. 
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 es as 
uch as 
ed to 
 
les 
the vaccine as they provide the host with required tools for needed immunomodulation. 
nd they are readily 
available. B
In conclusion, there is no current treatment for Alzheimer’s disease. 
Immunotherapy is emerging as a potential therapy not just for AD but other diseas
well. Previous vaccines were very effective yet came with undesired side effects for a 
small population of patients. Since then, the accent have been given to safety as m
to efficacy of any treatment. Alternative routes, adjuvants, and antigens could be us
bypass this problem. Here, we showed that transcutaneous immunization of a whole Aβ 
peptide with a cholera toxin adjuvant could be the answer. This vaccine could further be
enhanced with inhibitors of yet to be identified specific CD40-40L signaling molecu
involved in inflammation. Lastly, human cord blood cells could be used in parallel with 
In addition, these cells do not represent any ethical concerns a
ased on these finding and current trends in research it is highly likely that 
future AD treatments will incorporate both the vaccine- and the cell-based therapies. 
Future studies are needed to further examine the safety of these approaches since both 
have shown very effective. 
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